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Summary 	  
PRMT5 is a member of a group of proteins that mediate arginine methylation. 
It is involved in diverse cellular processes, including cell differentiation, splicing, 
transcription elongation and epigenetic silencing, and its expression is dysregulated 
in many cancers. Due to its pleiotropic functions, PRMT5 is subject to multi-level 
regulation. Post-translational modification (PTM) of proteins can modulate an array 
of cellular processes by regulating both protein interactions and protein structural 
changes. PRMT5 is commonly found associated with other proteins; these 
interactions seem to control both its catalytic activity and its substrate specificity. 
Recently, it became clear that PRMT5 is phosphorylated at a number of residues, 
which prompted us to investigate whether phosphorylation of PRMT5 regulates its 
subcellular localization and/or substrate choice, by facilitating phospho-dependent 
protein-protein interactions. 
To study how phosphorylation affects PRMT5 function, protein microarrays 
were used to identify novel phosphodependent-interacting proteins. This analysis 
revealed that phosphorylation mediates the interaction of PRMT5 with several SH2-
domain containing proteins, 14-3-3 proteins and the FHA domain of MDC1. These 
novel phospho-dependent PRMT5 interactions suggest that crosstalk between 
kinases and arginine methyltransferases may play a pivotal role in modulating the 
different cellular functions of PRMT5. 
 Additionally, we have found that the C-terminal region of PRMT5 has a 
recognition motif shared by PDZ domains and 14-3-3 proteins. In order to bind to 
this motif, 14-3-3 proteins require the C-terminus to be phosphorylated, while PDZ 
domain recognition is phospho-independent. From these data, a new regulatory 
mechanism that affects PRMT5 behavior was proposed; the action of kinases and 
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phosphatases on PRMT5 may function as a switch to regulate interactions between 
14-3-3 and PDZ domain-containing proteins. We additionally observed this paradigm 
with a number of proteins, suggesting that this phosphorylation dependent switch, 
regulating binding to 14-3-3 and PDZ domains, occurs in a wide range of protein-
protein interactions.  
Among the recently discovered PDZ-binding partners, we have found that 
PRMT5 interacts with NHERF2, a membrane-associated protein that regulates the 
sodium ion exchanger NHE3. Through this interaction, PRMT5 is placed in close 
proximity to the membrane and therefore may regulate the influx of ions through 
selective ion channels. Overall, we hypothesize that the direct interaction of PRMT5 
with selected partners mediates the appropriate localization of PRMT5, allowing it to 
methylate specific substrates. 
Physiological processes including muscle contraction, cell homeostasis and 
neurotransmission are controlled by the selective conduction of ions across cell 
membranes. Ion channels and exchangers are proteins that span cell membranes 
and form a channel or pore, facilitating the movement of ions in and out of cells. 
Abnormal response of the cell to its microenvironment is one of the key factors in the 
progression of many diseases. To study the role of the C-terminus of PRMT5 in vivo, 
we used CRISPR/Cas9 technology to create a mouse with the last six amino acids 
of PRMT5 replaced with an HA tag, as well with an altered PRMT5 C-terminus. Both 
mouse models lack the critical 14-3-3/PDZ binding motif. This approach revealed 
that the C-terminus of PRMT5 is essential for viability as no homozygous mutant 
embryos were recovered. Likewise, no homozygous PRMT5Δ+HA ES cell lines could 
be created. The results described here represent progress toward understanding 
PRMT5 function and regulation.   
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Chapter 1: General Introduction 
 
1.1. Post-translational modification 
 
Although protein levels are primarily regulated by gene transcription and 
translation, fine-tuning the turnover and functional availability of proteins requires 
more dynamic control. This control is achieved in part by post-translational 
modifications (PTMs). The complete protein repertoire of a cell is termed the 
proteome (Kahn, 1995). The proteome is greatly influenced by PTMs. Indeed, 
immediately following protein synthesis, most proteins are modified through a series 
of intricate and tightly regulated steps. The resulting modifications include cleavage 
of the protein backbone, or modifications of specific amino acids by the covalent 
additions of one or more chemical groups, proteins, lipids, or sugars. PTMs can 
result in altered protein structure, changes in interaction with other proteins, altered 
protein localization, and changes in overall protein stability. Thus a relatively small 
number of expressed proteins lead to a much larger functional repertoire of proteins 
via PTMs. Consequently, PTMs are fundamental to the regulation of molecular 
mechanisms and cellular functions that impact the health of an entire organism. 
Of the 20 standard amino acids, 15 are known to be modified totaling more 
than 200 different PTMs (Table 1). Modification of amino acids most often occurs by 
enzymatic reactions mediated by specialized proteins. There are a vast number of 
enzymes that modify the proteome, either adding or removing functional groups. 
These functional groups can be classified according to the cosubstrate or coenzyme 
they depend on, such as S-adenosylmethionine (SAM) for methylation, ATP for 
phosphorylation, and acetyl CoA for acetylation (Walsh et al, 2005). 
One essential characteristic of most amino acid modifications is reversibility, 
which brings plasticity to the proteome and allows rapid response to a specific 
stimulus. Many PTMs alter the structure of a given protein and consequently 
modulate the protein’s activity. For instance, phosphorylation of a conserved residue 
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within the activation loop of a kinase is a classical example of a covalent 
modification that rapidly switches protein activity on or off (Steichen et al, 2012). 
Likewise, the reversibility of PTMs also helps in the formation and dissociation of 
protein complexes. PTMs create a binding motif for specific domains, thus mediating 
protein interactions. Indeed, more than 60% of PTM sites contribute to protein-
protein interactions mediated by protein domains (Duan & Walther, 2015).  
1.2. Protein domains 
 
Protein domains correspond to functional, structural features of proteins that 
are evolutionarily conserved. Domains can be identified in silico by comparing 
protein sequences and/or predicted structures. According to the NCBI Conserved 
Domain Database (CDD), there are more than 1000 protein domains identified to 
date (Marchler-Bauer et al, 2015). 
Protein domains are discrete elements that fold and function independently 
from one another. It is common for proteins to contain multiple domains, the 
particular combination of domains within a protein is key for a protein’s biological 
function and its interaction within the global protein network. Yet, a particular domain 
can also have an independent function, and can cooperate with other domains in 
multi-domain proteins. 
Protein domains have a variety of functions, including recognition and binding 
to cellular molecules, such as DNA, RNA or other proteins (Figure 1). Many protein-
protein interactions are mediated by the recognition of a particular motif in one 
protein and a domain in another. A protein motif, like a protein domain, may be 
conserved in a large number of proteins, however, unlike a protein domain, it only 
consists of a short, specific amino-acid sequence. The interactions between protein 
domains and protein motifs are usually transient, and are frequently regulated by 
PTMs (Akiva et al, 2012).  
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Adapted from (Walsh et al, 2005)  
Residue Modification 
Asp phosphorylation isomerization to isoAsp 
Glu 
methylation 
carboxylation 
polyglycination 
polyglutamylation 
Ser 
phosphorylation 
O-glycosylation 
phosphopantetheinylation 
autocleavages 
Thr phosphorylation O-glycosylation 
Tyr 
phosphorylation 
sulfation 
ortho-nitration 
TOPA quinone 
His 
phosphorylation 
aminocarboxypropylation 
N-methylation 
Lys 
N-methylation 
N-acylation by acetyl, biotinyl, lipoyl, ubiquityl groups 
C-hydroxylation 
Cys 
S-hydroxylation (S-OH) 
disulfide bond formation 
phosphorylation 
S-acylation 
S-prenylation 
protein splicing 
Met oxidation to sulfoxide 
Arg N-methylation N-ADP-ribosylation 
Asn 
N-glycosylation 
N-ADP-ribosylation 
protein splicing 
Gln transglutamination 
Trp C-mannosylation 
Pro C-hydroxylation 
Gly C-hydroxylation N-myristoylation 
Table 1: Post-translational modification of amino acids. 
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Each domain family recognizes motifs with similar features. Some of the 
examples illustrated in Figure 1 include the acetylation or methylation of lysine 
residues, which creates a binding motif for bromo and chromo domains, 
respectively. Similarly, methyllysine and methylarginine residues can be recognized 
by tudor domains. These PTMs and their association with protein binding domains 
have gained increasing importance since scientists began to recognize that these 
PTMs play a key role in the epigenetic regulation of gene expression.  
 
1.3. Phosphorylation 
 
Phosphorylation was described over a half century ago and is the most 
commonly studied PTM. In eukaryotes, phosphorylation is the covalent attachment 
of a negatively charged phosphate group to an amino acid, mainly serine, threonine 
and tyrosine residues. Protein phosphorylation is highly dynamic: addition of 
phosphate groups is catalyzed by kinases, whereas removal of phosphate groups – 
dephosphorylation – is catalyzed by phosphatases. Both kinases and phosphatases 
regulate multiple cellular processes (Jin & Pawson, 2012). 
Phosphorylation is a potent regulatory mechanism. It can modify the function 
of proteins by inducing conformational changes. Phosphorylation may also control 
the subcellular location and stability of proteins. Additionally, it can alter the activity 
of proteins by mediating interactions between protein domains and phosphorylated 
ligands, resulting in phospho-dependent protein networks. Tyrosine phosphorylation 
is recognized by distinct binding domains, the Src homology 2 (SH2) and 
phosphotyrosine binding (PTB) domains. Serine and threonine phosphorylation 
generate docking sites for a number of domains such as forkhead-associated (FHA) 
domains, Polo-box domains (PBDs), WD40 repeats, WW domains, BRCT domains 
and 14-3-3 proteins. (Hunter, 2014). 
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1.4. Phosphotyrosine binding domains 
 
1.4.1. SH2 and PTB domains 
 
Phosphorylation of tyrosine residues creates a binding site for 
phosphotyrosine recognition domains such as such SH2 and PTB domains. SH2 
domains are present in more than a hundred distinct proteins (Liu et al, 2006), 
comprising the largest class of known phosphotyrosine-recognition domains. PTB 
domain are present in 79 human proteins; however, only a fraction of them have the 
capacity to recognize the phosphotyrosine-motif. The others recognize 
nonphosphorylated peptide ligands or phosphoinositides (Liu et al, 2006).  
The SH2 domain consists of about 100 amino acids organized into six beta-
sheets and two alpha-helices. The phosphopeptide binding site lies perpendicular to 
the central beta-sheets (Liu et al, 2006; Yaffe, 2002). The specificity of the SH2 
domain is given by the recognition of not only the phosphotyrosine but also the 
adjacent carboxy-terminal residues (Liu et al, 2006; Yaffe, 2002). 
SH2 domains play a critical role as adaptor proteins and signaling molecules 
downstream of receptor tyrosine kinase (RTK) activity, and protein-protein 
interactions (Yaffe, 2002). Several human diseases are associated with mutations in 
SH2-encoding genes (Liu et al, 2006), arising from either the loss- or the gain-of-
function of SH2. Additionally, developmental studies using knockout mouse models 
of SH2 proteins show a variety of phenotypes, ranging from early embryonic lethality 
to no visible abnormality. 
1.5. Phosphorylated serine and threonine binding domains 
 
Serine and threonine phosphorylation plays an important role in multiple 
cellular processes, either directly, by regulating the activity of enzymes, or indirectly, 
by promoting specific protein-protein interactions. 14-3-3 proteins were the first 
family of phosphoserine- or phosphothreonine- binding proteins to be discovered. 
xxx  
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Figure 1: Protein domains that recognize particular motifs 
Distinct domains, depicted with different colors and shapes are able to recognize 
specific motifs. Some domains recognize motifs that harbor PTMs, while others 
recognize distinct molecules such as DNA or RNA. ϕ, hydrophobic residue; p, 
phosphorylation; me, methylation; ac, acetylation; ub, ubiquitination; PIP, 
phosphoinositides. 
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Subsequently, other proteins have been identified as integral components of these 
phospho-binding domain networks. 
 
1.5.1. 14-3-3 proteins 
 
First identified as abundant brain proteins, 14-3-3 proteins are found in almost 
all human tissues, predominantly in the cytoplasm of cells (Uhlen et al, 2015). There 
are seven distinct 14-3-3 isoforms that are encoded by different genes, denoted α/β, 
γ, ε, η, σ, τ/θ, and ζ. They are small proteins of 28 to 33 KDa, forming homo- and 
heterodimers that resemble a horseshoe-shaped structure (Wilker et al, 2005). Each 
monomeric unit is formed by nine alpha helices. The dimerization interface is 
present at the N-terminal alpha helices. The central channel forms the binding 
groove, which is highly conserved across the different 14-3-3 isoforms (Xiao et al, 
1995; Yaffe et al, 1997). Each unit contains an independent binding groove; 
consequently, the dimer can interact with two motifs simultaneously (Uhart & Bustos, 
2013). 
14-3-3 proteins have two canonical consensus binding motifs RSXpSXP 
(Motif I) and RX[Y/F]XpSXP (Motif II) (Yaffe et al, 1997) as well as  a C-terminal 
binding motif p(S/T)X1−2-COOH (Motif III), in which an upstream arginine residue is 
frequently present, likely facilitating 14-3-3 interaction and kinase recognition 
(Coblitz et al, 2006; Ganguly et al, 2005). 
Phosphorylation on either serine or threonine is required for 14-3-3 binding. 
Accordingly, the 14-3-3-binding site has several common features with the optimal 
substrate sequences for many kinases, including protein kinase A (PKA), protein 
kinase G (PKG), protein kinase C (PKC), protein kinase B (PKB/Akt), Ca2+-
calmodulin-dependent kinase (CamK), serum- and glucocorticoid-induced kinase 
(SGK) family members, and the checkpoint effector kinases: Chk1, Chk2, and MK2 
(Kobayashi et al, 1999; Mohammad & Yaffe, 2009; Smith et al, 2011). 
Interestingly, motif III located at the extreme C-terminus of 14-3-3 ligands has 
a notable similarity with the PDZ binding motif. However, 14-3-3 interactions require 
phosphorylation, whereas PDZ binding does not.  
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Via its phospho-dependent binding groove, 14-3-3 proteins interact with 
hundreds of proteins implicated in cell cytoskeleton organization, cell cycle 
regulation, signal transduction, protein metabolism, protein synthesis, chromatin 
structure, protein folding, apoptosis, and several other cellular processes (Chen et 
al, 2010; Jin et al, 2004; Meek et al, 2004; Pozuelo Rubio et al, 2004). 
Mechanistically, 14-3-3 proteins regulate cellular processes by obstructing 
specific motifs, thus blocking protein-protein interactions; retaining proteins in the 
cytoplasm; regulating the catalytic activity of its bound ligand; linking enzymes and 
substrates; and preventing protein degradation (Morrison, 2009). 
 
1.5.2. FHA domains 
 
FHA domains are phospho-binding domains, commonly found in DNA repair-
associated proteins, and specifically recognize only phosphothreonine motifs. Based 
on sequence analysis, the FHA domain core homology region is about 55 to 75 
amino acids. However, based on structural analysis, the FHA domain extends to 
include 95 to 121 residues. Although FHA domains may have low sequence 
homology, structurally, they adopt a similar fold that consists of 11 beta strands. The 
phosphothreonine-binding region in a FHA domain includes the loops and turns 
between β3-β7 and β10-β11 strands (Mahajan et al, 2008). 
The binding motif of FHA domains consists of four different types: i)“pT+3 
rule”, in which the FHA domain recognizes phosphothreonine and the 3 adjacent C-
terminal residues pTXX(I/L/V), and favors a nonpolar residue at the pT+3 position; ii) 
The “N- and C-terminus to pT” encompasses amino acid residues both N-terminal 
and C-terminal to the phosphothreonine residue; iii) The “pT-pT+3” includes two 
phosphothreonine residues and the 3 C-terminal residues pTXXpTXXS; and iv) The 
“pT + an extended binding surface”, which is considerably different from the other 
FHA domain binding motifs, as the ligand interaction requires a longer binding 
surface (Mahajan et al, 2008). 
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1.5.3. BRCT domains 
 
The BRCT domain (breast cancer 1 (BRCA1) C-terminus) was originally 
identified as a tandem repeat on the C-terminus of BRCA1. BRCT domains are 
composed of 85–95 amino acids, and are arranged as either a single domain or 
multiple tandem domains, usually together with other domains in multidomain 
proteins (di Masi et al, 2011). BRCT motifs are arranged in a parallel four-stranded β 
sheet flanked on one side by α helices 1 and 3, and on the other side by α helix 2. 
BRCT domains have a binding preference for phosphoserine present in a pSXXF 
motif (Glover et al, 2004; Yu et al, 2003). 
In humans, at least 23 proteins harbor BRCT domains. BRCT mediated 
protein–protein interactions are essential for DNA replication and repair as well as 
cell cycle regulation (Gerloff et al, 2012; Glover et al, 2004). BRCT domain function 
is important for cell homeostasis since cancer susceptibility is linked to mutations 
found within the BRCT domains of BRCA1, Nijmegen breakage syndrome (NBS) 
protein and microcephalin (MCPH1) protein (Glover et al, 2004). 
 
1.6. Methylation 
 
In the mid-sixties, researchers anticipated the existence of at least two 
methyl-enzyme systems, one that methylates lysine and one that methylates 
arginine residues. With a visionary interpretation of their experimental results, these 
researchers suggested a possible role of methyltransferases during repression or 
derepression of gene expression (Paik & Kim, 1968). Methylation is a widespread 
post-translational modification affecting many cellular processes.  
In the case of lysine, this modification is mediated by lysine methyl 
transferases (KMT). KMTs possess an evolutionarily conserved catalytic domain 
named the SET domain. Lysine residues of both histones and non-histone proteins 
can be monomethylated, dimethylated and trimethylated. The addition of more than 
one methyl group can be catalyzed by a single enzyme or sequentially by different 
enzymes. Thus, each methylation status is regulated by the interplay of dedicated 
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KMTs (Boriack-Sjodin & Swinger, 2016). In contrast, arginine residues can be 
monomethylated and symmetrically- or asymmetrically-dimethylated. These 
reactions are catalyzed by enzymes called protein arginine methyl transferases 
(PRMTs) (Figure 2A) (Cheng et al, 2007).  
Until recently, it was unclear whether demethylation of methylarginine 
residues exists. However, a new detailed analysis indicates that this modification is 
reversible. The removal of arginine methylation occurs via oxidation of the arginine 
guanidino nitrogen-methyl groups and loss of formaldehyde in a reaction similar to 
that of lysine demethylation (Walport et al, 2016). Therefore, the methyl group of 
both lysine and arginine residues can be removed by specialized JmjC-domain 
containing enzymes, lysine demethylases (KDMs) and arginine demethylases 
(RDMs). 
Like other PTMs, methyl-arginine and -lysine generate binding motifs for 
specific protein domains. Lysine methylation creates a binding motif for chromo, 
chromo barrel, plant homeodomain (PHD), tudor, malignant brain tumor (MBT), 
PWWP, and bromo adjacent homology (BAH) domains, whereas methylated 
arginine is recognized only by tudor domains (Chao Xu, 2015; Kim et al, 2006; Kuo 
et al, 2012). 
The addition of methyl groups to arginine residues of histones and non-
histone proteins not only modulates transcription, but also many distinct cellular 
functions, such as signal transduction, mRNA splicing, DNA repair, and protein 
translocation (Bedford & Clarke, 2009). 
 
1.6.1 Arginine methylation 
 
Of the 20 amino acids, arginine has the longest side chain with the end of the 
side chain carrying a net positive charge. It has two potential hydrogen bond donors 
that promote interactions with negatively charged molecules, hydrogen bond 
acceptors, such as DNA, RNA and proteins (Lakowski & Frankel, 2009). The 
addition of a methyl group to arginine residues does not alter the total charge; 
xxxxxx  
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Figure 2: Arginine methylation is catalyzed by PRMTs 
(A) PRMT family members. Conserved catalytic core region containing the signature 
motifs I, post-I (PI), II, and III, and the conserved THW loop.  
(B) PRMT family members catalyze the formation of monomethylarginine (MMA), 
asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Type 
I catalyzes ADMA and is comprised by PRMT1, PRMT2, PRMT3, PRMT4/CARM1, 
PRMT6 and PRMT8. Type II enzymes mediate SDMA and include PRMT5 and 
PRMT9. In addition, type I and type II enzymes can catalyze the formation of MMA 
as an intermediate. PRMT7 is the only type III enzyme, which mainly generates 
MMA. Whether PRMT7 catalyzes SDMA is controversial. The main enzymes for 
each form of methylation are indicated. Adapted from Molecular Cell. Bedford MT, 
Clarke SG. Protein arginine methylation in mammals: who, what, and why. 33: 1-13 
(2009), with permission from Elsevier.  
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instead, it removes a potential hydrogen bond donor through replacement of the 
available hydrogen atoms by methyl groups (Raman et al, 2001).  
Methyl groups in terminal guanidino nitrogen atoms of arginine residues can be 
incorporated in three distinct forms: monomethylarginine (MMA) contains only one 
methyl group; symmetric dimethylated arginine (SDMA) contains two methyl groups 
placed on each of the terminal nitrogen atoms; and asymmetric dimethylarginine 
(ADMA) contains two methyl groups positioned on the same terminal nitrogen atom 
(Figure 2B). All three forms are created by PRMTs. 
 
1.6.2. Protein arginine methyltransferases 
 
PRMTs are classified according to the type of methylation they catalyze. 
Types I, II and III are all able to generate MMA, however, type III solely catalyzes 
MMA at the terminal nitrogen of arginine residues (Zurita-Lopez et al, 2012). Further 
methylation is carried out once more by type I enzymes (PRMT1, PRMT2, PRMT3, 
PRMT4/CARM1, PRMT6, and PRMT8) to generate ADMA, or by type II enzymes 
(PRMT5 and PRMT9) to generate SDMA. Of these, PRMT5 is the major enzyme 
that generates SDMA.  
Sequence analysis of all PRMTs shows a highly conserved catalytic core 
region containing the signature methyltransferase motifs I, post-I, II and III. Motif I 
mediates the binding of SAM and contains the double-E loop (two glutamate 
residues). The C-terminus of the core region harbors the most highly conserved 
sequence of this domain the THW (threonine-histidine-tryptophan) loop. These 
sequences arrange the methyltransferase active site in this family of enzymes 
(Figure 2A) (Bedford & Richard, 2005; Weiss et al, 2000; Zhang et al, 2000). 
The structure of the catalytic core is also highly conserved, as shown by the 
crystal structures of PRMT1, PRMT3, PRMT4 and PRMT5 (Antonysamy et al, 2012; 
Ho et al, 2013; Sun et al, 2011; Troffer-Charlier et al, 2007; Yue et al, 2007; Zhang 
et al, 2000).   
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1.6.3. Arginine Mono-methyltransferases 
 
PRMT7 harbors two AdoMet-binding motifs and is the only enzyme described 
as having primarily type III activity. PRMT7 substrates are also substrates for all of 
the other characterized PRMTs (PRMT1, -2, -3, -4, -5, -6 and -8), including histone 
substrates (Zurita-Lopez et al, 2012). This correlates with the notion that 
monomethylarginine is the precursor for subsequent methylation by type I and II 
PRMTs (Dhar et al, 2013).  
 
1.6.4. Arginine Asymmetric-methyltransferases 
 
ADMA is the predominant type of arginine methylation, and is mediated by 
type I enzymes, largely PRMT1 (Tang et al, 2000). In the absence of PRMT1 and 
the consequent reduction of ADMA, an increase of SDMA and MMA marks was 
observed, indicating that the pre-existence of the ADMA mark can block the 
formation of SDMA and MMA marks on the same substrate (Dhar et al, 2013). 
PRMT1 substrates harbor a conserved glycine- and arginine-rich (GAR) motif (Lee & 
Bedford, 2002; Tang et al, 2000). Mouse embryos lacking PRMT1 die shortly after 
implantation and before gastrulation (Pawlak et al, 2000). PRMT1 is predominantly 
nuclear, and is involved in transcription activation, presumably by mediating the 
methylation of several transcription factors, cofactors, and histone H4 on arginine 3 
(H4R3). 
PRMT2 was identified by its homology with PRMT1 (Katsanis et al, 1997; 
Scott et al, 1998) and is the only PRMT containing a Src homology 3 (SH3) domain. 
PRMT2 binds to estrogen receptor α (ERα) and the androgen receptor (AR), 
enhancing ERα and AR-mediated transcription (Meyer et al, 2007; Qi et al, 2002). 
PRMT2 has been classified as a type I enzyme, although its activity is low in 
comparison with other PRMTs, and its optimal substrate is still unknown. However, it 
has been shown to have weak activity towards histones and proteins containing 
GAR motifs (Lakowski & Frankel, 2009). This weak activity correlates with the lack of 
phenotype associated with PRMT2 null mice living under normal physiological 
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conditions (Yoshimoto et al, 2006). This lack of phenotype could be explained by the 
loss of PRMT2 being compensated by other PRMTs.  
Like PRMT2, PRMT3 was discovered based on its sequence similarity to 
PRMT1. The catalytic regions of the two proteins are highly similar, however, the 
PRMT3 N-terminus contains a zinc-finger domain, which is responsible for its 
substrate specificity (Frankel & Clarke, 2000; Tang et al, 1998). Ribosomal protein 
RPS2 interacts with the zinc finger of PRMT3 and thus mediates methylation of its 
N-terminal GAR motif, making RPS2 an optimal substrate for PRMT3 (Swiercz et al, 
2005). Indeed, RPS2 methylation is decreased by 80% in Prmt3–/– MEFs (Swiercz et 
al, 2007). In contrast to PRMT1, PRMT3 is predominantly cytoplasmic (Tang et al, 
1998), consistent with its role in association with ribosomal proteins. Prmt3 deficient 
embryos are smaller than wild-type embryos; however, no size differences are 
observed between mutants and wild-types at weaning age (Swiercz et al, 2007). 
Another type I family member is co-activator-associated arginine 
methyltransferase 1 (CARM1). CARM1, also known as PRMT4, not only functions 
as a methyl transferase but also enhances transcriptional activation by binding to 
nuclear hormone receptor (NR) co-activators (Stallcup et al, 2000). CARM1 
substrates, unlike PRMT1 substrates, lack GAR motifs. Recent studies indicate that 
CARM1 methylates arginine residues within proline and glycine-rich (PGM) motifs 
(Gayatri et al, 2016). CARM1 substrates include TARPP, PABP1, CA150, H3R17 
and H3R26 (An et al, 2004; Bauer et al, 2002; Chen et al, 1999; Cheng et al, 2007; 
Lee & Bedford, 2002). Knock-out experiments showed that E12.5 CARM1 null mice 
are smaller than wild-type and die just after birth (Yadav et al, 2003). The lethality is 
driven by the lack of CARM1 enzymatic activity as catalytically-dead knock-in 
CARM1 mice phenocopy the null mouse phenotype (Kim et al, 2010). 
PRMT6, like PRMT1, is mainly localized to the nucleus and methylates GAR 
motifs (Frankel et al, 2002). An early characterization of PRMT6 identified it as a 
repressor of transcription, mainly because that study indicated that PRMT6 
predominantly methylated histone H3 arginine 2. Methylation of H3R2 prevents the 
formation of H3K4 trimethylation, which is correlated with activation of transcription 
(Guccione et al, 2007; Hyllus et al, 2007; Iberg et al, 2008). Additionally, PRMT6 
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catalyzes R11 and R29 methylation sites in H2A, and H2AR29me2 is specifically 
enriched at genes repressed by PRMT6 (Waldmann et al, 2011). However, PRMT6 
activity could be regulating transcription via other arginine residues on histone H2A 
and H4 (Hyllus et al, 2007).  
PRMT8 is the family member most closely related to PRMT1. It harbors a 
myristoylation motif on its distinctive N-terminal region. PRMT8 distribution is largely 
limited to the brain. More specifically, it is localized to the plasma membrane by N-
terminal myristoylation (Lee et al, 2005a). The N-terminus may also provide an 
autoregulatory function to this enzyme (Sayegh et al, 2007). 
 
1.6.5. Arginine Symmetric-methyltransferases 
 
 PRMT9 and PRMT5 have symmetric methyl transferase activity 
(Hadjikyriacou et al, 2015; Lee et al, 2005b). Almost two decades ago, PRMT5 was 
described as a 72 KDa protein interacting with the chloride conductance regulatory 
protein (pLCln) (Krapivinsky et al, 1998). Pollack et al, described PRMT5 as a Jak2 
binding protein, characterized its biochemical function as a methyltransferase, and 
identified three of its substrates: histone H2A, histone H4 and myelin basic protein 
(MBP) (Pollack et al, 1999). Further biochemical characterization, carried out by the 
Clarke group, showed that PRMT5 catalyzes the formation of SDMA, thus identifying 
the first enzyme of this type (Branscombe et al, 2001). Four years later, Lee et al. 
identified a second symmetric dimethyltransferase, PRMT7 (Lee et al, 2005b). 
Recently, PRMT9 has also been identified as catalyzing SDMA (Hadjikyriacou et al, 
2015). It is important to note that PRMT5 is the major enzyme responsible for the 
SDMA of a diverse number of proteins, (Hadjikyriacou et al, 2015) and its biological 
function is essential; loss of PRMT5 function causes early embryonic lethality (Tee 
et al, 2010). PRMT5 protein is conserved from yeast to humans (Boulanger et al, 
2004; Hung & Li, 2004; Krapivinsky et al, 1998; Lee et al, 2000), suggesting that 
PRMT5 has a pivotal role that has been preserved throughout speciation.  
PRMT5 functions as part of a multimeric complex, engaged with a variety of 
partner proteins that regulate its activity and specificity. The major binding partner of 
	  17	  
PRMT5 is MEP50. The structure of the PRMT5-MEP50 complex has been studied 
independently by two groups, revealing consistent results (Antonysamy et al, 2012; 
Ho et al, 2013). The PRMT5-MEP50 interface forms between the N-terminal domain 
of PRMT5 and the second and third of the seven β-propeller blades of MEP50. Four 
PRMT5-MEP50 heterodimers form an octameric complex whose surface is 
negatively charged, a convenient feature for recognition of positively-charged 
substrates, such as the canonical GAR motifs (Antonysamy et al, 2012; Ho et al, 
2013). 
 
1.7. Multiple roles of PRMT5 
 
1.7.1. PRMT5 in mRNA splicing 
 
 The diversity of the cell proteome is greatly increased by alternative splicing; 
however, improper functioning of proteins involved in RNA processing is linked to 
neurodegenerative disorders such as spinal muscular atrophy (Zhang et al, 2008). 
PRMT5 plays a crucial role in mRNA processes. It methylates multiple members of 
the splicing machinery, including fibrillarin, which is a protein that methylates RNA. 
The engagement of PRMT5 with a fibrillarin-associated subcomplex may be 
coordinating the methylation of both RNA and protein substrates during mRNA 
processing in Cajal bodies (Yanagida et al, 2004). Additionally, PRMT5-MEP50 
mediates the methylation of substrates within the methylosome, such as Sm proteins 
D1 and D3, thus promoting their interaction with the survival motor neuron (SMN) 
complex and its assembly into the pre-mRNA splicing core (Friesen et al, 2001; 
Friesen et al, 2002; Meister et al, 2001; Meister & Fischer, 2002). Absence of 
PRMT5 triggers defects in the core splicing machinery, causing the generation of 
unstable products. In particular, alternatively spliced Mdm4 acts as a sensor of 
splicing defects. Normally MDM4 inhibits p53 activity, however, abnormal splicing 
results in unstable Mdm4 transcripts, leading to a reduction in MDM4 protein levels, 
thus activating the p53 signaling pathway (Bezzi et al, 2013). 
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1.7.2. PRMT5 in transcriptional regulation 
 
PRMT5 plays an important role in transcription. By chromatin 
immunoprecipitation (ChIP) experiments, it was shown that association of PRMT5 at 
the transcription start site of the Cyclin E1 gene represses its expression, providing 
the first evidence that PRMT5 is involved in transcription regulation and proliferation 
(Fabbrizio et al, 2002). In addition, PRMT5 was found in two chromatin-remodeler 
complexes involved in gene silencing, hSWI/SNF and mSin3A/HDAC2 (Pal et al, 
2003). hSWI/SNF-associated PRMT5 targets histones H3R8 and H4R3 as 
substrates for symmetric dimethylation. Using microarray analysis, it was found that 
PRMT5 represses a number of genes, among them suppressor of tumorigenicity 7 
(ST7) and nonmetastatic 23 (NM23), thus indicating the involvement of PRMT5 in 
cell growth and proliferation (Pal et al, 2004).  
Although PRMT5 is mainly associated with transcriptional repression by 
selectively methylating histones H2AR3, H4R3, and H3R8 (Pal et al, 2004), new 
data indicate that it may function as an activator as well. Histone H3R2 is 
monomethylated and symmetrically dimethylated by PRMT5, promoting the binding 
of WDR5, a component of coactivator complexes (Chen et al, 2016a; Migliori et al, 
2012).  
 
1.7.3. Association of PRMT5 and CpG methylation 
 
Symmetric dimethylation of histone H4R3, mediated by PRMT5, creates a 
docking site for the DNA methyltransferase DNMT3, well know for its ability to 
repress transcription (Rank et al, 2010; Zhao et al, 2009). In addition, PRMT5 
interacts with and methylates MBD2, a protein that binds methylated DNA (Le 
Guezennec et al, 2006; Tan & Nakielny, 2006). MBD2 can be symmetrically and 
asymmetrically dimethylated. High levels of methylation reduce the affinity of MBD2 
for methylated DNA, suggesting that methylation of MBD2 inhibits its function as a 
transcriptional repressor (Tan & Nakielny, 2006). Thus, PRMT5 fine-tunes 
transcription via its interactions with different protein complexes. 
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1.7.4. Role of PRMT5 in development 
 
PRMT5 is essential for development. PRMT5 RNA is maternally loaded and 
is degraded as the blastula stage progresses, but is synthesized de novo in the 
developing embryo by the 16-cell and blastocyst stages (McGraw et al, 2007). 
During preimplantation and in primordial germ cells, PRMT5 helps defend the 
genome during global DNA demethylation, which leaves cells vulnerable to the 
activation of transposable elements (TE). Enrichment of the PRMT5 mediated 
methylation of H2A/H4R3 might have a specific role in the repression of TE (Kim et 
al, 2014). 
The absence of PRMT5 results in early embryonic lethality (Tee et al, 2010). 
To overcome the early embryonic lethality of Prmt5 knockout mouse model, new 
investigations made use of a conditional deletion allele of Prmt5. Prmt5 inducible 
germline-specific knockout mice showed that PRMT5 is required in primordial germ 
cell development and survival between E10.5 and E13.5 (Li et al, 2015). Inactivation 
of PRMT5 in adult skeletal muscle stem cells resulted in a severe loss of muscle 
volume, indicating that PRMT5 is required for muscle regeneration (Zhang et al, 
2015). Targeted deletion of Prmt5 in the central nervous system resulted in mouse 
lethality 14 days after birth (Bezzi et al, 2013), and a conditional deletion of Prmt5 in 
adult hematopoietic stem cells caused severe anemia, and mice were moribund 
shortly after PRMT5 loss (Liu et al, 2015). 
 
 
1.7.5. Role of PRMT5 in cancer 
 
PRMT5 expression is elevated in many cancers including gastric cancer, 
gliomas, lymphoma, and epithelial ovarian cancer (Bao et al, 2013; Han et al, 2014; 
Kanda et al, 2016; Pal et al, 2007), and correlates with tumor growth, invasion and 
migration, and consequently with poor prognosis. One of the factors that may 
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contribute to the overexpression of PRMT5 is the nuclear transcription factor Y (NF-
Y), which causes the elevated expression of oncogenes in many cancers. NF-Y 
binds to two inverted CCAAT boxes present in the proximal promoter of PRMT5 
(Zhang et al, 2014). Furthermore, the proto-oncogene Myc upregulates the 
transcription of PRMT5 and the core small nuclear ribonucleoprotein, both of which 
are key regulatory elements of pre-messenger-RNA splicing. Absence of Myc results 
in a partial reduction of PRMT5, thereby causing aberrant splicing, increases in 
apoptosis and reduced tumorigenic potential in hematopoietic malignancies (Koh et 
al, 2015). 
PRMT5 can exert its oncogenic effect directly via methylation of a particular 
substrate, or indirectly as a transcriptional regulator. For example, PRMT5 
methylates the tumor suppressor programmed cell death 4 (PDCD4) protein at 
R110, altering its function. Coexpression of PRMT5 and PDCD4 reverses the tumor 
suppressive properties of PDCD4 in an orthotopic model of breast cancer. These 
observations were consistent with the poor outcome of a cohort of breast cancer 
patients displaying elevated expression of PRMT5 and PDCD4 (Powers et al, 2011).  
Additionally, methylation of Sm proteins by PRMT5 controls the splicing 
machinery and maintains splicing fidelity in several genes associated with cell 
proliferation (Koh et al, 2015; Lacquet, 1985). As a transcriptional regulator, the roles 
of PRMT5 have been extensively studied in the last few years. Transcriptional 
regulation mediated by PRMT5 enhances malignant phenotypes in many cancers 
such as lung adenocarcinoma, lung squamous cell carcinoma, breast carcinoma, 
acute myeloid leukemia and nasopharyngeal carcinoma (Chen et al, 2016a; Tarighat 
et al, 2016; Yang et al, 2016). 
Several studies have placed PRMT5 not only as a potential prognostic 
marker, but also as a therapeutic target. Inhibition of PRMT5 may aid in the 
treatment of many cancers, such as MTAP/CDKN2A-deleted tumors, MYCN 
oncogene driven neuroblastoma, and glioblastoma (Kryukov et al, 2016; Mavrakis et 
al, 2016; Park et al, 2015; Yan et al, 2014). Recently, a potent inhibitor of PRMT5, 
EPZ015666, has demonstrated dose-dependent antitumor activity in mantle cell 
lymphoma (MCL) xenograft models (Chan-Penebre et al, 2015). Additionally, 
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another PRMT5 inhibitor, GSK591/EPZ015866, has been recently studied in cancer 
and normal cells. In the A549 human lung adenocarcinoma epithelial cell line, 
GSK591/EPZ015866 treatment abrogated cell migration and cell invasion, but did 
not effect normal IMR90 fetal lung fibroblasts (Chen et al, 2016a). Moreover, these 
PRMT5 inhibitors not only promise to become a potential therapeutic drug, but also 
valuable probes for investigating the biological functions of PRMT5. 
 
1.8. Regulation of PRMT5 activity 
 
1.8.1. Regulation of PRMT5 by binding partners 
 
Early studies indicated that the formation of multimers activates PRMT5 
catalytic function toward MBP (Lim et al, 2005). Today, it is well known that MEP50 
is the major binding partner of PRMT5 and together they form an octameric 
complex. The PRMT5-MEP50 complex promotes histone methylation; however, 
nucleosomes are not a substrate for PRMT5-MEP50 (Burgos et al, 2015). Other 
PRMT5 protein cofactors, such as Blimp1 (Ancelin et al, 2006), COPR5 (Lacroix et 
al, 2008), Menin/Men1 (Gurung et al, 2013), and the hSWI/SNF chromatin 
remodeling complex (Pal et al, 2004), may trigger methylation activity toward 
nucleosomes. Also, other components of hSWI-SNF complexes, such as BRD7 
interacts with PRMT5 and colocalizes with PRC2 on the promoter of ST7 and 
retinoblastoma-like protein 2 (RBL2) (Tae et al, 2011). In addition, it was shown that 
Schwann cell factor 1 (SC1) recruits PRMT5 to mediate symmetric dimethylation of 
histone H4R3 (Chittka et al, 2012). 
The transcription repressor protein Blimp1 associates with PRMT5 and 
regulates its methyltransferase activity in a time- and stage-dependent manner. In 
mouse primordial germ cells (E8.5), PRMT5-Blimp1 is localized to the nucleus, and 
is correlated with high levels of H2A/H4R3 methylation; however, by E11.5 PRMT5-
Blimp1 translocates to the cytoplasm and levels of H2A/H4 R3 methylation decrease 
(Ancelin et al, 2006). 
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RioK1 and plCln interact with PRMT5 in a similar manner, but have distinct 
outcomes. The association of RioK1 or plCln with the PRMT5-MEP50 complex is 
mutually exclusive and directs PRMT5 substrate specificity. Whereas PRMT5-
MEP50-RioK1 targets nucleolin, PRMT5-MEP50-plCln targets Sm proteins 
(Guderian et al, 2011). The plCln mediated methylation of Sm proteins is inhibited by 
the interaction of PRMT5 with DAL-1/4.1B (Jiang et al, 2005).  
 
1.8.2. Existing PTMs on histones regulate PRMT5 association and specificity 
 
At the chromatin level, pre-existing acetyl marks modulate arginine 
methylation on histones. H4K5ac facilitates symmetrical dimethylation of H4R3. In 
contrast, H4K16ac weakens the binding affinity of PRMT5 to H4. Interestingly, 
H4K5ac together with H4K8ac and/or H4K12ac decreases the asymmetric 
dimethylation of H4R3; Conversely, H4K16ac alone or in combination with H4K5ac 
or H4K8ac increases it (Feng et al, 2011). This indicates that acetylation coordinates 
the type of arginine methylation deposited on the histones, by making histones a 
more suitable substrate either for PRMT5 or PRMT1. In addition, histone H2AS1 and 
H4S1 phosphorylation may sterically block the arginine residues of histone H2A/H4 
tail region, thus preventing PRMT5-mediated methylation (Stopa et al, 2015). 
 
 
1.8.3. Cellular localization 
 
PRMT5 is predominantly cytoplasmic, but is also found in the nucleus. The 
ratio of cytoplasmic to nuclear PRMT5 varies depending on the cell type. 
Cytoplasmic or nuclear localization of PRMT5 results in distinct functionalities and 
outcomes. In zygotes and two-cell-stage embryos, PRMT5 is cytoplasmatic, but from 
the four- to eight-cell stage until the early E3.5 blastocyst stage, PRMT5 is nuclear. 
Thereafter, PRMT5 is mostly cytoplasmic. Notably, the nuclear localization of 
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PRMT5 coincides with an enrichment of H2A/H4R3me2s in the nucleus (Kim et al, 
2014). 
PRMT5-MEP50 cellular localization changes according to cell type (Liang et 
al, 2007). In fetal germ cells, PRMT5-MEP50 is cytoplasmic, whereas in Leydig cells 
and in adult non-neoplastic testes, it is nuclear. However in human seminoma and 
Leydig tumor cells, MEP50-PRMT5 shows an increased cytoplasmic localization, 
indicating a particular role within the subcellular localization of this complex (Liang et 
al, 2007). In lung adenocarcinoma, cytoplasmic localization of PRMT5 correlates 
with poor prognosis, but strong nuclear localization was frequently identified in low-
grade adenocarcinomas (Ibrahim et al, 2014). Likewise, in non-small cell lung 
carcinomas and pulmonary neuroendocrine tumors, cytoplasmic PRMT5 was 
associated with poorly differentiated tumors, whereas nuclear PRMT5 expression 
was frequently observed in well-differentiated tumors (Shilo et al, 2013). Finally, in 
prostate cells, cytoplasmic PRMT5 promotes cancer cell growth, whereas nuclear 
PRMT5 inhibits cell growth (Gu et al, 2012).  
These data indicate that the function of PRMT5 is altered by its localization 
and plays an important role in cancer. However, these differences may be cell type 
dependent and regulated by factors that are yet to be identified. Among other 
mechanisms, PTMs or interaction with other proteins may regulate its localization 
and substrate choice. Further studies are necessary to determine the mechanism of 
PRMT5 localization as this may lead to a more robust understanding of the 
oncogenic role of PRMT5. 
 
1.8.4. Crosstalk between phosphorylation and methylation 
 
Recent studies indicate possible connections between the methylation and 
phosphorylation status of proteins. Methylation may influence the phosphorylation of 
nearby residues. Such is the case for the sterol regulatory element-binding protein 
(SREBP) and apoptosis signal–regulating kinase 1 (ASK1), both substrates of 
PRMT5. When symmetrically dimethylated, SREBP (R321me2s), prevents S430 
phosphorylation by GSK3, thus stabilizing SREBP and promoting the growth of 
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cancer cells in vivo and in vitro (Liu et al, 2016). There are other examples where 
methylation occurs near phosphorylation sites. For example, PRMT5 also interacts 
with and methylates ASK1 (R89). ASK1 methylation promotes its interaction with 
Akt, which then phosphorylates ASK1 on S83, thereby inhibiting its apoptotic 
function (Chen et al, 2016b). 
Additionally, PRMT5 may influence cell signaling and differentiation. 
Experimental work by two independent groups revealed that methylation plays an 
important role in signaling through the ERK1/2 pathway. Indeed, PRMT5 methylates 
the transmembrane cell-surface receptor tyrosine kinase EGFR at R1175, which 
induces phosphorylation at Y1173. pY1173 serves as a docking site for SH2-
domain-containing protein tyrosine phosphatase 1 (SHP1). The interaction of EGFR 
with SHP1 results in attenuation of EGFR-dependent ERK activation. Therefore, 
methylation of EGFR suppresses ERK activation. Moreover, PRMT5 affects MAPK 
signaling cascades by methylating RAF proteins. PRMT5-dependent methylation 
enhances the degradation of CRAF and BRAF, consequently decreasing activation 
of downstream kinases including MEK1/2 and ERK1/2. Methylation of RAF proteins 
by PRMT5 results in hypo-phosphorylation of ERK1/2, which in turn culminates in 
cell proliferation. Interestingly, inhibition of methylation leads to augmentation of 
ERK1/2 phosphorylation and switches the biological effect from proliferation to 
differentiation (Andreu-Perez et al, 2011; Hsu et al, 2011). 
Lastly, PRMT5 itself can be phosphorylated. PRMT5 has been shown to be 
phosphorylated at three tyrosine sites, which affects its binding with MEP50, its main 
co-activator, consequently reducing PRMT5 enzymatic activity (Liu et al, 2011). 
Tyrosine phosphorylation of PRMT5 will be addressed in more detail in Chapter 3. 
 
1.9. Topics to be covered for this study 	  
This study is based on the hypothesis that phosphorylation of PRMT5 
regulates its subcellular localization and/or substrate choice, by facilitating phospho-
dependent protein-protein interactions. The topics to be covered will include: (1) The 
identification of phosphodependent-interacting proteins and data showing that 
	  25	  
phosphorylation of PRMT5 mediates its interaction with several SH2-domain 
containing proteins, 14-3-3 proteins and the FHA domain of MDC1. (2) The 
delineation of mechanisms underlying 14-3-3 and PDZ C-terminal motif recognition. 
We showed that the C-terminal region of PRMT5 has a recognition motif shared by 
PDZ domains and 14-3-3 proteins. 14-3-3 protein interaction requires a 
phosphorylated residue at the C-terminus, while PDZ domain recognition occurs 
when the C-terminus is unphosphorylated. (3) The examination of the interaction of 
the PRMT5 with the PDZ domain of NHERF2 and its functional consequences. The 
rationale is that membrane-associated NHERF2 binding to the PRMT5 C-terminal 
region, positions PRMT5 near the cell membrane. We also investigate the effect of 
PRMT5 on ion exchanger activity. These studies will provide better understanding of 
the cell biology of PRMT5 and provide mechanistic insights into regulation of its 
function. 
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Chapter 2: Material and Methods 
 
2.1. Plasmid constructs 
2.1.1. Mammalian expression vectors 
All expression constructs containing PRMT5 are derivatives of human wild-
type cDNA. The Myc-PRMT5 construct was cloned into the pVAK vector containing 
an N-terminal myc epitope tag (EQKLISEEDL). EcoRI sites flank PRMT5 
sequences. PRMT5, Myc-PRMT5T634, and Myc-PRMT5Δ were generated by 
mutagenesis using the QuikChange site-directed mutagenesis kit according to the 
manufacturer's protocol (Agilent). Primers were generated harboring the desired 
mutation, the presence of the desired mutation was verified by sequencing.  
List of primers used for mutagenesis: 
PRMT5 Y280A#1: 5’-AGA GAA GGA GTT CTG CTC CGC CCT CCA ATA CCT 
GGA ATA C-3’ 
PRMT5 Y280A#2: 5’-GTA TTC CAG GTA TTG GAG GGC GGA GCA GAA CTC 
CTT CTC T-3’ 
PRMT5 Y283A#1: 5’-AGG AGT TCT GCT CCT ACC TCC AAG CCC TGG AAT ACT 
TAA GC-3’ 
PRMT5 Y283A#2: 5’-GCT TAA GTA TTC CAG GGC TTG GAG GTA GGA GCA 
GAA CTC CT-3’ 
PRMT5 Y286A#1: 5’-CTA CCT CCA ATA CCT GGA AGC CTT AAG CCA GAA 
CCG TCC T-3’ 
PRMT5 Y286A#2: 5’-AGG ACG GTT CTG GCT TAA GGC TTC CAG GTA TTG 
GAG GTA G-3’ 
PRMT5 Y283A-Y286A#1: 5’-TCT GCT CCG CCC TCC AAG CCC TGG AAG CCT 
TAA GCC AGA ACC GTC-3’ 
PRMT5 Y283A-Y286A#2: 5’-GAC GGT TCT GGC TTA AGG CTT CCA GGG CTT 
GGA GGG CGG AGC AGA-3’ 
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PRMT5 Delta276-309#1: 5’-CAA CCA CCA CTC AGA GAA AGG ATC CCC GCT 
TCA-3’ 
PRMT5 Delta276-309#2: 5’-TGA AGC GGG GAT CCT TTC TCT GAG TGG TGG 
TTG-3’ 
PRMT5 T634A#1: 5’-CCACAGGCCGCTCATATGCCATTGGCCTCTA-3’ 
PRMT5 T634A#2: 5’-TAGAGGCCAATGGCATATGAGCGGCCTGTGG-3’ 
PRMT5 Δ#1: 5’-ATAACCCCACAGGCCGCTGACATATACCATTGG-3’ 
PRMT5 Δ#2: 5’-CCAATGGTATATGTCAGCGGCCTGTGGGGTTAT-3’ 
GFP-PRMT5: cDNA fragments encoding PRMT5 amino acids 340 to 637 
were cloned into the EcoRI site of pEGFP-C1 (Clontech). GFP-PRMT5T634A was 
created using site-directed mutagenesis using the primers described above. 
pBabe-Myc-PRMT5 constructs were generated by PCR using pVAK-PRMT5 
as template, including the Myc-tag. Fragments were subcloned into the BamHI site 
of the pBabe-hygromycin vector. 
For expression of PRMT5 in PRMT5-KD cells, we generated shRNA resistant 
PRMT5 constructs by mutating the shRNA target sequence without changing the 
amino acid sequence. Primers were generated harboring silent point mutation for the 
shRNA target sequence KD4. An EcoRI restriction site was created to screen for the 
desired mutation. 
PRMT5 KD4r#1:  
5’-TGTCTTCCATCCGCGGTTTAAACGAGAATTCATTCAGGAACCTGC-3’ 
PRMT5 KD4r#2:  
5’-GCAGGTTCCTGAATGAATTCTCGTTTAAACCGCGGATGGAAGACA-3’ 
The mouse Myc-PRMT5 constructs were generated by PCR using cDNA 
template extracted from a heterozygous female PRMT5 Δ+HA mouse. An N-terminal 
myc-tag was inserted in PRMT5WT and PRMT5Δ+HA and then cloned into pLOC 
(Thermo Scientific) using BamHI and NheI sites. Myr-Akt delta4-129 was obtained 
from Addgene (plasmid # 10841) (Kohn et al, 1996). 
2.1.2. Bacterial expression vector 
The constructs pDEST15-SH2 domains were a kind gift from Dr. Shawn Li 
from Western University. 
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The PDZ domain array content was selected considering the biophysical 
interactions described by Stiffler et al, 2007. The protein content is listed in Appendix 
B. 14-3-3 proteins encoded the full-length sequence. cDNAs that contained the 
codon-optimized sequence for expression in bacteria were synthesized by Biomatik 
with flanking BamHI and XhoI restriction sites, used for cloning into pGEX 6P-1. 
Human NHERF2 constructs were amplified by PCR and cloned into pGEX 6p-1 
using BamHI and EcoRI. The plasmid named NHERF2 PDZ FL encodes full-length 
NHERF2, whereas NHERF2-PDZ 1 encodes amino acids 1 to 152, and NHERF2-
PDZ 2 encodes amino acids 107 to 337. 
 
2.3. shRNA knockdown 
HeLa PRMT5 stable knockdown cell lines and shRNAs for PRMT5 were a 
kind gift from Dr. Sharon Dent, MD Anderson Cancer Center. The lentivirus based 
PRMT5 shRNA targeting codons were CCAGTTTGAGATGCCTT (KD2) and 
GTTTCAAGAGGGAGTTC (KD4). SK-CO15 PRMT5 stable knockdown cell lines 
were generated using pLKO.1-shPRMT5.  HEK 293T cells were co-transfected with 
pLKO.1 shPRMT5-KD2 or –KD4 along with pMD2.G and psPAX2 (viral envelope 
and packaging plasmids) using Lipofectamine 2000. After 48 hours, viral 
supernatants were harvested and filtered through a 0.45-µm pore filter. SK-CO15 
cells were infected with viral supernatants with the addition of 8 µg/ml polybrene 
(Sigma-Aldrich). Clones stably expressing the shRNAs were selected with medium 
containing 5 µg/ml puromycin. Empty vector control cells lines were generated by 
infecting with pLKO.1 and selecting for puromycin resistence. SK-CO15 cell were a 
gift from Dr. Rodriguez-Boulan, Weil Cornell Medical College. 
 
2.4. Protein purification 
GST fusion proteins were purified following standard methods. Briefly, protein 
was expressed in BL21 cells for 4 h at 37°C with 0.1 mM isopropyl-β-d-
thiogalactopyranoside (IPTG). For SH2 containing constructs, BL21-AI cells were 
induced with 0.2 % L-arabinose and 0.1 mM IPTG for protein expression. Cells were 
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resuspended in PBS buffer, then lysed by sonication (30% amplitude) for 10 sec. 
Lysates were cleared by centrifugation and incubated with Glutathione Sepharose 
4B resin at 4°C with tumbling (GE Life Science). Subsequently, Sepharose-
immobilized GST-tagged proteins were washed with PBS and eluted with Elution 
Buffer (100 mM Tris HCl pH8.0; 120 mM NaCl and 40 mM reduced glutathione). 
 
2.5. GST pulldown studies 
GST-tagged proteins (~10 µg) were incubated with cell lysates (from one 
confluent 10 cm dish, lysed with 1 ml of mild buffer [50 mM Tris-HCl, pH 7.5, 150 
mM NaCl, 0.1% Nonidet P-40 (NP-40), 5mM EDTA, 5 mM EGTA, 15 mM MgCl2 and 
Proteinase inhibitor cocktail (Roche)] for 2 h at 4°C with tumbling in a final volume of 
1 ml. Equilibrated Glutathione Sepharose 4B resin was then added for an additional 
1 h with tumbling. Samples were washed 4 times with mild lysis buffer prior to 
elution, SDS-PAGE, and Western blotting.  
 
2.6. Cell culture 
MCF7, U2OS, Src-deficient MEF (SYF-/-) (ATCC CRL-2459) and MEF-Src+/+ 
(ATCC CRL-2498) cells were cultured in high glucose Dulbecco’s modified Eagle’s 
medium (DMEM, Sigma) containing 1X PenStrep (Gibco), 1X MEM non-essential 
amino acids (Gibco), and 10% newborn calf serum (NCS) under standard conditions 
(37°C and 5% CO2). 
HeLa and SK-CO15 cells, were cultured in high glucose Dulbecco’s modified 
Eagle’s medium (DMEM, Sigma) supplemented with 1X PenStrep (Gibco), 1X MEM 
non-essential amino acids (Gibco), 15 mM HEPES, and 10% heat-inactivated fetal 
bovine serum (FBS), under standard conditions (37°C and 5% CO2).  
 
2.7. Immortalization and culture of MEFs 
The inducible PRMT5 KO MEF cell line was generated from primary MEFs 
derived from a conditional knockout mouse harboring LoxP (F/F) sequences flanking 
exon 7 of the Prmt5 gene and expressing tamoxifen-inducible Cre (kind gift from Dr. 
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Ernesto Guccione, Institute of Molecular and Cell Biology, A*STAR Singapore). 
Immortalized MEFs were created according to the standard 3T3 protocol. Cells were 
grown in DMEM containing 10% FBS. Immortalized cells were treated every 3 days 
with 2 µM 4-hydroxy tamoxifen for 21 days.   
 
2.8. Transient transfection 
Cells were transfected with various mammalian expression constructs using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to manufacturer's 
specification. Cells were transfected overnight and harvested the following day for 
analysis. 
 
2.9. Stable transfection 
The pBABE-hygromycin retroviral constructs were transfected with FuGENE 
into the Phoenix-Eco packaging cell line. Forty-eight hours later, the supernatant 
was harvested and filtered through a 0.45-µm filter. SK-CO15 PRMT5 KD cells were 
incubated with filtered transducing supernatant and 8 µg/ml polybrene (Sigma). 
Clones stably expressing the pBabe-Myc-PRMT5 constructs were selected with 
medium containing 1 mg/ml hygromycin. 
 
2.10. In cell phosphorylation 
For induction of threonine phosphorylation, SK-CO15 cells were transiently 
transfected with either GFP-PRMT5 or GFP-PRMT5T634A and treated with one of the 
following: 30 µM forskolin (CST) for 30 min; 1 nM angiotensin II (Sigma) for 45 min; 
1 µM dexamethasone (Sigma) for 24 hrs; or overexpression of constitutive active 
myr-AKT. All treatments were followed by a 10 min 0.05 µM Calyculin A treatment. 
Samples were immunoprecipitated with anti-GFP antibody and blotted with a pan 
anti-phosphotheonine antibody. Quantification was performed using ImageJ 
software, measuring the band intensities of immunoprecipitated samples as detected 
by both an anti-pT-specific antibody and an anti-GFP antibody.  
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For Induction of tyrosine phosphorylation, MCF7 or NIH-3T3 cell were treated 
with sodium pervanadate, (2 mM Na3VO4 dissolved in H2O pH 10, 88 mM H2O2) and 
incubated at 37°C in a CO2 incubator for 1 hour. 
2.11. In vitro phosphorylation 
In vitro phosphorylation assays of PRMT5 [T634] were conducted by Kinexus 
laboratory using a radiometric method with [gamma-33P]-ATP (Appendix A). In the 
first stage, phosphorylation of the PRMT5 wild type C-terminus peptide 
(KKPTGRSYTIGL-COOH) was assayed against 295 protein kinases. In the second 
stage, kinases from the first stage that generated signals greater than 250 cpm were 
used for further examination against the wild type PRMT5 [T634] and its mutated 
peptide, PRMT5 [A634] (KKPTGRSYAIGL-COOH). In vitro kinase assays were 
performed at ambient temperature for 20-40 min in a final volume of 25 µl containing 
a mixture of 10-50 nM active protein kinase, peptide and 5 µl of [gamma-33P] ATP in 
a suitable buffer. After the incubation period, 10 µl of the reaction mixture was 
spotted onto a phosphocellulose P81 plate and counted in the presence of 
scintillation fluid in a Trilux scintillation counter. 
 
2.12. Antibodies 
The following antibodies were used in this study: anti-PRMT5 (Active Motif 
61001), anti-PRMT5 (Millipore 07-405), Pan Phospho-Akt S/T Substrate (CST 
9614), Pan Symmetric Di-Methyl Arginine (anti-SDMA) [CST D2C3D6 not 
commercially available], anti-NHERF2 (CST 9568), 14-3-3 (CST 8312), Pan-
Cadherin (CST 4068), myc (9E10) (Sigma M4439), GFP (Santa Cruz sc-9996), AKT 
(CST 9272), anti-HA (CST-37245) and anti-MEP50 (CST 2823). 
 
2.13. Immunofluorescence microscopy 
Epifluorescence microscopy was performed using a Zeiss Observer.D1 
microscope. Methanol fixed cells were incubated with primary antibodies overnight 
at 4°C. Secondary antibodies (Molecular Probes) were diluted 1:1,000 and 
incubated with cells for 1 h at RT. Alternatively, cells growing on glass coverslips 
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were fixed with 4% paraformaldehyde at RT for 10 min. Cells were permeabilized in 
a solution containing 0.5% Triton X-100 in PBS for 15 min. After permeabilization, 
cells were blocked with 10% newborn calf serum in PBS for 1 hour at RT. Mouse 
anti-γH2AX (1:1,000), mouse anti-Myc (1:1,000), rabbit anti-NHERF2 (1:1,000) or 
rabbit anti-H4/H2AR3me2s (1:500) antibodies were incubated with fixed cells 
overnight at 4°C. After three washes, the cells were stained with Alexa Fluor 488-
conjugated anti-rabbit and Alexa Fluor 555-conjugated anti-mouse secondary 
antibodies. DNA was stained with DAPI (4′,6′-diamidino-2-phenylindole). 
 
2.14. GFP immunoprecipitations 
For GFP immunoprecipitations, GFP-nAb magnetic Sepharose and agarose 
resin (Allele Biotech) were used following the manufacturer’s procedures. Briefly, 
cells were harvested in PBS, then cleared by centrifugation. Cell pellets were 
resuspended in 200	  µl of lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl,1 mM 
EDTA, 0.5% NP-40, proteinase inhibitor cocktail and phosphatase inhibitors) and 
then lysed by sonication (10 cycles of 30 sec on/off using Bioruptor, Diagenode). 
After centrifugation at 20,000 x g for 10 min at 4oC, the supernatant was collected 
and diluted with binding buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, and 
proteinase inhibitor cocktail and phosphatase inhibitors) to a final volume of 700 µl. 
Equilibrated beads were incubated with lysate with tumbling for 1 h at 4°C. The 
immunoprecipitated samples were cleared using wash buffer (10 mM Tris-HCl pH 
7.5, 500 mM NaCl and proteinase inhibitor cocktail and phosphatase inhibitors) 
using either a magnetic stand or spin columns. The harvested beads were then 
resuspended in 30 µl of loading buffer and boiled for 5 min to elute the proteins. 
Samples were separated by SDS-PAGE and transferred onto PVDF membranes for 
western blot analysis.  
 
2.15. Western blots 
Lysates were separated on SDS-polyacrylamide gels (SDS-PAGE). Proteins were 
transferred onto PVDF membrane using a semi-dry transfer apparatus. Blots were 
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blocked in blocking buffer (PBS, 0.1 %Tween-20 and 5% milk) for 1 h at RT, then 
incubated with primary antibody diluted in the blocking buffer, overnight at 4°C. The 
blots were washed with PBS 0.1% Tween-20, probed with the appropriate HRP-
conjugated secondary antibody and detected by enhanced chemiluminescence (GE 
Healthcare Life Sciences). 
 
2.16. Peptide synthesis 
Biotinylated peptides were synthesized by the W.M. Keck Center (KC) and 
CPC Scientific, Inc. (CPC). Peptides are listed below. Phosphorylated residues are 
indicated as pY/T/S: 
(KC) PRMT5 273-293:  
Free –SEKEFCSYLQYLEYLSQNRPP-(biotin)-COOH 
(KC) PRMT5 pY280: 
Free –SEKEFCSpYLQYLEYL(biotin)-COOH 
(KC) PRMT5 pY283: 
Free –EFCSYLQpYLEYLSQN (biotin)-COOH 
(KC) PRMT5 pY286: 
Free –SYLQYLEpYLSQNRPP(biotin)-COOH 
(KC) PRMT5 pY280 pY283: 
Free –SEKEFCSpYLQpYLEYLSQNRPP(biotin)-COOH 
(KC) PRMT5 pY280 pY286: 
Free –SEKEFCSpYLQYLEpYLSQNRPP(biotin)-COOH 
(KC) PRMT5 pY283 pY286: 
Free –SEKEFCSYLQpYLEpYLSQNRPP(biotin)-COOH 
(KC) PRMT5 pY280 pY283 pY286: 
Free –SEKEFCSpYLQpYLEpYLSQNRPP(biotin)-COOH 
 (KC) PRMT5 623-637: 
Biotin – SAIHNPTGRSYTIGL-COOH 
(KC) PRMT5 pT634: 
Biotin – SAIHNPTGRSYpTIGL-COOH 
(KC) E6 (HPV16): 
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Biotin – SSRTRRETQL-COOH 
(KC) E6 (HPV16) pT156: 
Biotin – SSRTRREpTQL-COOH 
(KC) ERBB4*: 
Biotin – GTVLPPPPYRHRNTVV -COOH 
(KC) ERBB4 pT1306*: 
Biotin – GTVLPPPPYRHRNpTVV-COOH 
(KC) PGHS-2 : 
Biotin – SGSGVLIKRRSTEL-COOH 
(KC) PGHS-2 pT602: 
Biotin – SGSGVLIKRRSpTEL-COOH 
(KC) IRK-1: 
Biotin – SGSGPRPLRRESEI-COOH 
(KC) IRK-1 pS425: 
Biotin – SGSGPRPLRREpSEI-COOH 
(CPC) PRMT5 623-636: 
Biotin – SAIHNPTGRSYTIG-COOH 
(CPC) PRMT5 623-636 pT634: 
Biotin – SAIHNPTGRSYpTIG-COOH 
(CPC) PRMT5 623-637 R631K: 
Biotin – SAIHNPTGKSYTIGL-COOH 
(CPC) PRMT5 623-637 R631K pT634: 
Biotin – SAIHNPTGLSYpTIGL-COOH 
(CPC) PRMT5 623-637 R631A: 
Biotin – SAIHNPTGASYTIGL-COOH 
(CPC) PRMT5 623-637 R631A pT634: 
Biotin –SAIHNPTGASYpTIGL-COOH 
(* kind gift from Dr. Marius Sudol) 
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2.17. Peptide pull-down 
15 µg of biotin-labeled peptides were immobilized on streptavidin-agarose 
beads (Sigma) in peptide-binding buffer (50 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1 
mM EDTA, 2 mM dithiothreitol, 0.5% NP-40) overnight at 4°C and washed three 
times with binding buffer to remove unbound peptides. To reduce nonspecific 
binding, GST-fusion proteins were preincubated with streptavidin-agarose beads 
overnight. Beads were harvested by centrifugation, and the supernatants were 
incubated with immobilized peptide in 300 µl of binding buffer overnight. The beads 
were washed with binding buffer, harvested by centrifugation and then resuspended 
in 30 µl of loading buffer and boiled for 5 minutes. The samples were resolved by 
SDS-PAGE prior to transfer to PVDF membrane and detection with anti-GST 
antibody.  
 
2.18. Protein domain microarray 
Protein domain microarrays were generated as previously described (Espejo 
et al, 2002). Briefly, proteins were arrayed in duplicate using a Flexys robotic 
workstation (Genomic Solution) or an Aushon 2470 Microarrayer (Aushon 
Biosystems). GST fusion proteins were arrayed from a 384-well plate, which 
contained 10 µl of each protein at an approximate concentration of 1 µg/ul. The 
protein arrays are composed of blocks, each organized in a matrix of columns and 
rows as shown in Figures 5, 15 and 29. Each protein is printed in duplicate with a 
unique orientation. Samples are printed with a distance of 600 µm between spots. 
GST alone is printed on each block as negative control. Proteins were printed on 
nitrocellulose coated glass slides (Grace Bio-labs).  
Peptides were synthesized by Keck Biotechnology or by CPC Scientific, Inc., 
10 µg of biotinylated peptides were bound to Cy3-streptavidin or Cy5-streptavidin 
(GE Healthcare) in 500 µl PBST- 0.1% Tween 20). Labeled peptides were cleared of 
unconjugated straptavidin label by incubation with biotin-agarose beads (Sigma, St. 
Louis, MO, U.S.A.) Arrays were probed with fluorescently labeled peptides overnight 
at 4°C, unbound peptides were washed away with PBST-0.1% Tween 20. 
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The fluorescent peptide bound signal was detected using a GenePix 4200A 
microarray scanner (Molecular Devices). 550 nm and 675 nm filters were used for 
the detection of Cy3 and Cy5-labeled probes. GST signal was detected with anti-
GST and 555-conjugated rabbit secondary antibodies.  
 
2.19. Membrane fractionation 
This protocol was adapted from (Jorgensen, 1988). Three 15 cm plates at 80 
to 100% confluency were used. Cells were washed 3 times with homogenization 
buffer (25 mM imidazole, 250 mM sucrose, 1 mM EDTA, pH 7.2 and protease 
inhibitors), and harvested by scraping into 10 ml of homogenization buffer.  
Cells were lysed with six passages through an 18 gauge needle, followed by 
six passages through a 27 gauge needle. Lysate were cleared by centrifugation 
(5,800 x g for 15 minutes at 4oC). Supernatants were collected and the pellets were 
resuspended into 5 ml of ice-cold homogenization buffer by vortexing, and then 
centrifuged at (5,800 x g for 15 minutes at 4oC). Supernatants were combined and 
cleared again by centrifugation (47,800 x g, 30 minutes at 4oC). The resulting 
supernatant contained the cytoplasmic proteins and the pellet contained the 
membrane and membrane-associated proteins. Pellets were resuspended in 1 ml of 
homogenization buffer containing protease inhibitors. The samples were analyzed 
by immunoblotting after resolution on SDS-PAGE gels. 
 
2.20. Intracellular pH 
Intracellular pH (pHi) was determined using the fluorometric, pH-sensitive dye 
2′,7′-bis-(2-carboxyethyl)-5-carboxyfluorescein acetoxymethyl ester (BCECF-AM) 
(Invitrogen Molecular Probes), according to (Levine et al, 1993) with modifications. 
Briefly, cells were grown to 70-80% confluence in a 96 well plates. Cells were 
incubated with 5 µM BCECF-AM in Hank’s Balanced Salt Solution (HBSS) (Gibco) 
for 1 h at RT, then washed with “Na+free” medium (130 mM tetramethylammonium-
Cl, 5 mM KCl, 2 mM CaCl2, 1 mM MgSO4, 10 mM glucose, and 20 mM HEPES, pH 
7.4) to remove the excess of dye. Medium was replaced with 30 mM NH4Cl in 
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“Na+free” for 5 min at 37°C, in a CO2 cell culture chamber. NH4Cl was removed by 
washing with Na+free medium. Then Na+ medium (130 mM NaCl, 5 mM KCl, 2 mM 
CaCl2, 1 mM MgSO4, 1 mM NaPO4, 25 mM glucose and 20mM HEPES, pH 7.4) was 
added and data points were collected approximately every 90 sec for 20 min. 
Fluorescence was measured using a filter for detecting emission at 520 nm and at 
620 nm (the isosbestic point) when excited at 488 nm. Experimental fluorescence 
was adjusted by subtracting the background intensity. All the fluorescence intensity 
measurements after NH4Cl recovery were normalized by the fluorescence intensity 
at time zero. 
 
2.21. Generation of the PRMT5Δ+HA mouse model 
We used CRISPR/Cas9 to generate a mouse model in which we replaced the 
last 6 amino acids of PRMT5 with an HA tag, which we refer to as PRMT5Δ+HA. To 
generate the PRMT5Δ+HA knock-in mice, we co-injected sgRNA, Cas9 mRNA, and 
an oligo donor into one-cell stage mouse embryos.  
The oligo donor is a double-stranded gBlock fragment that has 80 bp of 
homology in each arm, with DNA encoding the HA tag (60 bp) in the middle: 
TGCAGCAATTCCAAGAAAGTGTGGTACGAGTGGGCGGTGACGGCCCCCGTCT
GTTCTTCTATTCACAACCCTACCGGCCGGGGATATCCATATGATGTTCCTGATT
ATGCTTAGCCCTGCACACAGTGTCAAAACCTTGGAAGCAGCTCTGAGTTCTCTT
CCTACAGCACAGAAGGTGTAGAACA. The guide RNA and Cas9 were generated 
by Sage Laboratories, gRNA/PAM sequence: ATGGTATAGGAGCGGCCGGTAGG. 
Guide RNA and donor sequence were generated by Sage laboratory (Appendix C). 
 
2.22. Mouse genotyping 
All mouse procedures were performed in accordance with The University of 
Texas MD Anderson Cancer Center guidelines. Genomic DNA was isolated from tail 
biopsies and analyzed by PCR. The PRMT5 C-terminus WT and Δ+HA alleles were 
identified using the following oligonucleotides:  
5′- CCGCCTGTGTCTTTCGTATT -3′ 
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 5′- GTTGGCCACCATGACATTAG -3′  
PCR reactions generated a 336 bp band for the wild-type allele and a 348 bp 
band for the PRMT5Δ+HA allele. The PCR products for founder mice were sequenced 
to verify the fidelity of the mutation. 
 
2.25. Derivation of mouse embryonic stem cells 
Mouse embryonic stem cells were derived from pregnant female mice 
essentially as described elsewhere (Czechanski et al, 2014). Briefly, heterozygous 
PRMT5Δ+HA mice were mated 48 hours after intraperitoneal injection with 5 IU of 
pregnant mare's serum gonadotropin (PMSG), and checked for the presence of 
vaginal plugs. At embryonic day 3.5 (E3.5), mice were euthanized and blastocysts 
were collected by flushing them out of the uterine horn with M2 medium (Sigma). 
Blastocysts were plated in feeder-coated wells with serum-free ES medium 
containing LIF, CHIR99021 and PD0325901 inhibitors, and then incubated at 37 °C 
with 5% CO2 for 48 hours. Serum-free medium was replaced after blastocysts 
hatched from the zona pellucida. Once inner cell mass outgrowths were prominent, 
the entire well was disaggregated with 0.05% trypsin and pipetting, and then plated 
in a new feeder-coated well with ES medium containing FBS, LIF, CHIR99021 and 
PD0325901 inhibitors. ES colonies were generally visible 5 days after 
disaggregation. Once the wells reached 70-90% confluency, ES cells were passed 
into a 0.2% gelatin-coated well (labeled as passage 1), and further cultured in 
feeder-free conditions. ES cells were harvested for genotyping and western blot 
analysis after at least 4 passages in feeder-free conditions. Experiments were 
performed by Dr. Jeesun Kim and Nicolas Veland, B.S. in Dr. Taiping Chen's 
Laboratory. 
 
2.24. Chromatin immunoprecipitation (ChIP) assay 
The ChIP assay was performed as described previously (Biswas et al, 2014). 
Briefly, U2OS expressing ER-I-PpoI control or 4-hydroxy tamoxifen treated cells 
were cross-linked with 1% formaldehyde for 10 min at RT. Cross-linking reactions 
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were quenched by the addition of glycine followed by incubation for 5 min at RT. 
Nuclei were isolated and sonicated in ChIP buffer containing a protease inhibitor 
cocktail (Roche) and a phosphatase inhibitor cocktail (Roche) to generate DNA 
fragments of approximately 200 to 1000 bp. Primers for sequences flanking an I-
PpoI cut site was used to examine enrichment at a DNA double-strand break. 
 
2.26. Ionizing radiation treatment 
Cells were irradiated at a dose of 5 Gy at RT using a RS-2000 Biological 
Irradiator (Rad Source). After IR treatment, the cells were returned to an incubator 
and maintained at 37 °C for further analysis.  
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Chapter 3: Regulation of PRMT5 by Tyrosine Phosphorylation 
 
3.1. Introduction 
 
Distinct PTMs, including acetylation, ubiquitination and phosphorylation, have 
been experimentally identified across PRMT5, and have been deposited in 
PhosphoSitePlus (Hornbeck et al, 2015) (Figure 3). In addition to these, we have 
identified new phosphoserine and phosphothreonine sites on PRMT5 by means of 
mass spectrometric analysis of PRMT5 purified from hyperphosphorylated cells 
(Figure 3). However, the functions of modified PRMT5 are largely unkown. Here, we 
investigate the significance of some of these phosphotyrosine sites, with respect to 
whether they play a role in mediating protein-protein interactions. 
 
3.2. Results 
 
3.2.1. Tyrosine phosphorylation regulates PRMT5 activity 
 
We were particularly interested in the phosphotyrosine sites located in the 
central region of PRMT5. There are at least six tyrosine residues potentially 
phosphorylated in this region and all are conserved between humans and mice. 
Phosphorylation of Y297, Y304 and Y307 of PRMT5 had already been established 
by Dr. Nimer’s group (Liu et al, 2011). Phosphorylation on these residues impairs 
MEP50-PRMT5 interaction and consequently, PRMT5 activity is diminished (Liu et 
al, 2011). Additionally, phosphorylation of Y280, Y283 and Y286 has been found 
multiple times by mass spectrometry and at least one residue is predicted to be a 
substrate for Src. Experimental data from our laboratory showed that 
immunopreciptated Myc-PRMT5 from cells co-transfected with vSrc was 
phosphorylated, indicating that PRMT5 is a substrate for vSrc kinase (Figure 4A). 
Moreover, an in vitro methylation assay performed with Myc-PRMT5 
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immunopreciptated from cells with or without cotransfected vSrc, demonstrated that 
the activity of PRMT5 towards H3, H4 and MBP was reduced when PRMT5 was 
phosphorylated by vSrc (Figure 4B). This indicates that the methyltransferase 
activity of PRMT5 might be regulated by its tyrosine phosphorylation. 
 
 
Figure 3: PRMT5 is phosphorylated at multiple residues 
Schematic representation of PRMT5. The relative positions of predicted and 
observed phosphorylated residues are indicated; ⦁ observed by mass spectrometry-
based analysis in hyperphosphorylated samples, * observed by mass spectrometry 
reported at PhosphoSite Plus, ○ reported in literature, ‡ predicted AKT phospho-site. 
The catalytic core is indicated in purple. The signature methyltransferase motifs are 
boxed in the following order: I, post-I, II, III and THW loop. 
 
3.2.2. Phosphorylation of PRMT5 creates a binding motif for SH2 domains 
 
We postulate that phosphorylation of PRMT5 regulates its enzymatic activity 
and substrate specificity by mediating phospho-dependent protein-protein 
xxxxxxxxxx  
	  42	  
 
 
Figure 4: PRMT5 is tyrosine-phosphorylated by the Src kinase 
A) Myc-PRMT5 was co-transfected into HeLa cells with or without a vSrc plasmid as 
indicated. A western blot analysis for vSrc, using an actin loading control is shown. 
Phosphorylated tyrosine in myc-PRMT5 inmunoprecipitates was detected using a 
pan-phosphotyrosine antibody (pY-100). The phosphorylation level of Myc-PRMT5 
increased with vSrc overexpression. 
B) To test whether the tyrosine phosphorylation of PRMT5 can affect its enzymatic 
activity, an in vitro methylation assay using H3, H4 and MBP substrates was 
performed using immunopurified myc-PRMT5 from HeLa cells with or without vSrc 
overexpression. Overexpression of vSrc led to a decrease in PRMT5 activity, 
indicating that the methyltransferase activity of PRMT5 might be regulated by its 
tyrosine phosphorylation. Experiments were performed by Dr. Yong Kee Kim.   
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interactions. SH2 domains are the major protein module that recognizes 
phosphotyrosine motifs. To perform a comprehensive and unbiased screen of 
phosphotyrosine-dependent interactions, we purified over 70 different GST-fusions 
of SH2-containing protein domains and generated an SH2-domain array (Figure 5). 
The use of protein microarrays for studying protein interactions with peptide ligands 
has been well-validated, and is a reliable and reproducible approach for identifying 
binding partners (Espejo et al, 2002; Kim et al, 2006; Yang et al, 2010). Using the 
online database PhosphoSite Plus we observed a cluster of three putative tyrosine 
phosphorylation sites (Y280, 283 and 286). To identify PRMT5 phosphorylation-
dependent binding partners and determine whether these were functional 
phosphorylation sites, we used peptides harboring phospho-tyrosine residues to 
screen for potential SH2 domain-containing proteins that could bind each of these 
three phospho-motifs. 
 These PRMT5 peptides were fluorescently labeled and probed on a protein 
SH2-array (Figure 6). We observed that the combination of two or more pY sites 
enhanced the interaction with SH2-domains, but overall, did not show an exclusive 
preference for a specific combination of pY residues, for example, PIK3R1_N 
(magenta oval). However, a few interactions only occurred with a particular 
combination of phosphotyrosines, for example PTK6 (yellow oval), which interacted 
only with the peptide containing both pY280 and pY283 (Figure 6). In conclusion, 
SH2 domains recognize one or more phosphotyrosine residues on PRMT5 either 
singly or in combination. This suggests that PRMT5 may be regulated by SH2 
domain containing proteins for a variety of cellular functions, or that these SH2-
containing proteins may themselves be substrates of PRMT5. 
 
3.2.3. Endogenous PRMT5 interacts with SH2 domain-containing proteins 
 
Our comprehensive SH2 domain array screen revealed a broad set of SH2-
domains that interact with PRMT5 phosphotyrosine peptides. As a result of this 
screen, 25 phosphorylation-dependent protein-peptide interactions were discovered  
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Figure 5: Phosphotyrosine-binding microarray 
Protein microarray containing 73 different GST-fusion SH2 domains. Each protein is 
printed in duplicate in a specific orientation as designated in the key. Each block 
harbors up to 10 GST-fusion proteins, plus GST protein as negative control.  
  
Kinases
A1   LYN (P07948)
A2   HCK (P08631)
A3   LCK (P06239)
A4   BLKSH2 (P51451)
A5   FYN (P06241)
A6   YES (P07947)
A7   SRC (P12931)
A8   PTK6 (Q13882)
A9   FRK (P42685)
Kinases
B1   ABL1 (P00519)
B2   ABL2 (P42684)
B3   FER (PI6591)
B4   FES (P07332)
B5   TXK (P42681)
B6   ITK (Q08881)
B7   BTK (Q06187)
B8   TEC (P42680)
B9   BMX (P51813)
Kinases
C1   SYK-C  (Q5T6N8)
C2   SYK-N (Q5T6N8)
C3   ZAP70-C (P43404)
C4   ZAP70-N (P43404)
C5   MATK (P42679)
C6   CSK (P41240)
Phosphatases
C7   PTPN11-C (Q06124)
C8   PTPN11-N (Q06124)
C9   PTPN6-C (P29350)
Scaffolds
D1   BLNK (Q8WV28)
D2   SLNK (Q7Z4S9)
D3   SHC1 (P29353)
D4   SHC3 Q92529)
D5   SHC4 (Q8IYW3)
Small GTPase signalling
D6   RASA1-N (P20936)
D7   RASA1-C (P20936)
D8   VAV1(P15498)
D9   VAV2 (P52735)
Signal Regulation
E1   DAPP1 (Q9UN19)
E2   HSH2D (Q96JZ2)
E3   GRB7 (Q14451)
E4   GRB10 (Q13322)
E5   GRB14 (Q14449)
E6   SHB (Q15464)
E7   SHD (Q96IW2)
E8   SHE (Q5VZ18)
E9   SHF (Q96IE8)
Cytoskeletal Regulation
F1   BRDG1(Q9ULZ2)
F2   SH3BP2 (P78314)
F3   SH2D1A (O60880)
F4   SH2D1B (O14796)
F5   TNS1 (Q9HBL0)
F6   TNS2 (Q76MW6)
F7   TNS3 (Q8IZW7)
F8   TNS4 (Q8IZW8)
Signal Regulation
F9   APS (O14492)
Adapters
G1   GRAP (Q13588)
G2   GRAP2 (O75791)
G3   GRB2 (P62993)
G4   CRK (P46108)
G5   CRKL (P41240)
G6   NCK1 (P16333)
G7   NCK2(O43639)
Phospholipid signaling 
G8   SHIP1 (O00145)
G9   SHIP2 (O15357)
Phospholipid signaling
H1   PIK3R1_C (P27986)
H2   PIK3R1_N (P27986)
H3   PIK3R2_C (O00459)
H4   PIK3R2_N (O00459)
H5   PIK3R3_C (Q92569)
H6   PIK3R3_N (Q92569)
H7   PLCg1-C (P19174)
H8   PLCg1-N (P19174)
H9   PLCg2-C (P16885)
H10 PLCg2-N (P16885)
Plasmids were kindly provided by Dr. Shawn Li, Department of Biochemistry, University of Western Ontario 
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Figure 6: Identification of PRMT5 phosphotyrosine specific binding partners 
Tyrosine phosphorylation of PRMT5 regulates its interactions with SH2 domain 
containing proteins. Tyrosine phosphorylated peptides harboring pY280, pY283, 
pY286 and all possible combinations were probed on a protein microarray harboring 
73 different SH2 domains-containing proteins. Ovals highlight two of the 27 putative 
binding partners; PTK6 (yellow) and PIK3R1_N (magenta). It is important to note 
that while PTK6 binds exclusively with the PRMT5 pY280-Y283 peptide, PIK3R1_N 
does not show such preference. A List of the arrayed proteins is shown in Figure 5. 
PRMT5 pY283-pY286
PRMT5 un-phosphorylated
PRMT5 pY286 PRMT5 pY280-pY283-pY286
 PRMT5 pY280-pY286PRMT5 pY280
PRMT5 pY283
PRMT5 pY280-pY283
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(Table 2). To validate these PRMT5-binding interactions, we used purified GST-SH2 
domains and performed pull-down assays. We selected four representative samples 
from the array results; PIK3R1_N (which interacted with all the phosphotyrosine 
peptides), PTK6 (which bound only the peptide containing pY280 and pY283), Abl1 
(which bound peptides containing pY280 together with other combinations of pY) 
and VAV1 (which bound only to peptides containing multiple combinations of pY). 
GST-SH2 domains were incubated with the lysates of cells that were 
hyperphosphorylated using sodium pervanadate treatment, which specifically 
increases the levels of phosphotyrosine by inhibiting endogenous phosphatase 
activity. This pull-down verified the interaction of PTK6-SH2 with PRMT5 and 
revealed a weak interaction with PIK3R1 (Figure 7A). PTK6 and PIK3R1 were not 
only able to pull-down PRMT5, but also other phosphotyrosine-containing proteins 
from sodium pervanadate-treated cells (Figure 7C). In a similar experiment, we 
treated NIH-3T3 cells and confirmed the interaction of PRMT5 with PTK6 along with 
the SH2 domains of Fyn, HCK, LCK, RASA1, and Yes (Figure 7B). The summary of 
the interactions validated by GST pull-down is shown in Table 2, column 1. 
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Figure 7: Endogenous PRMT5 interacts with SH2 domain-containing proteins 
To validate the PRMT5 binding proteins found in the protein microarrays, we purified 
GST-fusion proteins of candidate phospho-dependent partners and incubated these 
with MCF7 and NIH-3T3 whole cell lysates and performed western blotting with anti-
PRMT5 antibody. (A) GST-fusion proteins were incubated with lysates from 
untreated or sodium pervanadate-treated MCF7 cells and (B) NIH-3T3 cells. (C) 
Inputs are shown to demonstrate hyperphosphorylation in cells using α-
phosphotyrosine antibody. Molecular size markers (in kilodaltons) are indicated.  
  
H2O2-NaVO4 +-
2% Input αPRMT5
GST-SH2 PTK6 (Q13882)
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yes A2   HCK (P08631) no yes no no yes no yes yes 
yes A3   LCK (P06239) no no no no yes no no yes 
yes A5   FYN (P06241) no no no no yes yes yes yes 
yes A6   YES (P07947) no no no no yes no yes yes 
yes A8   BRK/PTK6 (Q13882) no no no no yes no no no 
N/T A9   FRK (P42685) no yes no no yes yes yes yes 
no B1   ABL1 (P00519) no yes no no yes yes yes yes 
N/T B2   ABL2 (P42684) no yes yes yes yes yes yes yes 
N/T C7   PTPN11-C (Q06124) no no no no yes no no no 
N/T C8   PTPN11-N (Q06124) no no no no yes no no yes 
N/T D1   BLNK (Q8WV28) no no no no yes no no no 
yes D6   RASA1-N (P20936) no yes yes no yes yes yes yes 
no D8   VAV1(P15498) no no no no yes yes yes yes 
N/T D9   VAV2 (P52735) no yes yes yes yes yes yes yes 
N/T E3   GRB7 (Q14451) no no no no yes no no no 
N/T F7   TNS3 (Q8IZW7) no no yes no yes no no no 
no F8   TNS4 (Q8IZW8) no no no yes no no no no 
N/T F9   APS (O14492) no no no no yes no no yes 
N/T G3   GRB2 (P62993) no no no yes no no no no 
N/T G4   CRK (P46108) no no no no yes yes no no 
N/T G5   CRKL (P41240) no no no no yes no no no 
N/T G9   SHIP2 (O15357) no no no no yes no no yes 
yes H2   PIK3R1_N (P27986) no yes yes yes yes yes yes yes 
yes H4   PIK3R2_N (O00459) no yes yes yes yes yes yes yes 
yes H6   PIK3R3_N (Q92569) no yes yes no yes yes yes yes 
Table 2: Phosphotyrosine Interactions 
Summary of SH2 domain interactions detected using the protein domain microarray 
with positive interactions highlighted in green. The first column indicates whether the 
interaction was validated by GST pull-down experiments. Positive interactions are 
highlighted in yellow, negative in red and N/T: not tested. A letter followed by a 
number before the protein name indicates the array code position. Protein accession 
numbers are indicated in parentheses. 	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3.3. Discussion  
 
In this work, we used comprehensive and unbiased approaches to define 
phosphotyrosine-dependent interactions between PRMT5 and SH2 domain 
containing-proteins. First, we found that Src phosphorylates PRMT5 and that 
tyrosine phosphorylation reduces PRMT5 activity. Second, we established that 
Y280, Y283 and Y286 are functional phosphorylation sites, allowing interaction with 
over 20 distinct PRMT5 phosphotyrosine-dependent binding partners. Third, we 
showed that multiple combinations of PRMT5 phosphotyrosine may form a code to 
recruit specific effectors.  
Phosphorylation of PRMT5 regulates its association with MEP50. 
Phosphorylation of Y297, Y304 and Y307 negatively affects the interaction of 
PRMT5 with MEP50, and therefore impedes PRMT5 catalytic function (Liu et al, 
2011). However, these sites are phosphorylated by a mutated form of Jak2 and not 
by the wild type kinases. On the other hand, the tyrosine phosphorylation sites we 
have described here, Y280, Y283 and Y286, have been identified numerous times 
by mass spectrometry (reported in PhosphositePlus), while the tyrosine sites 
investigated by Dr. Nimer’s group have not been observed using this technique. 
These data lead us to believe that phosphorylation occurs predominantly at Y280, 
Y283 and Y286 and that these sites may play a pivotal role in PRMT5 function. 
Nonetheless, we have also observed that phosphorylation on Y297, Y304 and Y307 
promotes PRMT5 interaction with a number of SH2 domains (Figure 8). 
Interestingly, PRMT5 activity regulates kinases involved in signaling pathways, 
suggesting regulatory crosstalk between kinases and arginine-methyltransferases. 
(Andreu-Perez et al, 2011; Hsu et al, 2011). 
Here, we observed that the activity of PRMT5 was reduced when 
phosphorylated by Src. Src is one of many phosphotyrosine kinases that is 
associated with the plasma membrane via amino terminal myristoylation. We also 
showed that PRMT5 is phosphorylated by Src, and in the next chapter, we will show 
that PRMT5 is associated with the plasma membrane via its C-terminus. These 
observations support the idea that PRMT5 could be a target for Src kinase. 
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Figure 8: Additional SH2 interactions 
Tyrosine phosphorylated peptides harboring pY297, pY304 and pY307 were probed 
on a SH2 protein microarray. Positive interactions are circled. List of SH2 domain 
proteins represented on the array is shown in Figure 5. 
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Many signaling processes are mediated by three components, a writer 
enzyme that post-translationally modified proteins, one or more erasers that reverse 
the effect of the writer, and one or more readers that can sense and respond to a 
change in the condition of the system. This three component model can be applied 
to many cellular functions, from cell membrane signaling to the histone code. Post-
translational modifications play fundamental roles in regulating molecular pathways, 
and tyrosine phosphorylation is a central component of molecular signaling 
pathways, governed by kinases (writers), phosphatases (erasers) and SH2-domain 
containing proteins (readers). 
Tyrosine phosphorylated proteins make up a small proportion of the proteome 
relative to the much more abundant serine and threonine phosphorylated proteins 
(Hunter, 1989). The presence of constitutively activated PTK in cancer cells 
increases the levels of phosphotyrosine-containing proteins causing deleterious 
effects. Therefore, in healthy cells, proper regulation of PTK is a critical process, and 
the number and diversity of phosphotyrosine-motif readers may provide the 
necessary precision to regulate the outcomes of PTK. Thus, SH2 domains play a 
critical role in signaling by mediating the formation of protein complexes. 
PTK6 is one of 25 novel SH2 domain-containing phosphotyrosine-dependent 
PRMT5 binding partners. PTK6 belongs to a family of non-receptor tyrosine kinases, 
somewhat similar to the Src family, but lacking a N-terminal myristoylation site of the 
Src kinase (Brauer & Tyner, 2010). In addition to the tyrosine kinase domain, PTK6 
contains both SH2 and SH3 domains, which bind to phosphotyrosine and proline-
rich sequences (PXXP), respectively. 
PTK6 is known to associate with and phosphorylate a small number of 
substrates, including Src-associated in mitosis 68 kDa protein (Sam68) (Derry et al, 
2000). Sam68 is an RNA-binding protein, which binds RNA via its KH domain. It also 
contains a recognition motif for SH2 domains and for SH3 or WW domains, both of 
which bind to PXXP motifs. Interestingly, these proline-rich sequences are flanked 
by a glycine- and arginine-rich (GAR) motif, which is also characteristic of PRMT1 
and PRMT5 substrates. Indeed, Sam68 is predominantly methylated by PRMT1 
(Bedford et al, 2000; Cote et al, 2003). Methylation of Sam68 is required for its 
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nuclear localization, but also prevents SH3 domain binding, yet has no effect on WW 
domain binding (Bedford et al, 2000; Cote et al, 2003). 
One can hypothesize that the phosphotyrosine-dependent interaction of 
PRMT5 with PTK6 may place Sam68 into close proximity with PRMT5, where it 
becomes a target for symmetric methylation. This suggests that PRMT1 and PRMT5 
may compete for the same substrate, which can be asymmetrically and 
symmetrically dimethylated. The simultaneous occurrence of both asymmetrically 
and symmetrically methylated arginine has been reported on another protein, MBD2 
(Tan & Nakielny, 2006). MBD2 interacts with the HDAC complex and specifically 
binds to methylated DNA. Arginine methylation of MBD2 inhibits both its protein-
protein and protein-DNA interaction (Tan & Nakielny, 2006). 
Both asymmetric arginine dimetylation and phosphorylation of Sam68, 
mediated by PRMT1 and PTK6, respectively, abolishes the ability of Sam68 to bind 
RNA (Derry et al, 2000; Rho et al, 2007). Because we speculate that PRMT5 and 
PTK6 are in the same complex as Sam68, it would be interesting to understand what 
is the biological significance of symmetric versus asymmetric arginine methylation. 
ADMA affects the RNA binding function of another protein, the trans-activating 
regulatory (TAT) protein of the Human immunodeficiency virus (HIV-1). TAT studies 
revealed that both forms of arginine methylation reduce the affinity of the protein-
RNA interaction, with the biggest reduction occurring with ADMA, and only a weak 
reduction with SDMA (Kumar & Maiti, 2013). Further studies will be necessary to 
determine whether Sam68 contains SDMA and what the specific roles of ADMA and 
SDMA are. 
 
3.4. Future studies 
 
These studies raise several questions that need to be experimentally 
addressed. In particular, it remains to be determined whether the in silico identified 
phosphorylation sites are present in vivo on PRMT5. To address this question, we 
attempted to develop an antibody using a peptide containing pY280, pY283 and 
pY286. Unfortunately, this antibody was not phosphospecific, (Figure 9A and C). 
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However, pan phosphotyrosine 4G10 recognized all combinations of 
phosphotyrosine studied here. Despite that, some pY combinations were better 
recognized than others (Figure 9B), this antibody proved suitable for identification of 
phosphorylated sites in immunoprecipitated PRMT5 (Figure 9C). 
Additionally, we generated several myc-tagged PRMT5 constructs. These 
included constructs with a single Y substitution (Y280, Y283, or Y286), all three 
substitutions and a construct deleted for residues 276 to 309, thus removing our 
sites of interest as well as the sites identified by Dr. Nimer’s group (Y297, Y304 and 
Y307). The use of these constructs together with the 4G10 antibody may reveal 
whether tyrosine phosphorylated sites of PRMT5 exist in vivo. 
Finally, considering our preliminary data, we can hypothesize that the 
absence of Src may reduce PRMT5 interaction with SH2 domains. To further 
analyze the contribution of Src to PRMT5 phosphorylation, GST fusion pull-down 
experiments will be performed with purified PTK6- and PIK3R1- proteins incubated 
with lysates from either untreated or pervanadate-treated Src-deficient MEF (SYF-/-) 
cells and c-Src expressing MEF cells (Src+/+). We expect that the levels of co-
precipitated PRMT5 will be reduced in Src-deficient MEFs compared to the control 
cells.  
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Figure 9: Dot blot analysis of phospho-tyrosine PRMT5 antibodies 
 (A) Antibodies were developed using a peptide containing all phospho-tyrosine 
residues (pY280, pY283 and pY286). Peptides containing single modifications and 
all possible combination were spotted onto nitrocellulose membranes and probed 
with (A) final bleed 5415 and 5416 and (B) pTyr mAb 4G10. Strepavidin-HRP was 
used as a loading control. 4G10 antibody detects phosphotyrosine peptides, 
although it shows a weaker signal for PRMT5-pY280 and -pY283. (C) Myc-PRMT5 
was co-transfected into HeLa cells with a vSrc expressing plasmid as indicated. 
Immunoprecipitated Myc-PRMT5 was analyzed with all three antibodies sources. 
The 4G10 antibody produced a stronger signal in conditions leading to myc-PRMT5 
hyperphosphorylation (+ vSrc). 
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Chapter 4: Phosphorylation at the C-terminus triggers a binding switch between 14-
3-3 proteins and PDZ domains 
 
4.1. Introduction 
 
PRMT5 is commonly found associated with other proteins, and these 
interactions control its catalytic activity and substrate specificity. Recently, it has 
become clear that PRMT5 is phosphorylated at several residues, which prompted us 
to investigate whether phosphorylation of PRMT5 regulates its subcellular 
localization and substrate choice by mediating phospho-dependent protein-protein 
interactions. While investigating the role of phosphorylation on the regulation of 
PRMT5, we found that the phosphorylated C-terminal tail of PRMT5 interacts with 
14-3-3 proteins. However, what is more interesting is that the unphosphorylated C-
terminus binds the PDZ domains of a membrane-associated protein, NHERF2, as 
well as other PDZ containing proteins. Thus, the C-terminus of PRMT5 has a shared 
recognition motif for PDZ domain and 14-3-3 proteins. In order to bind to this motif, 
14-3-3 proteins require the site to be phosphorylated. In contrast, PDZ domain 
recognition is phospho-independent. We also observed this phenomenon in a 
number of proteins, suggesting that this potential phosphorylation-dependent switch 
between binding to 14-3-3 and PDZ domains occurs among a wider range of 
proteins. 
 
4.2.1. PDZ domains 
 
The PDZ domain was identified as a set of conserved sequence repeats in 
three related proteins; the postsynaptic density-95 (PSD-95) protein, the Drosophilia 
tumor suppressor protein disks-large-1 (DLG), and the tight junction protein zonula 
occludens 1 (ZO-1), and named for these three proteins in which the repeats were 
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initially observed (Kennedy, 1995). PDZ domains constitute one of the largest 
families of interaction domains in eukaryotes and are found in more than 400 human 
proteins (Zhang & Wang, 2003). PDZ domains are typically between 80-90 amino 
acids in length, and are composed of 5 to 6 β strands and 2 α helices. 
PDZ domains preferentially recognize a short peptide motif at the extreme 
carboxyl terminus of their target proteins. Recognition is mediated through a binding 
pocket formed by the second β strand, second α helix and the carboxylate-binding 
loop which contains the conserved sequence motif K/R-X-X-X-G-Φ-G-Φ (X 
represents any natural amino acid and Φ is a hydrophobic residue) (Lee & Zheng, 
2010; Zhang & Wang, 2003). Based on the sequence of their preferred ligands, PDZ 
domains are grouped into numerous classes, nonetheless, the most classical 
organization consists of 3 classes: X[T/S]XΦ-COOH (Class I motif), XΦXΦ-COOH 
(Class II motif) and X[D/E]XΦ-COOH (Class III motif) (Lee & Zheng, 2010). 
Interestingly, the PDZ class I motif has remarkable similarity to 14-3-3 binding motif 
III. 
PDZ domains are often organized in a tandem arrangement. Recent studies 
have shown that in order to fold properly, some PDZ domains require contact with 
other PDZ domains. This association may occur intramolecularly with a neighboring 
tandem repeat or intermolecularly by PDZs forming heterodimers via their PDZ 
domains. The structural rearrangements can either leave the binding pockets of both 
PDZs open, or preserve only one open pocket for interaction with the target protein 
(Lee & Zheng, 2010).  
For most PDZ-containing proteins, individual domains are usually well folded 
and their presence in tandem repeats allows the association with other proteins 
through each PDZ domain. Such PDZ-containing scaffold proteins can assemble 
large molecular complexes. Interestingly, most of the PDZ domains are associated 
with the cell membrane, despite lacking a transmembrame domain (Zhang & Wang, 
2003). PDZ scaffolds play an important function in the establishment of epithelial 
polarity, clustering ion transporters and signaling receptors on membranes, 
connecting plasma membrane and cytoskeletal proteins, and regulating protein 
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trafficking (Kiela & Ghishan, 2009; Kim & Sheng, 2004; Kundu & Backofen, 2014; 
Nourry et al, 2003; Romero et al, 2011). 
 
4.2.2. NHERF 
 
NHERF family proteins (Na+/H+ exchanger regulatory factor) are PDZ 
containing proteins that comprise a group of structurally related adapter proteins that 
are highly expressed in the apical portion of the plasma membrane of polarized 
epithelial cells. Members of this group include NHERF-1 (also known as NHERF, 
EBP50), NHERF-2 (E3KARP), NHERF-3 (CAP70, PDZ-dc1), and NHERF-4 (IKEPP) 
(Figure 10). NHERF1 and NHERF2 are highly homologous, containing a C-terminal 
sequence that binds to the ezrin-radixin-moesin (ERM-Binding domain) family of 
membrane-cytoskeletal proteins and two tandem PDZ domains.  
NHERF proteins interact with many cellular proteins via their PDZ domains. 
Moreover, the NHERF family of proteins homodimerize and heterodimerize, 
suggesting they can form a mesh at the apical region of epithelial cells that binds 
and modulates protein complexes (Wade et al, 2003). The multi-PDZ domain 
structure permits them to interact with multiple binding partners to mediate the 
formation of large protein networks (Donowitz et al, 2005). NHERF members can 
associate with a number of membrane proteins, including the cystic fibrosis 
transmembrane regulator (CFTR) anion channel and the sodium/hydrogen 
exchanger NHE3 (Ghishan & Kiela, 2012). Indeed, NHERF proteins were originally 
identified as regulators of NHE3 through its association via PDZ domains and the C-
terminus of NHE3 (Kiela & Ghishan, 2009). 
NHE3 belongs to a family of sodium/hydrogen exchangers (NHEs) ubiquitous 
transmembrane proteins that maintain cellular volume, intracellular sodium 
concentration and whole-organism acid-base homeostasis. NHE3 is expressed 
predominantly in the plasma membrane of renal and intestinal epithelia where it 
mediates the majority of sodium absorption (Zachos et al, 2005).  
NHERF1 and NHERF2 regulate the localization of NHE3 activity in intestinal 
microvilli by organizing signaling complexes (Yang et al, 2015). Although all NHERF 
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members are present in a single cell, their localization varies. NHERF1 and 
NHERF3 are localized at the outer-most apical region of the microvillus, NHERF2 
and NHERF4 are present in the inner part of the microvillus, and NHERF4 is also 
cytoplasmic (Hryciw et al, 2006; Murtazina et al, 2011) (Donowitz et al, 2005). 
(Figure 10).  
 
 
Figure 10: Localization of PDZ proteins in epithelial cells 
NHERF family proteins homodimerize and heterodimerize, suggesting that they form 
a mesh at the apical region. The localization of PDZ domain-containing proteins 
(purple) is indicated. 
 
Ion exchangers play an important role during the normal digestive process. 
The epithelium of the gastrointestinal tract secretes and absorbs large quantities of 
anions and fluid. This process is predominantly mediated by the Na+/H+ exchanger 
NHE3 and the CFTR Cl− channel (Lamprecht & Seidler, 2006). Interestingly, both 
proteins, NHE3 and CFTR, interact with NHERF2 and other PDZ containing 
proteins, suggesting the importance of interactions between PDZ proteins and 
epithelial ion transporters (Lamprecht & Seidler, 2006). 
A number of NHERF2 null mouse models have been generated. NHERF2 KO 
mice are born phenotypically normal (Seidler et al, 2009), but models developed by 
two different groups are inconsistent with regard to the role of NHERF2 in regulating 
the subcellular localization of NHE3, and the role of cAMP in the inhibition of NHE3 
(Chen et al, 2010; Murtazina et al, 2011). Despite these discrepancies, the collective 
data indicate that loss of NHERF2 presents no obvious phenotype, but that NHERF2 
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is necessary for Ca2+- and cGMP-mediated inhibition of NHE3 (Chen et al, 2010; 
Murtazina et al, 2011). 
 
4.3. Results 
 
4.3.1. PRMT5 is phosphorylated at the C-terminus 
 
Members of the PRMT family are phosphorylated and this modification 
regulates their activity. In particular, PRMT5 is phosphorylated at three tyrosine 
sites, which affect its binding with MEP50, its main co-activator. Moreover, additional 
phosphorylatable tyrosine, threonine and serine sites have been discovered either 
experimentally or in silico. Using bioinformatics, we identified the C-terminal residue 
T634 as having a high probability of being phosphorylated by AKT (Figure 11A).  
To validate the phosphorylation of T634, we generated a GFP-PRMT5 
construct harboring PRMT5 amino acids 340 to 637 (Figure 11A). Using this 
construct, we exclude other putative phosphothreonine sites located on the N-
terminal half of PRMT5. GFP-PRMT5 and GFP-PRMT5T634A were co-expressed with 
constitutively active myr-AKT in HeLa cells. We observed that GFP-PRMT5 but not 
GFP-PRMT5T634A was detected by a pan-phosphothreonine antibody (Figure 11B), 
suggesting that PRMT5 is phosphorylated at T634 in vivo. We next investigated 
additional kinases that could potentially phosphorylate PRMT5 at T634. We 
conducted in vitro kinase assay experiments to test over 250 kinases for their ability 
to phosphorylate a peptide harboring the last 10 amino acids of PRTM5 (Figure 
12A).  
Because the C-terminus of PRMT5 contains additional residues that could be 
phosphorylated, a second in vitro kinase assay was performed, using those kinases 
that generated signals greater than 250 cpm in the first stage. WT and mutant-A634 
peptides were used for further comparison of their phosphorylation efficiency with 18 
xxx  
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Figure 11: PRMT5 is phosphorylated at its C-terminus 
A) Schematic representation of N-terminally truncated PRMT5. Position of predicted 
AKT-phosphorylated residue T634 is indicated. The sequence of the C-terminus, 
which includes the recognition motifs for 14-3-3 and PDZ binding is shown. The 
signature methyltransferase motifs are marked by black boxed in the following order: 
I, post-I, II, III and THW loop. 
B) A threonine to alanine substitution at position 634 abrogates the Akt/Calyculin-A 
induced phosphorylation of GFP-PRMT5 WT. GFP-PRMT5 harbors amino acids 340 
to 637. HeLa cells were transiently transfected with GFP-tagged WT or mutant 
(T634A) expression plasmids with or without constitutively active Akt (myr-Akt). Cells 
were treated with 0.1 µM Calyculin-A (a phosphatase inhibitor) for 1 hour prior to 
lysis. Proteins were immunoprecipitated with anti-GFP agarose resin and 
immunoblotted with pan anti-phosphothreonine and anti-GFP antibodies. Input 
lysates were immunoblotted with antibodies specific to GFP-tagged proteins and 
phosphor-threonine residues.  
A
B
Myr-AKT 
IB
: α
-G
FP
IB
: α
-p
T
IB
: α
-G
FP
IP
: α
-G
FP
IB
: α
-p
T
In
pu
t
GFP-PRMT5
GFP-PRMT5 T634A
--+ +
++- -
+-- +
-75
-50
-75
-50
-75
-50
-75
-50
-100
-37
-25
634 
IHNPTGRSYTIGL-COOH
340 637
THW loopI Post-II III
GFP
	  61	  
 
 
Figure 12: Radiometric assay of the PRMT5 C-terminus peptide 
phosphorylation 
A) The activity of 295 protein kinases was tested against a PRMT5 C-terminal 
peptide. These assays were based on the direct quantification of radiolabeled 
phosphate transferred from ATP (gamma-33P) to the peptide substrate. In vitro 
kinase activity was ranked as excellent (over 300 cpm), good (299-250 cpm), low 
(249-100 cpm), and non-phosphorylated (under 99 cpm). 
B) The 18 most active kinases (excellent and good ranking) were used to validate 
the initial in vitro phosphorylation screen using PRMT5 WT and T634A C-terminal 
peptides as substrates. Kinase assays were performed by Kinexus. 
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previously identified kinases (Figure 12B). This assay confirmed that the T634 of 
PRMT5 can be phosphorylated not only by Akt, but also by calcium/calmodulin-
dependent protein kinase II (CAMK2), ribosomal S6 kinase (RSK) and by 
serum/glucocorticoid regulated kinase (SGK) family members.  
To confirm and extend the results of our in vitro kinase experiments, we 
determined whether PRMT5 is phosphorylated in cells. We studied PRMT5 
phosphorylation using agents capable of increasing kinase activity. To test the 
involvement of PKA, we used forskolin, which increases intracellular cAMP, thus 
activating PKA (Kocinsky et al, 2007). CaMKII activity was stimulated with 
angiotensin II, which induces the elevation of calcium, to activate CaMKII (Costa-
Pessoa et al, 2013). Since SGKs are regulated by glucocorticoid, dexamethasone (a 
synthetic glucocorticoid compound) was used to assess PRMT5 C-terminal 
phosphorylation induced by SGK kinases.  
Preliminary experiments indicated that AKT strongly phosphorylates PRMT5, 
therefore we compared the levels of PRMT5 phosphorylation when induced by AKT, 
PKA, CamKII and SGK. As expected, overexpression of constitutively active AKT 
induced PRMT5 phosphorylation in the WT but not in GFP-PRMT5T634A construct. 
Additionally SGK activation induced an increase of threonine phosphorylation at the 
C-terminus of PRMT5 (Figure 13). 
 
4.3.2. PRMT5 interacts with PDZ domains and 14-3-3 proteins 
 
Phosphorylation of serine and threonine residues generates docking sites for 
a number of proteins including 14-3-3 proteins. 14-3-3 proteins binding sites share 
several common features with optimal AKT phosphorylation sites, hence many Akt 
substrates are 14-3-3 ligands (Smith et al, 2011). Given that PRMT5 contains a 14-
3-3 consensus binding motif at its C-terminus (Figure 14A and 14B), which overlaps 
with an AKT phosphorylation sites, we wanted to study the interaction of PRMT5 
with 14-3-3 proteins and whether phosphorylation by Akt might affect those 
interactions. Notably, the 14-3-3 consensus binding site is nested within a PDZ 
xxxxxxxxx  
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Figure 13: AKT and SGK regulate PRMT5 phosphorylation 
SK-CO15 cells were transfected with GFP-PRMT5 WT or the point mutant GFP-
PRMT5 T634A. Cells were exposed to the indicated agents to induce specific 
kinases; angiotensin II (induces the elevation of calcium activating CaMKII); 
dexamethasone, a synthetic glucocorticoid compound (glucocorticoid regulates 
SGK); forskolin (increases intracellular cAMP, activating PKA); and overexpression 
of constitutively active AKT. Samples were immunoprecipitated with anti-GFP 
antibody followed by western blotting using anti-pT and anti-GFP antibodies. The 
input samples were probed with anti-AKT. β-actin was used as a loading control. 
The bar graph represents the normalized ratio of phosphorylated GFP-PRMT5 (anti-
pT) and total GFP-PRMT5 (anti-GFP). Quantification was performed by 
densitometry of the top two panels and a duplicate experiment. Three independent 
measurements were taken for each band from the two different blots. S.D. is 
denoted by error bars, *P<0.01 and **P<0.001, generated by an unpaired Student’s t 
test. 
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Figure 14: The PDZ domain and 14-3-3 proteins share a common binding motif 
A) A comparison of 14-3-3 and PDZ domain binding motifs. The consensus binding 
sequences of PDZ motif I and the distal C-terminal motif III of 14-3-3 are highly 
similar, differing only in the phosphorylation-dependent characteristic of 14-3-3 
binding. Single-letter amino acid code or symbols are shown, where X is any 
residue, ϕ is a hydrophobic residue and p represents a phosphorylated residue. 
B) Proteins harboring PDZ and 14-3-3 binding motifs. Schematic diagram of 
predicted (*) phosphorylation sites (ERBB4 & PGHS2) and reported phosphorylation 
sites (PRMT5, IRK1 & E6). Predictions were performed using iGPS1.0 software. 
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domain binding site, which differs only in the phosphorylation status of the serine or 
threonine present in the motif, leading us to hypothesize that phosphorylation of 
PRMT5 T634 would steer the interaction towards 14-3-3 proteins at the expense of 
PDZ domain proteins. 
To explore our hypothesis, we generated phosphorylated and 
unphosphorylated peptides corresponding to the C-terminus of PRMT5 harboring 
the threonine 634 site, and used protein microarray technology to investigate 
whether the association between PDZ domain/14-3-3 proteins and the C-terminus of 
PRMT5 is mediated by phosphorylation. To do this, we developed a customized 
microarray consisting of more than 70 purified GST-tagged PDZ domains and all 
seven 14-3-3 isoforms (Figure 15) (Appendix B). The GST-PDZ microarray content 
was selected based on the functional analysis performed by the MacBeath group 
(Stiffler et al, 2007). 
As predicted, the phosphorylated peptide (but not the unphosphorylated 
peptide) bound 14-3-3 proteins (α, γ, ε, and ζ). In contrast, the unphosphorylated 
peptide bound a selected group of PDZ domains (GRIP1, MPP7, PDZ-LIM5, 
NHERF1 FL, NHERF2 FL, SCRIB1 and PDZ-LIM2), whereas the phospho-peptide 
only showed interaction with PDZ-LIM2 (Figure 16A and B).  
It was recently reported that the C-terminus of the human papillomavirus E6 
oncoprotein undergoes PDZ/14-3-3 interaction switching in a phospho-dependent 
manner (Boon & Banks, 2013). Our results indicate that PRMT5 can switch between 
PDZ and 14-3-3 binding modes in a similar phospho-dependent fashion. This 
prompted us to hypothesize that this signaling paradigm may occur in other 
mammalian proteins. To explore this idea using other proteins with predicted 
overlapping Akt phosphorylation sites and 14-3-3/PDZ binding sites, we used 
Scansite and NetPhorest. We selected three such proteins: 1) the receptor tyrosine 
kinase ERBB4, 2) the inward rectifier potassium channel IRK1 (Kir2.1), and 3) the 
prostaglandin-endoperoxide synthase PGHS-2 (COX2) (Figure 164B). 
Using the protein domain microarray platform, we tested peptide sets from 
these three candidate proteins together with E6 as control and observed that they all 
undergo PDZ/14-3-3 switching (Figure 16A and B). This finding suggests that this   
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Figure 15: Map of PDZ/14-3-3 protein Array 
The protein domain microarray consisting of GST-fusion proteins of all 14-3-3 
isoforms, and 76 PDZ domains. Each GST fusion protein was arrayed in duplicate, 
at a different angle to facilitate the identification of the spots. Within each block, 
unfused GST protein was used as negative control.  
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Figure 16: C-terminal pT634 triggers a binding switch between 14-3-3 and PDZ 
(A) Phosphorylated and unphosphorylated PRMT5, ERBB4, E6 (HPV16), PGHS2 
and IRK1 peptides were labeled with Cy5 (red) and Cy3 (green), respectively, and 
probed on a protein microarray containing 14-3-3 and PDZ domains. Bottom right 
panel shows the array probed with α-GST as a loading control. The position of the 
PDZ domains (red block) and 14-3-3 (green block) proteins are indicated. A 
complete list of protein is displayed in Figure 15.  
(B) Graphical depiction of the interactions observed in (A). Red and green squares 
indicate interactions with unphosphorylated and phosphorylated peptides, 
respectively. (Experiments were performed by Karynne Black in Dr. Bedford’s 
laboratory). 
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signaling paradigm may be a broad mechanism used by biological systems to 
modulate protein-protein interactions, and that it is not limited to viral proteins like 
E6. 
Following this screening step, we confirmed these interactions using peptide 
pull-down assays with the seven GST-PDZs identified in the protein microarrays, 
using GST as a negative control (Figure 17). The results of the peptide pull-down 
experiment confirmed the direct interaction of the unphosphorylated PRMT5 peptide 
with the GST-PDZ proteins and also allowed the detection of the relative strength of 
the peptide-protein interaction (Figure 17 – bottom panel). This result indicates that 
the stronger interaction occurs with GST fused to full-length NHERF2, which harbors 
two PDZ domains (Figure 17).  
 
4.3.3. Endogenous PRMT5 interacts with 14-3-3 proteins and the NHERF2 PDZ 
domain. 
 
As mentioned earlier, the presence of tandem PDZ repeats in proteins is a 
common feature of PDZ containing-proteins, facilitating the formation of protein 
complexes. NHERF2 contains two PDZ domains; therefore we speculated that one 
would interact with PRMT5, while the other would bind to another protein, thus 
creating a complex. To investigate which of the NHERF2 PDZ domains interacted 
with the PRMT5 C-terminal peptide and to confirm the PDZ/14-3-3 phospho-switch, 
we performed a peptide pull-down assay with the proteins described in Figure 16A. 
Given that NHERF2 mouse and human orthologs share an 86% identity, we wanted 
to validate this interaction using human proteins. Therefore we generated NHERF2 
constructs encoding individual PDZ domains as well as the full-length human 
NHERF2 protein (Figure 18A). This analysis revealed that the PRMT5-NHERF2 
interaction occurs via the first PDZ domain, but that the interaction is stronger with 
the GST-NHERF2 full-length proteins, suggesting that other parts of the proteins 
contribute to binding. In contrast, phosphorylation of the PRMT5 peptide prevented 
xxx 
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Figure 17: PRMT5 peptide pull-down assays 
GST-fused PDZ domains of GRIP1 (672-754), MPP7 (139-220), PDZ-LIM5 (2-85), 
NHERF1 FL (1-355), NHERF2 FL (1-337), SCRIB1 (714-801), PDZ-LIM2 (1-84) and 
GST were incubated with biotinylated PRMT5 unphosphorylated peptide. Bound 
proteins were detected by western blot with anti-GST antibody (short and long 
exposure are shown). Peptide loading was assessed by western blot with HRP-
conjugated streptavidin. Relative GST-fused PDZ domain quantities were analyzed 
by Coomassie stain.  
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NHERF2 binding, but enable 14-3-3ε binding (Figure 18B). This data supports the 
phospho-switch paradigm we first observed in our microarray experiments. 
To determine whether interactions between endogenous PRMT5 and 
NHERF2 or 14-3-3ε could be detected in cells, we performed GST pull-downs with 
NHERF2 and 14-3-3ε from lysates of HeLa cells cultured in the presence or absence 
of the phosphatase inhibitor, calyculin A. Under hypophosphorylated conditions, 
endogenous PRMT5 interacted with NHERF2, but in calyculin A-treated cells, it 
interacted with the 14-3-3ε protein (Figure 18C). PRMT5 knockdown cells were 
used as a control to confirm that the bands we see by western analysis correspond 
to the PRMT5 protein. 
To confirm that the NHERF2 and 14-3-3ε  interactions observed by GST Pull-
down were driven by direct binding with the C-teminal region of PRMT5, we 
performed a similar experiment using full-length myc-tagged PRMT5 WT, and two 
different Myc-PRMT5 C-terminus mutants: one with a deletion of the last 6 residues 
of PRMT5 (Δ), and the other with a single amino acid change (T634A). 
It is important to note that PRMT5 homodimerizes (Stopa et al, 2015), and to 
reduce the influence of the myc-tagged PRMT5 proteins interacting with 
endogenous PRMT5, we performed these experiments in PRMT5 shRNA knock-
down HeLa cells, using shRNA resistant expression vectors. These experiments 
demonstrated that the hyperphosphorylation induced by calyculin A treatment is 
required for the 14-3-3 interaction and inhibits the NHERF2 interaction with PRMT5 
(Figure 18D). Additionally, the intact C-terminus is necessary as either truncation or 
the substitution of a single amino acid resulted in the total loss of both NHERF2 and 
14-3-3 binding (Figure 18D). 
 
4.3.4.The C-terminus of PRMT5 facilitates its plasma membrane association.  
 
The majority of PDZ domain containing proteins are associated with the 
plasma membrane, where they function as scaffolding for membrane proteins such 
as receptors and ion channels (Ivarsson, 2012). That is the case for six of the seven 
xxx  
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Figure 18: PRMT5 interacts with NHERF2 and 14-3-3 
A) Schematic representation of the constructs used for peptide pull-down.  
B) PRMT5 interacts with the first PDZ domain of NHERF2. Purified recombinant 
GST, GST-tagged full-length NHERF2, PDZ1 (amino acids 1 to 152 NHERF2-PDZ 
1), PDZ2 (amino acids 107 to 337 NHERF2-PDZ 2) and 14-3-3ε were incubated with 
biotinylated unphosphorylated PRMT5 peptide bound to streptavidin–agarose beads 
and detected by anti-GST immunoblot. The C-terminal peptide of PRMT5 interacted 
with GST-fusion proteins containing the full-length or with only the first PDZ domain 
of NHERF2, indicating that the interaction between PRMT5 and NHERF2 requires 
the first PDZ domain. The left lane shows the GST fusion protein inputs.  
C) Endogenous PRMT5 proteins are pulled-down by GST_14-3-3 and GST_PDZ 
proteins in the presence or absence of phosphatase inhibitors. GST pull-downs were 
carried out to validate protein microarray findings. Wild-type and knock-down 
PRMT5 HeLa cells were treated with and without calyculin A. GST pull-down 
confirmed the interaction observed in the microarray system.  
D) GST-pull-down of myc-PRMT5 proteins. GST-Pull-down of myc-PRMT5 from 
HeLa cells. shRNA PRMT5 (KD4) transiently transfected with sh4 resistant Myc- 
PRMT5 WT, Δ (6 amino acid deletion of the C-terminus) and mutant T634A.  
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PDZ domain proteins that interacted with the C-terminal region of PRMT5, including 
the strong binder NHERF2. Interestingly, a number of membrane associated 
proteins are symmetrically methylated by PRMT5 (Beltran-Alvarez et al, 2013; 
Boisvert et al, 2003; Guo & Bao, 2010; Hsu et al, 2011; Likhite et al, 2015). Hence, 
we reasoned that the C-terminus of PRMT5 may bring it to the plasma membrane. 
To explore this idea we performed cell fractionations from the intestinal epithelial cell 
line SK-CO15, which expresses NHERF2 (Yoo et al, 2012). The results indicate that 
endogenous PRMT5 is preferentially localized in the cytoplasm, but a portion of 
PRMT5 is clearly distinguishable in the membrane fraction (Figure 19A).  
Whilst the above results indicate that PRMT5 associates with the plasma 
membrane, it does not indicate whether this process is mediated by the C-terminal 
motif. To address this issue, cell fractionation were performed using full-length myc-
PRMT5 and the C-terminal deletion mutant (PRMT5Δ) transfected into SK-CO15 
cells. This approach revealed a dramatic reduction of the myc-PRMT5Δ present in 
the membrane fraction (Figure 19B) relative to myc-PRMT5, which remained 
associated with the membrane. This result confirmed that PRMT5 is membrane 
associated, and it requires its C-terminus for this sub-cellular localization.  
 
4.3.5. PRMT5 symmetrically methylates membrane-associated proteins. 
 
PRMT5 symmetrically methylates membrane proteins such as EGF receptor, 
Nav.1.5 and srGAP2, GPCRs, and dopamine receptor D2, (Beltran-Alvarez et al, 
2013; Boisvert et al, 2003; Guo & Bao, 2010; Hsu et al, 2011; Likhite et al, 2015), as 
well as membrane associated proteins such as MBP (Branscombe et al, 2001). 
Additionally, a systematic characterization of arginine-methylated proteins has 
identified numerous monomethylated receptor and membrane proteins in mouse 
brain that play an important role in synaptic transmission (Guo et al, 2014). Because 
PRMT5 is able to catalyze the symmetric dimethylation and monomethylation of 
arginine residues, (Branscombe et al, 2001), it may contribute to the methylation of 
proteins involved in synaptic transmission. Because NHERF2 is highly expressed in 
the apical portion of the plasma membrane of polarized epithelial cells, we wanted to  
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Figure 19: PRMT5 associates with membrane via its PDZ recognition motif 
A) PRMT5 is a membrane-associated protein. Human intestinal epithelial cell line 
SK-CO15 expresses high levels of NHERF2. Cellular membranes were fractionated 
by ultracentrifugation. Fractions were immunoblotted with antibodies against 
PRMT5, members of the cadherin family as integral membrane markers, NHERF2, 
which is membrane associated, and 14-3-3 as cytosolic protein marker. 
B) The C-terminus of PRMT5 positions it at the plasma membrane. Myc-tagged 
PRMT5 and PRMT5Δ were transiently transfected into SK-CO15 cells. Myc-tagged 
PRMT5 is present in the membrane fraction, while the mutant construct lacking the 
last 6 amino acids, myc-PRMT5Δ, has its membrane localization impaired. The low 
levels of Myc-PRMT5 Delta protein observed at the membrane fraction could be a 
result of homodimerization with endogenous PRMT5. Fractionation was tested with 
the indicated antibodies. Anti-pan 14-3-3 and anti-pan cadherin antibodies are 
shown as quality controls for cytoplasmic and membrane fractions, respectively. 
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investigate whether PRMT5 symmetrically methylates membrane-associated 
proteins in these types of cells. To explore this idea, we generated stable SK-CO15 
PRMT5 knockdown (SK-CO15 PRMT5-KD) cells using shRNA and repeated the cell 
fractionations as described above. Levels of PRMT5 are significantly reduced in SK-
CO15 PRMT5-KD cell lines (Figure 20, top panel). To assess the effects of PRMT5 
depletion on symmetric dimethylarginine content on membranes, cell fractions were 
probed with a pan antibody that specifically binds to symmetrically methylated 
arginine residues. This result showed that symmetric methylation is present in the 
membrane fraction; moreover, some proteins are only enriched in the membrane but 
not cytoplasmic or total cell fractions (Figure 20). Depletion of PRMT5 clearly 
decreases the level of methylation of these proteins, indicating that they are 
substrates of PRMT5. 
4.3.6. Physiological importance of PRMT5-complexes relies on its C-terminus 
 
Na+/H+ exchanger regulatory factor 2 (NHERF2) plays an important role in 
linking Na+/H+ exchanger 3 (NHE3) to the cytoskeleton. NHE3 accounts for most 
Na(+) absorption and pH homeostasis in the renal and intestinal epithelia. NHEs are 
membrane transporters that mediate the simultaneous efflux of hydrogen ions and 
influx of sodium ions across the plasma membrane to regulate intracellular pH and 
cell volume. Hence, NHE3 function is highly regulated and can be modulated by its 
interaction with multiple regulatory proteins and by post-translational modifications, 
particularly phosphorylation (Alexander & Grinstein, 2009). The second PDZ domain 
of NHERF2 interacts with NHE3 (Park et al, 2005), and we have demonstrated that 
the first PDZ domain of NHERF2 binds to PRMT5. Therefore, PRMT5 may be 
recruited to an NHE3-associated complex. 
To determine the physiological importance of membrane-associated PRMT5, 
we tested the ability of PRMT5 to affect the intracellular pH (pHi) of SK-CO15 
intestinal epithelial cells. To evaluate the activity of the Na+/H+ exchange system, 
we tested SK-CO15 control and PRMT5 KD cells using the fluorescent probe 2’,7’-
bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein BCECF-AM  (Invitrogen) that can 
xxxxxxx  
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Figure 20: Subcellular localization of SDMA proteins 
Whole-cell extracts, cytoplasm and membrane were fractionated by 
ultracentrifugation. Fractions from SK-CO15 control and knocked down PRMT5 cells 
were assessed using a pan-SDMA antibody. The antibodies against PRMT5, 
NHERF2, pan-14-3-3 and pan-Cadherin were used to demonstrate the 
compartmentalization of different proteins with the cellular fractions.  
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be used to monitor changes in pHi. PRMT5 KD cells displayed lower fluorescence 
than SK-CO15 control cells, indicating a more acidic pHi. As expected, cells treated 
with the PRMT5 inhibitor EPZ01566 also displayed a lower fluorescence (Figure 
21A). 
The Na+/H+ exchange activity of NHE3 is determined by the rate of pH 
recovery after the addition of NH4Cl, which causes intracellular acidification of 
BCECF-loaded SK-CO15 cells, and its recovery depends on the Na+ influx 
regulated by NHEs. After acidification induced by NH4Cl, the rise of the pHi indicates 
an increase in Na+ influx across the membrane (Figure 21B). This influx can be 
inhibited in both PRMT5 deficient cells and cells treated with PRMT5 inhibitor, 
indicating that PRMT5 regulates, in part, the activity of NHE3. 
To evaluate the specific contribution of the PRMT5-NHERF2 complex to pHi, 
myc-tagged PRMT5 and PRMT5T634A constructs were stably transfected into SK-
CO15 PRMT5 KD cells. Expression of myc-tagged PRMT5 effectively increased the 
pHi of SK-CO15 PRMT5 KD cells. Notably, expression of Myc-PRMT5T634A failed to 
rescue the pHi. This data further supports the idea that PRMT5 may have multiple 
roles at the plasma membrane (Figure 21C). 
To determine whether the intrinsic methyltransferase activity of Myc-PRMT5 
is altered by mutation of the T634 site, we evaluated the SDMA levels on total cell 
lysates from SK-CO15 PRMT5 KD cells rescued with either Myc-PRMT5 or Myc-
PRMT5T634A. We observed no differences in the levels of symmetric dimethylarginine 
in cells rescued with either Myc-PRMT5 or Myc-PRMT5T634A (Figure 22), indicating 
that the activity of both myc-PRMT5 forms is comparable. It is important to note that 
the interaction of PRMT5 with NHERF2 does not exclude MEP-50 from the complex, 
since MEP50 is also detected by a pull-down with GST-NHERF2 (Figure 23).  
Additionally, the subcellular localization of myc-tagged PRMT5 and Myc-
PRMT5T634A, as examined by immunofluorescence microscopy were 
indistinguishable. Further, PRMT5 membrane localization was not observed, 
probably because its was masked by the predominant cytosolic localization of 
PRMT5 (Figure 24).   
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Figure 21: A role for PRMT5 in regulating intracellular pH 
A) Intracellular pH was measured using the pH-sensitive dye BCECF-AM. The 
fluorescence of control SK-CO15 cells, PRMT5-KD cells or cells treated with 5 µM of 
PRMT5 inhibitor EPZ015666 for 48 h. pHi is determined by obtaining the ratio of 
fluorescence emission at 520 and 620 nm excited at 488 nm. The box plot 
represents the mean ± standard deviation (SD) of the ratio of fluorescence among 
the different cell lines. The p-values are indicated, p<0.05 indicates significant 
differences between two groups. 520/620 nm fluorescence emission ratios excited at 
488 nm. 
B) Na+/H+ exchange activity in SK-CO15 cells was determined by measuring the 
rate of Na-dependent pH recovery after acid loading induced by 30 mM NH4Cl. 
C) SK-CO15 PRMT5-KD cells were transfected with either Myc-PRMT5 or Myc-
PRMT5T634A, and selected with hygromycin to obtain stably transfected cell lines. 
Expression of Myc-PRMT5T634A in SK-CO15 PRMT5-KD cells resulted in a reduction 
in pHi, while the introduction of Myc-PRMT5 rescued the steady-state pHi observed 
in control SK-CO15 cells. pHi was measured as in A. 
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Figure 22: SK-CO15 PRMT5-KD rescued characterization 
SK-CO15 PRMT5 KD cells were transfected with shRNA-resistant constructs for 
Myc-PRMT5 WT or Myc-PRMT5 T634A and stable cell lines were generated. Cell 
lysates from SK-CO15 control, KD and rescued lines were characterized by western 
blotting followed by incubation with anti-PRMT5, anti-myc and anti-NHERF2 
antibodies. The activity of the myc-PRMT5 constructs was evaluated with pan anti-
SDMA antibody. 
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Figure 23: NHERF2 associates with the PRMT5-MEP50 complex 
Purified full length NHERF2 FL fused to GST and GST alone were incubated with 
SK-CO15 lysates. GST-NHERF2 FL, but not GST alone, was able to interact with 
endogenous PRMT5 and MEP50. 
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Figure 24: Myc-PRMT5 WT and Myc-PRMT5T634A cellular localization 
SK-CO15 PRMT5-KD cells stably transfected with either Myc-PRMT5 WT or Myc-
PRMT5 T634A were fixed and stained with anti-Myc (red), and anti-NHERF2 (green) 
antibodies, DAPI was used for nuclear localization (blue).  
	  83	  
4.3.7. The C-terminal motif of PRMT5 is required for mouse viability 
 
To evaluate the biological function of the C-terminus of PRMT5 in vivo, we used 
CRISPR/Cas9 to generate a mouse model in which we replaced the last 6 amino 
acids of PRMT5 with an HA tag (PRMT5Δ+HA). A guide RNA was generated by Sage 
laboratories and injected in a one-cell embryo together with a donor sequence that 
encoded PRMT5Δ+HA. Two founders for PRMT5Δ+HA knock-in mice (#2 & #6) that had 
the expected insertion of a HA-tag and the concomitant removal of the last 6 
residues of PRMT5 were obtained (Figure 25A). Two additional founders (#8 & #10) 
had distinct C-termini due to the presence of indels that generated frameshifts 
(Figure 25A). PRMT5Δ+HA lines #6 & #10 were bred to homozygosity, but of 71 E9.5 
and E11.5 embryos analyzed, none were PRMT5Δ+HA homozygotes. This indicates 
that an intact PRMT5 C-terminus is required for mouse viability, given that the HA-
tagged truncated protein is expressed in heterozygotes (Figure 25B). 
Analysis of heterozygous embryos demonstrated not only that the PRMT5Δ+HA 
protein is expressed, but also that the total levels of PRMT5 and MEP50 are similar 
between heterozygous PRMT5Δ+HA and wild-type littermates (Figure 25B). This is 
important because MEP50 is PRMT5 main co-activator for methylation. Further, the 
levels of H2AR3me2s are identical, but the total levels of symmetric methylation, 
examined using a pan-SDMA antibody, are different between heterozygous 
PRMT5Δ+HA and wild-type littermates, suggesting that a subset of proteins is not 
methylated efficiently in the heterozygous PRMT5Δ+HA embryos (Figure 25B). 
Neither heterozygous adults (data not shown) nor E11.5 embryos displayed an 
obvious phenotype (Figure 25C).  
To overcome the limits of our homozygous PRMT5Δ+HA mouse model, we 
attempted to develop homozygous PRMT5Δ+HA ES cell lines derived from 
intercrosses of heterozygous PRMT5Δ+HA mice. We established four wild-type and 
six heterozygous lines, but no homozygous lines. This suggests that the PDZ/14-3-3 
switching motif is required for the derivation of ES cells. The function that depends 
upon the PRMT5 C-terminus may account for our inability and the inability of other 
groups to generate PRMT5 null ES cells (Li et al, 2015; Tee et al, 2010).  
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Figure 25: PRMT5Δ+HA mouse generated by CRISPR/Cas9 
(A) Schematic showing PRMT5 C-terminal sequences of the founder mice. Four 
founder mice were obtained, #2 & #6 display the expected insertion of HA-tag, while 
mouse #8 & #10 represent alterations at the C-terminus due to indels, resulting in a 
shift of reading frame.  
(B) Western blot analysis of PRMT5Δ+HA in E11.5 WT and heterozygous embryo 
lysates using anti-HA, anti-PRMT5, anti-MEP50, anti-SDMA and anti-H2AR3me2s 
(BL14494 M12-5079) antibodies. β-actin was used as a loading control.  
(C) WT and heterozygous PRMT5Δ+HA embryos at E11.5 show no obvious 
phenotype. 
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4.3.8. Discussion 
 
PRMT5 by itself is catalytically inactive, as shown by its failure to methylate 
its preferred substrates when recombinant PRMT5 is expressed in bacteria. Yet, 
PRMT5 immunoprecipitated from either mammalian or insect cells is catalytically 
active in in vitro methylation assays, implying that PRMT5 activity depends upon the 
formation of protein complexes and/or post translational modifications in eukaryotic 
cells. As such, understanding the mechanisms that govern the formation of the 
PRMT5 complex is critical in the field of arginine methylation. 
Phospho-dependent protein-protein interactions can regulate PRMT5 
enzymatic activity by either serving as a platform for different binding partners, thus 
dictating substrate recognition, or by blocking the binding sites of PRMT5 co-
activators. Indeed, PRMT5 has been shown to be phosphorylated at three tyrosine 
residues, which alters its binding with MEP50, its main co-activator, consequently 
reducing PRMT5 enzymatic activity (Liu et al, 2011). 
In our current work, we have examined the phosphorylation of PRMT5. 
Through the use of protein microarrays, we showed that phosphorylation at the C-
terminus serves to switch between two binding module interactions, PDZ and 14-3-
3. That is, when PRMT5 is unphosphorylated, its interaction with PDZ domain-
containing proteins is promoted, but when it is phosphorylated, it dissociates from 
PDZ domain proteins and preferentially binds 14-3-3 proteins. The 14-3-3/PDZ 
overlapping binding motif exists in other proteins, suggesting that this binding switch 
may be a common protein binding paradigm. 
We have demonstrated that PRMT5 is phosphorylated by AKT and SGK at 
the C-terminus, creating a binding motif that controls its interaction with other 
proteins, including 14-3-3 proteins. Although PRMT5 has been previously identified 
as a 14-3-3 interacting protein by two independent groups, neither the motif that 
mediated the interaction nor the kinase that phosphorylated PRMT5 was known. (Jin 
et al, 2004; Weimann et al, 2013). Our studies provide a guide for future 
investigations of PRMT5 in the context of its phosphodependent interactions with 14-
3-3 proteins. 
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We have also observed the interaction between PRMT5 and the PDZ domain 
of NHERF2, which contrary to the interaction with 14-3-3 proteins, is inhibited by 
phosphorylation. The study of PRMT5 interaction with the PDZ domain of NHERF2 
has enabled us to investigate, for the first time, the membrane association of 
PRMT5. Furthermore, we demonstrate the existence of PRMT5’s substrate at the 
plasma membrane, suggesting that they may play a role in the regulation of 
membrane associated proteins, such as ion exchangers.  
Indeed, NHE3 and CFTR are ion exchangers that play an important role 
during the normal digestive process, which is regulated by PDZ-containing proteins. 
In fact, the CFTR Cl− channel is one of the best known ion transport proteins 
involved in anion secretion, and NHE3 is the predominant Na+/H+ exchanger for 
sodium absorption. Both CFTR and NHE3 proteins interact with NHERF2 and other 
PDZ-containing proteins (Lamprecht & Seidler, 2006). Therefore, we hypothesize 
that PRMT5 may regulate the function of ion exchangers by engaging protein 
complexes assembled via NHERF2. 
Alteration of the pHi results in response to changes in NHE3-mediated 
sodium influx. Our studies evaluating pHi clearly demonstrate that in cells lacking 
PRMT5, the intracellular pH is significantly reduced and its recovery after an acidic 
load is altered. Additionally, rescue experiments using myc-tagged mutant 
PRMT5T634A fail to recover the pHi when compared with myc-tagged PRMT5. 
Interestingly, NHERF2 has a high affinity for Ezrin, a important protein in cell 
surface structure (Yang et al, 2015), and this association is regulated through 
phosphorylation of NHERF2 on serine 303 by SGK. This phosphorylation decreases 
the affinity between NHERF2 and Ezrin and induces the redistribution of NHERF2 
toward the cytosolic compartment (Yang et al, 2015). Thus, simultaneous 
phosphorylation of NHERF2 and PRMT5 by SGK may be a combined mechanism to 
prevent the interaction of PRMT5 with NHERF2 in the cytoplasm, thereby promoting 
the interaction of PRMT5 with 14-3-3 proteins and preventing its re-engagement with 
PDZ domain-containing proteins. 
Finally, we explored whether the C-terminus of PRMT5 is essential for its in 
vivo functions by creating CISPR/Cas9 mice with the last six amino acids replaced 
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with an HA tag, as well as mice with an altered C-terminus. Both set of mice lacked 
the critical 14-3-3/PDZ binding motif. We found that the C-terminus of PRMT5 is 
essential for viability as no homozygous mutants embryos were recovered. Likewise, 
no homozygous PRMT5Δ+HA ES cell lines could be created. The precise reason for 
this lethality remains to be explored. 
We further investigated the nature of the C-terminal motif of PRMT5 by 
studying its interaction with 14-3-3 proteins and PDZ domains by utilizing protein 
microarrays and a number of modified peptides (Figure 26A). First we removed the 
last C-terminal hydrophobic residue required for the interaction with PDZ domains. 
As expected, this modification blocked the binding of this peptide with PDZ domains 
and greatly enhances the interaction with 14-3-3 proteins. Because an upstream 
arginine residue is frequently present in the 14-3-3 motif III (Coblitz et al, 2006; 
Ganguly et al, 2005), we wanted to investigate whether it is necessary for interaction 
with 14-3-3 proteins. Mutation of R631 to alanine reduces 14-3-3 interactions, but 
enhances PDZ interaction with the PRMT5 peptides, whereas mutation of R631 to 
lysine, thus preserving the positive charge of the residue, slightly reduces the 
interactions with 14-3-3 and PDZ. Interestingly, the mutation of arginine to alanine or 
lysine enhances the interaction with PDZ but only when the peptide is 
phosphorylated (Figure 26B). This result was unexpected and further research will 
be needed to understand the nature of this motif, and will help us to design mouse 
models that block either 14-3-3 or PDZ binding, but not both. The summary of 
observed interactions are listed in Figure 26C.  
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Figure 26: Mutation in the C-terminus of PRMT5 alters 14-3-3 and PDZ 
recognition 
A) Sequence of peptides. Red residues indicate mutations the underscore indicates 
a missing residue. 
B) 14-3-3/PDZ microarray probed with Cy-5 labeled peptides. Phosphorylated 
peptides (right) and unphosphorylated peptides (left). List of proteins in Figure 15.  
C) Graphical depiction of the interactions observed in (B). Red squares indicate 
interactions with phosphorylated peptides. (Experiments were performed by Karynne 
Black in Dr. Bedford’s laboratory).  
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4.4. Future Studies 
 
From our PRMT5Δ+HA mouse model study we can infer that the C-terminus of 
PRMT5 is vital for its full biological function. However, because the homozygous 
PRMT5Δ+HA model was embryonic lethal, we could not investigate the precise role of 
this motif. Therefore, to evaluate the function of the PRMT5 C-terminus in adult 
tissues displaying an abundance of PDZ domain activity, such as heart, kidney and 
neurons, we need to generate a conditional knock-in mouse. By crossing our 
PRMT5Δ+HA mouse with a PRMT5flox mouse, we will generate PRMT5Δ+HA/flox mice, 
which can then be crossed to a tissue-specific Cre line to obtain tissues that only 
express the C-terminally truncated form of PRMT5. 
For example, by using a Nestin-Cre/PRMT5Δ+HA/flox cross, a conditional knock-
in will be generated in neurons, where the PDZ domain plays an important role in 
neuron function (Kim & Sheng, 2004). The unphosphorylated C-terminus of PRMT5 
interacts with the PDZ domain containing proteins NHERF2, Grip1, Pdlim5 and 
Scrb1, which have been shown to play a role in neuronal development and at nerve 
synapses (Filippov et al, 2010; Geiger et al, 2014; Murdoch et al, 2003; Ren et al, 
2015). 
Because the C-terminus harbors both the 14-3-3 and PDZ binding motif, it is 
difficult to assess the separate functions of PRMT5 related to either the 14-3-3 
binding module or PDZ domain binding module. To investigate the role of each 
binding module independently, it will be necessary to disrupt the interaction with one 
protein module without disturbing the other. This could be done by introducing single 
amino acid changes into the PDZ/14-3-3 binding motif. We used our protein domain 
array platform to assess this option (Figure 26).  
By removing the last amino acid (L), we could successfully preserve phospho-
dependent interactions with 14-3-3 proteins, while still disrupting the PDZ interaction. 
On the other hand, mutation of an arginine that is usually present on 14-3-3 binding 
motifs, partially disrupted the interaction with these proteins, however future studies 
will be needed to establish a mutation that will effectively alter the binding with 14-3-
3 proteins. 
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The establishment of mutations that will shift PRMT5 interaction toward 14-3-
3 or PDZ domain-containing proteins will allow us to create knock-in mice with 
sgRNA and Cas9 mRNA as before. These mouse models will give us the 
opportunity to evaluate the role of each binding module in vivo. 
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Chapter 5: Role of PRMT5 in DNA damage response 
 
5.1. Introduction 
 
5.1.1. The DNA Damage Response 
 
Cells must respond appropriately to DNA damage and replication stress for 
their survival. Genomic integrity is crucial to preserve life, and not surprisingly the 
basic mechanisms to cope with DNA damage are conserved among species. 
Organisms are continuously exposed to DNA-damaging agents present in the 
environment. These include DNA damaging compounds released from our own 
metabolic processes, and exogenous agents like ultraviolet (UV) radiation, ionizing 
radiation (IR), and other agents that attack DNA and produce a variety of alterations 
in the chemical structure of DNA (De Bont & van Larebeke, 2004).  
To cope with genomic instability, cells count on DNA repair protein 
complexes, orchestrated in defined signaling pathways termed DNA damage 
response (DDR) pathways. However, DDR faces a complicated challenge: DNA 
compaction. In eukaryotic cells, a high level of compaction is necessary to 
accommodate the DNA inside the nucleus. Although necessary, compaction of DNA 
into chromatin represent a barrier for accessing DNA for various cellular processes, 
including DNA repair. Thus, DDR studies should not only take chromatin structure 
into consideration, but also the mechanisms involved in its compaction or relaxation. 
The coordination of different molecular processes that activate DDR will 
determine cell destiny, either DNA repair or cell death. Unfortunately, improperly 
repaired damage can generate mutations and chromosomal aberrations, leading to 
oncogenic transformation and tumor progression. Understanding the molecular basis 
of DDR is crucial not only for gaining insight into the molecular mechanisms of 
carcinogenesis, but also to establish the effect of genotoxic drugs in cancer therapy. 
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Cells can withstand a large number of DNA lesions per day, and repair can 
occur via diverse pathways, as depicted in Figure 27: direct repair (DR), base-
excision repair (BER), nucleotide-excision repair (NER), mismatch repair (MMR), 
homologous recombination (HR), and nonhomologous end joining (NHEJ). DNA 
double-strand breaks (DSBs) are the most dangerous form of DNA damage and are 
one of the most common events that cause genomic instability. Efficient repair of 
DNA damage is particularly important for dividing cells, that is why in response to a 
DSB, the cell has acquired an intricate signaling system to detect the lesion, initiate 
repair, and also to stop the cell cycle thus enabling the repair to be completed. To 
effectively repair a DSB, there are two different DDR pathways: nonhomologous 
end-joining (NHEJ) and homologous recombination (HR) (Chapman et al, 2012). 
 
Figure 27: DNA damage repair pathways 
From Luo M, He H, Kelley MR, Georgiadis MM (2010) Redox regulation of DNA 
repair: implications for human health and cancer therapeutic development. Antioxid 
Redox Signal 12: 1247-1269. Reprinted with permission of Mary Ann Liebert, Inc. 
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5.2. DNA Repair Mechanisms: NHEJ and HR 
 
5.2.1. Nonhomologous end-joining 
 
NHEJ is a process used to repair DNA ends at double-strand breaks (DSBs). 
It is particularly important when a homology donor is not in close proximity, such as 
in nondividing haploid organisms or in diploid organisms that are not in S phase. 
When a double-strand break occurs in eukaryotes, the broken DNA ends are bound 
by the Ku70-Ku80 heterodimer (Ku). Then the KU-DNA end complex can recruit the 
nuclease, polymerase and ligase, which work together to promote direct ligation of 
the DSB ends in an error-prone manner (Lieber, 2010). However, during S phase 
where the sister chromatid is available, homologous recombination is the preferred 
pathway (Scully & Xie, 2013). 
 
5.2.2. Homologous recombination 
 
 
In HR, the MRN (MRE11/RAD50/NBS1) complex localizes to the break site, 
recruiting ATM (ataxia telangiectasia–mutated protein) through the interaction with a 
C-terminal motif in NBS1. ATM phosphorylates multiple downstream proteins, 
including histone H2AX molecules, adjacent to the break site, thus marking nearby 
chromatin with γ-H2AX, and signaling the beginning of DSB recognition. The initial 
signal is spread and amplified by the recruitment of MDC1, which functions as a 
platform that mediates complex formation after the initial signal. MDC1 comprises a 
FHA domain at the extreme N-terminus, followed by a series of STD repeats, a 
series of TQXF motifs, and finally two tandem BRCT domains at the C-terminus. All 
these components are known to mediate MDC1 interaction with other proteins, thus 
BRCT domains bind to γH2AX; phosphorylated TQXF binds to the FHA domain of 
RNF8; phosphorylated SDT repeats bind to the FHA and BRCT domains of NBS1; 
and the FHA domain interacts with phosphorylated CHK2 and with N-terminus of 
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MDC1 itself mediating a head-to-tail dimerization (Jungmichel et al, 2012; Lou et al, 
2003; Mohammad & Yaffe, 2009). A number of other downstream factors involved in 
HR or NHEJ assemble on the γH2AX-MDC1 chromatin complex (Figure 28). These 
factors include BRCA1, RAP80 and 53BP1, which aid in forming larger complexes at 
the double strand break to allow its repair (Coster & Goldberg, 2010; Panier & 
Boulton, 2014; Scully & Xie, 2013). 
HR and NHEJ are orchestrated through a cascade of events requiring DNA 
damage sensors, transducers, and effectors. All of these events take place within 
the context of chromatin. Likewise, synchronized post-translational modifications 
occur on the histone N-terminal tails, which themselves help regulate the recruitment 
of DDR factors (Panier & Boulton, 2014) (Table 3). 
 
5.3. Histone code for DNA Double-Strand Break Repair 
 
Chromatin structure is well regulated in order to control the compaction of and 
accessibility to DNA. The basic structural unit of chromatin is the nucleosome. The 
nucleosome is composed of 146 bp of DNA wrapped around two units each of 
canonical histones H2A, H2B, H3, and H4. Different mechanisms cooperate to 
regulate chromatin structure and DNA accessibility. These include: remodeling 
complexes that will slide the nucleosomes and exchange or remove histones from 
the chromatin; histone chaperones that control the supply and distribution of 
histones and histone variants (Gurard-Levin et al, 2014); and post-translational 
modifications (PTMs) of histones. The N-terminal tail of each histone protrudes from 
the nucleosome and bears modifications such as acetylation, methylation, 
phosphorylation and ubiquitination. These modifications modulate docking sites that 
facilitate the interaction with non-histone proteins serving as readers, writers and 
erasers. The combinations of PTMs on the histone tail constitute what is known as 
the “histone code”. This code helps control DSB repair in a spatial and temporal 
manner. 
Almost two decades ago, the phosphorylation of histone H2A variant H2AX 
xxxxxxxxx  
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Figure 28: HR and NHEJ DNA Repair Mechanisms 
Two DDR pathways are depicted, homologous recombination (HR) and non-
homologous end joining (NHEJ). Both pathways depend on recruitment of MDC1 to 
sites of DNA damage marked previously with γ-H2AX. Reprinted by permission from 
Macmillan Publishers Ltd: Nature Structural & Molecular Biology (Lu & Matunis, 
2013), Copyright (2013).  
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on serine 139 (termed γ-H2AX) was shown to be involved in DNA DSB repair 
(Rogakou et al, 1998). This provided the first indication of the importance of histone 
variants and PTMs on the histone tail in the context of DDR. In mammalian cells, 
phosphorylation of H2AX serine 139 is mediated by ATM, ATR, and DNA PKcs 
(Williamson et al, 2012).  
Not only do phosphorylated histone variants play a role in regulating 
chromatin structure at the site of DNA damage, the phosphorylation of canonical 
histones are also important in DNA damage response (Table 3). Likewise, histone 
acetylation at sites of DNA damage is an important chromatin modification in DNA 
repair. Histone H4 and H3 acetylation on lysine is crucial for both NHEJ and HR 
(Table 3) (Tamburini & Tyler, 2005; Williamson et al, 2012). 
Another PTM, ubiquitination is essential for the recruitment of proteins during 
DDR. The E3 ubiquitin ligase RNF8 is recruited to chromatin following the 
incorporation of MDC1 to the break site by γ-H2AX. RNF8 ubiquitinates H2AX and 
other proteins leading to the focal accumulation of 53BP1 (Mailand et al, 2007). 
However, recruitment of 53BP1 is mediated not only by ubiquitination, but also by 
dimethylation of histone H4 lysine 20 of (H4K20me2) as well as other factors that 
provide a docking site for the binding of the 53BP1 tandem Tudor domain (Hsiao & 
Mizzen, 2013; Schotta et al, 2008).  
H4K20me2 is abundant and its levels do not appear to change following DNA 
damage when examined by using conventional techniques (Pei et al, 2011), 
suggesting a regulatory mechanism to limit the interaction of 53BP1 and H4K20me2 
(Hsiao & Mizzen, 2013). Dr. Durocher’s group showed that 53BP1 is a bivalent 
histone modification reader in which H4K20me2 and H2AK15ub are necessary for 
53BP1 recruitment to chromatin (Fradet-Turcotte et al, 2013), suggesting that 
ubiquitination of H2AK15 could be the limiting factor for the localization of 53BP1 to 
sites of DNA damage. 
H3 harbors four lysine residues that are methylated in response to DNA 
damage: K4, K9, K36 and K79 (Table 3). As was observed for H4K20, H3K4 and 
H3K9 methylation are not exclusively dedicated to DDR. It has recently been 
suggested that after DNA damage, euchromatin takes on a structure more similar to 
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heterochromatin as it also bears H3K9 methylation and forms a repressive structure, 
thus inhibiting local transcription. However, after DDR is established, this repressive 
structure is removed via a negative feedback mechanism that regulates release of 
the repressive complex associated with H3K9 methylation, thus leading to relaxation 
of chromatin structure (Ayrapetov et al, 2014). 
Methylation is a widespread modification occurring on lysine and arginine 
residues. Although arginine methylation on histones has been linked to other 
processes, including transcription regulation, it is currently unknown whether histone 
arginines are modified during or in response to DNA damage repair. Nevertheless, 
arginine methylation is observed on non-histone proteins associated with DDR, such 
as MRE11, 53BP1, BRCA1, PolBeta, P53, FEN1 and RAD9 (Auclair & Richard, 
2013). 
 
5.4. Arginine methylation and DDR 
 
As discussed earlier, arginine methylation is a common post-translational 
modification. In mammals, this modification is catalyzed by nine-known protein 
arginine methyltransferases (PRMT 1 - 9). These enzymes transfer one or two 
methyl groups to the side-chain nitrogen atoms of arginine residues. Recent studies 
have shown that PRMT7 is an epigenetic regulator of DDR: PRMT7 symmetrically 
dimethylates histones H2A and H4 to form H2AR3 and H4R3 at the promoter of 
DNA repair genes (Karkhanis et al, 2012). Hence, PRMT7 deficiency results in the 
enhanced expression of these DNA repair genes thereby increasing cellular 
resistance to genotoxic drugs (Karkhanis et al, 2012). PRMTs also play a role in 
DNA damage response by modifying non-histone proteins involved in DNA damage 
repair.  
Asymmetric dimethylation of arginine mediated by PRMT1 is found in a broad 
range of proteins, especially those bearing glycine and arginine-rich RGG/RG motifs 
(Tang et al, 2000). PRMT1 deficiency results in spontaneous DNA damage, 
checkpoint defects, hypersensitivity to DNA-damaging agents and chromosomal 
instability, as observed in conditional PRMT1 knockout MEFs (Yu et al, 2009). 
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These observations show that PRMT1 has an important role in DDR. Proteins 
involved in DDR that are modified by PRMT1 include MRE11, 53BP1, BRCA1, 
hnRNPUL1 and Pol β (Boisvert et al, 2005a; Boisvert et al, 2005b; El-Andaloussi et 
al, 2007; Guendel et al, 2010; Gurunathan et al, 2015).  
PRMT5 associates with a large number of proteins, and these interactions 
regulate its catalytic activity, generating SDMA on a variety of substrates, including 
DNA damage response proteins (Auclair & Richard, 2013). Like PRMT1, PRMT5 
also preferentially methylates RGG/RG motifs. PRMT5 targets proteins involved in 
the DNA damage response including p53, FEN1 and Rad9a (Guo et al, 2010; He et 
al, 2011; Jansson et al, 2008). 
The tumor suppressor p53 and its role as a transcriptional activator are of 
great importance for human health, thus, enormous effort has been dedicated to 
understanding the mechanisms of its regulation. A major advance in this area 
occurred following the discovery of PTMs on p53, which were shown to modulate its 
function, including arginine methylation mediated by PRMT5. p53 methylation occurs 
on arginines 333, 335 and 337 and increases in response to DNA damage. This 
event induces cell cycle arrest that depends on the activation of p21 expression in 
response to DNA damage (Jansson et al, 2008). 
The endonuclease FEN1 is also methylated by PRMT5. This endonuclease 
removes 5-prime overhanging flaps created during normal DNA replication and 
during DDR (Hosfield et al, 1998). The nuclease function of FEN1 must be regulated 
precisely, both temporally and spatially. A repertoire of PTMs regulates FEN1, 
including acetylation, phosphorylation, sumoylation, ubiquitination and methylation 
(Guo et al, 2012; Guo et al, 2010; Hasan et al, 2001). Methylation of FEN1 at 
arginine 192 facilities PCNA binding and the recruitment of FEN1 to the replication 
fork and also enhances DNA repair (Guo et al, 2010). 
RAD9 is a cell cycle checkpoint exonuclease that arrests the cell cycle upon 
DNA damage. Rad9 forms a checkpoint protein complex with RAD1 and HUS1 
xxxxx  
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RESIDUE PTM MODIFIER FUNCTION IN DDR REFERENCES 
H2AK15 Ub ENF168 
Promotes the 
recruitment of 53BP1 
to DSB 
(Fradet-Turcotte et 
al, 2013) 
H2AK119 Ub 
RNF8, 
RNF168 
Leads to the release of 
H2AX from damaged 
chromatin upon DSB 
(Ikura et al, 2007) 
H2AT120 Pho Bub1, NHK-1 
DDR sensitivity 
Activates the spindle 
checkpoint 
(Kawashima et al, 
2010; Yang et al, 
2012) 
H2AXK5 Ac TIP60 
Necessary for H2AX 
K119ub 
(Ikura et al, 2007) 
H2AXK36 Ac CBP/p300 
Regulates radiation 
sensitivity 
 
(Jiang et al, 2010)  
H2AXS139 Pho 
ATM, ATR, 
DNA-PKcs 
Recruits and 
accumulates MDC1 
and promotes histone 
acetylation 
(Paull et al, 2000; 
Rogakou et al, 
1998) 
H2AXK119 Ub 
RNF8, 
RNF168, 
TIP60-UBC13 
Recruits DDR proteins  
(Mailand et al, 
2007) 
H2AXY142 Pho WSTF, EYA 
Regulates foci 
formation upon DNA 
damage. 
Dephosphorylation 
favors recruitment of 
MDC1 to the tail of γ-
H2AX 
(Xiao et al, 2009) 
(Cook et al, 2009) 
H2BS14 Pho CK2 Detected upon DNA (Fernandez-
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damage induced by IR Capetillo et al, 
2004) 
H2BK120 Ub 
RNF20-
RNF40 
Recruitment of NHEJ 
and HR proteins 
Chromatin remodeling 
during HR 
(Moyal et al, 2011; 
Nakamura et al, 
2011) 
H3K4 Me3 SET1 
Stimulates V(D) J 
recombination via RAG 
complex. Required for 
DNA cleavage during 
Ig class switch 
recombination 
(Shimazaki et al, 
2009; Stanlie et al, 
2010) 
H3K9, K14, 
K23, K27 
Ac 
GCN5, 
CBP/p300 
Essential for viability 
following HR 
(Tamburini & Tyler, 
2005) 
H3K9 Me3 
Suv3-
9H1/Suv3-9H2 
Activates TIP60  
(Ayrapetov et al, 
2014; Sun et al, 
2009) 
H3K18 Ac 
GCN5, 
CBP/p300 
Regulates Ku protein 
recruitment during 
NHEJ 
(Ogiwara et al, 
2011) 
H3K36 Me2 
Metnase/SET
MAR 
Recruits NBS1 and the 
KU complex during 
NHEJ 
(Fnu et al, 2011) 
H3K56 Ac 
GCN5, 
CBP/p300 
RTT109 
K56ac is reduced upon 
DNA damage. K56ac 
is required to reinstate 
the chromatin structure 
after DDR 
(Chen et al, 2008; 
Miller et al, 2010) 
H3K79 Me3 DOT1 
Repair of UV damage 
in budding yeast 
(Bostelman et al, 
2007) 
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H3S10 Pho 
Ipl1 (Sc), 
AuroraB (Hs), 
RSK2, MSK1, 
ERK1, p38, 
Fyn, Chk1, 
PRK1 
Decrease of 
phosphorylation 
following DNA damage 
induced by UV 
irradiation 
(Shimada et al, 
2008) 
H3T11 Pho Chk1 
Decrease of 
phosphorylation 
following DNA damage 
induced by UV 
irradiation 
 (Shimada et al, 
2008) 
H4S1 Pho CK2 
Regulates chromatin 
acetylation 
(Cheung et al, 
2005; Utley et al, 
2005) 
H4K5, K8, 
K12, K16 
Ac 
MOF, TIP60, 
TRRAP, 
CBP/p300 
Recruits DDR factors  
(Ogiwara et al, 
2011; Sharma et 
al, 2010) 
H4K20 Me2 
Suv420H1/Su
v420H2, 
MMSET 
Recruits DDR factors 
(Sanders et al, 
2004) 
H4K91 Ub BBAP 
Promotes H4K20me 
and recruits 53BP1 
(Yan et al, 2009) 
Table 3: Histone modification in DDR 
Adapted from Hunt et al, 2013 
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(Volkmer & Karnitz, 1999). RAD9 is methylated at Arg172, Arg174 and Arg175. 
Arginine methylation occurs on proteins involved in the DNA damage 
response. In this study, we will demonstrate that PRMT5 interacts with the FHA 
domain of MDC1, and will show the localization of PRMT5 at induced DSB as well 
as an enrichment of H4R3 methylation at these sites. The regulatory role of histone 
modifications in DNA damage repair response is well established; however, despite 
the large number of arginine methylation sites identified on histones, none have yet 
been connected to DDR. 
 
5.5. Results 
 
5.5.1. Phosphorylated PRMT5 interacts with the FHA domain of MDC1 
 
We have demonstrated that the C-terminus of PRMT5 is phosphorylated at 
threonine 634 and that this modification allows the interaction of PRMT5 with 14-3-3 
proteins. In addition to 14-3-3 proteins, threonine phosphorylation generates docking 
sites for a number of domains such as, WD40 repeats, WW, BRCT and FHA 
domains. To identify additional phospho-dependent interactions, we created a 
phospho-threonine binding protein microarray containing FHA, WW and BRCT 
domains in addition to the seven 14-3-3 protein isoforms (Figure 29). 
To discover novel PRMT5 phospho-threonine binding partners, a synthetic 
PRMT5 peptide harboring pT634 was tested on this phospho-threonine binding 
array. As expected, the phosphorylated peptide (Figure 29 top panel) binds most of 
the 14-3-3 isoforms. Moreover, the PRMT5 pT634 peptide interacted with the FHA 
domain of MDC1, whereas the unphosphorylated peptide (Figure 29 middle panel) 
showed no interactions. We confirmed these interactions using peptide pull-down 
assays (Figure 30A).  
In order to investigate whether endogenous PRMT5 could interact with the 
FHA domain of MDC1, we performed a GST pull-down experiment. We could 
xxxxxxxx  
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Figure 29: PRMT5 phosphothreonine specific binding partners 
To identify the binding partner for phosphothreonine, a PRMT5 peptide harboring 
pT634 was tested using a protein microarray containing 14-3-3 proteins as well as 
FHA and BRCT domains. The phosphorylated peptide (top panel) binds 14-3-3 
isoforms as well as the FHA domain of MDC1. The unphosphorylated peptide 
(middle panel) shows no interactions. Anti-GST (bottom panel) is used as a protein 
microarray loading control.   
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Figure 30: PRMT5 interacts with FHA domain of MDC1 
(A) Peptide pull-down corroborates protein microarray findings. GST-fusion proteins 
of candidate phospho-dependent binding partners identified by protein domain 
microarray analysis were incubated with biotinylated PRMT5 phospho-threonine 643 
(pT634) or unphosphorylated (control) peptides bound to streptavidin–agarose and 
detected by anti-GST immunoblot. Inputs of the GST fusion proteins are shown.  
(B) Purified 14-3-3ε and MDC1 FHA domain GST-fusion proteins were incubated 
with whole embryo lysates.   
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detect the interaction between endogenous PRMT5 and the FHA domain of MDC1 
fused to GST in untreated whole embryo (E12.5) lysates (Figure 30B). It is 
important to note that this interaction occurs in an embryonic lysate that was not 
chemically hyperphosphorylated. However we did not see this interaction using 
HeLa, U2OS or MCF7 cells regardless of hypo- or hyperphosphorylated (data not 
shown). 
 
5.5.2. PRMT5 is recruited to sites of DNA double-strand breaks 
 
MDC1 binds to gamma-H2AX through its BRCT domain. Subsequently, it 
functions as an assembly platform, expanding the signal for DNA repair. To 
understand the functional implications of the MDC1-PRMT5 interaction, we 
examined whether PRMT5 is recruited to DNA double-strand breaks. To explore this 
idea, we used an inducible system that takes advantage of a rare cutting 
endonuclease I-PpoI. Expression of I-PpoI specifically cleaves a limited number of 
target sites, generating DSBs in the genome, at well defined locations. In this 
system, I-PpoI is fused to a mutant estrogen receptor (ER) hormone-binding domain 
that promotes rapid nuclear localization in response to 4-hydroxytamoxifen (4-OHT) 
(Figure 31A) (Berkovich et al, 2008). Using this system we analyzed whether 
PRMT5 is recruited to DSBs upon the induction of I-PpoI by performing ChIP 
assays. 
We found that upon induction of I-PpoI, PRMT5 was recruited to an I-PpoI 
cleavage site in U2OS cell. As expected we also observed the recruitment of 
phosphorylated ATM (Figure 31B). Interestingly, we identified an increase in 
symmetric methylation of histone 4 at arginine 3 (H4R3me2s), which correlates with 
the presence of PRMT5 at the site of damage. In contrast, no difference in the levels 
of asymmetric dimethylation of H4R3 (Figure 31B) was observed. These results 
demonstrate that PRMT5 is recruited to sites of DNA double-strand breaks and that 
its substrate, H4R3, is predominantly symmetrically dimethylated at the site of 
damage. 
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Figure 31. PRMT5 recruitment to DNA damage sites 
A) U2OS cells were infected with HA–ER–I-PpoI retrovirus. 24 h after infection, cells 
were induced with 4-OHT for 12 h. ChIP analysis was carried out using the indicated 
antibodies and a primer pair adjacent to a single I-PpoI cleavage site.  
B) Schematic representation of the I-PpoI system. I-PpoI is an endonucelase that 
has ~300 target sites in the human genome. This system allows for the examination 
of events occurring at a defined DNA DSB site. (Experiments were performed by Dr. 
Anup Biswas in Dr. Johnson’s laboratory). 
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5.5.3. H2AR3me2s is catalyzed by PRMT5 and does not vary after IR 
 
To further investigate the role of the interaction between PRMT5 and the FHA 
domain of MDC1, we developed a tamoxifen-inducible PRMT5 KO MEF cell line. 
After 4-OHT treatments for 21 days, cells were lysed and the protein levels of 
PRMT5 were analyzed by western blot using anti-PRMT5 antibody (Figure 32A). 
We also investigated whether the H4/H2AR3me2s mark was affected by the loss of 
PRMT5. We used a panel of antibodies generated by CST, together with a 
commercially available H4R3me2s antibody. We observed that the levels of 
symmetric dimethylation on H2A were reduced to a greater extent than on H4R3 
(Figure 32B). We have also further characterized, using immunofluorescence 
microscopy, one of the antibodies that by western blot specifically recognized 
H2AR3me2s. The signal of this antibody shows a strong nuclear localization in 
control MEF cells and is notably reduced in the absence of PRMT5 (Figure 33). 
Having characterized this antibody, we explored whether this PRMT5 
mediated mark changed after IR. Untreated MEF PRMT5 LoxP (F/F) cells were 
irradiated (5 Gy), then stained with the previously characterized antibody. Gamma-
H2AX was used as positive control for nuclear foci formation. The localization and 
intensity of H2AR3me2s staining did not considerably vary after IR. In contrast, 
gamma-H2AX was rapidly visualized after IR increasing to a maximum intensity at 1 
hour, and gradually disappeared by 12 hours (Figure 34). These results suggest 
that the activity of PRMT5 toward H2A does not change with the induction of DNA 
double strand breaks by IR. 
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Figure 32: MEF KO PRMT5 and anti-H4/H2AR3me2s characterization 
A) Cells were obtained from a conditional knockout mouse harboring LoxP (F/F) 
sequences flanking exon 7 in the Prmt5 gene (Bezzi et al, 2013) and expressing 
tamoxifen-inducible Cre. Cells were immortalized using the 3T3 protocol. 
Immortalized cells were treated every 3 days with 2uM 4-hydroxy tamoxifen 4-OHT 
for 21 days. Whole cell lysates from tamoxifen-treated or untreated cells were 
subjected to western blotting and probed with an anti-PRMT5 antibody. The 
percentage of total control and treated cell lysate loaded are indicated.  
B) The indicated antibodies were tested on nuclear extracts from tamoxifen-treated 
and untreated cells (left panel). Equal loading of histones was verified by Ponceau S 
staining (right panel).  
A B
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Figure 33: Validation of H2AR3me2s using immunofluorescence 
MEF PRMT5 LoxP (F/F) untreated (control) or 4-OHT treated for 21 days were 
examined by immunofluorescence microscopy following staining with H2AR3me2s 
antibody (BL14494 M12-5079). DAPI was used to stain DNA.  
CST 
anti H2AR3me2s
(M12-5079)
4-OHTControl
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Figure 34: Symmetric methylation on H2A does not vary in response to IR 
MEF PRMT5 LoxP (F/F) cells were irradiated with gamma rays (5 Gy) and cultured 
under normal conditions for the indicated times. Cells were fixed and co-
immunostained with anti-H2AR3me2s and γ-H2AX antibodies. 
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5.6. Discussion 
 
The basic mechanisms involved in DNA repair have been extensively studied. 
However, it is becoming more and more evident that there is a strong 
interconnection between chromatin status and DNA repair. In the context of 
chromatin, it has been suggested that after DNA damage, euchromatin and 
heterochromatin have similar attributes, such as the presence of H3K9me3, thus 
inhibiting local transcription (Ayrapetov et al, 2014). PRMT5 is also present in 
repressive chromatin supporting the possibility that PRMT5 may be recruited to DNA 
damage sites via its interaction with MDC1, in order to deposit repressive chromatin 
marks such as H3R8me2s, H4R3me3s, and H2AR3me2s, thus strengthening 
transcription inhibition at sites of DNA damage. 
It is also important to consider that recent studies have revealed that MDC1 
has a role as a transcriptional co-activator. MDC1 associates with the androgen 
receptor (AR) and estrogen receptor α (ERα) (Wang et al, 2015; Zou et al, 2015). 
The interaction of MDC1 with ERα and AR activates the transcription of hormone 
receptor-mediated genes and functions as tumor suppressor. Moreover, interaction 
of MDC1 with AR facilitates the association between AR and histone 
acetyltransferase GCN5, increasing histone H3 acetylation levels, thus activating 
androgen-induced target genes (Wang et al, 2015). Taking into consideration the 
transcription function of MDC1, the interaction of PRMT5 and MDC1 could also 
serve to modulate gene expression via arginine methylation of histones. 
In this section of our study, we have demonstrated that the FHA domain of 
MDC1 interacts with PRMT5 phosphorylated at T634. We further showed by ChIP 
that PRMT5 is localized to sites of DNA damage, coincident with the enrichment of 
H4R3me2. This result is consistent with a role for PRMT5 in DDR. 
MDC1 is recruited to gamma-H2AX foci, forming complexes with a number of 
proteins involved in DDR such as RNF8, 53BP1 and NBS1 (Lu & Matunis, 2013; 
Melander et al, 2008). MDC1 functions as an assembly platform, amplifying the 
signal for DNA repair. We have demonstrated that PRMT5 interacts with the FHA 
domain of MDC1 and that it may be recruited to DNA double-strand breaks. We also 
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observed an increase in symmetric methylation of H4R3me2s at the site of damage, 
indicating that the loading of PRMT5 may result in the rapid formation of repressive 
chromatin at the DSB. 
In addition, we investigated the presence of symmetric methylation of H2AR3 
over time following IR, by immunofluorescence microscopy. We observed no major 
change in H2AR3me2s localization or intensity during DNA repair (Figure 34). 
However, it is possible that because the H2AR3me2s mark has a strong presence in 
the nucleus of MEF cells, as is shown in Figures 33 and 34, subtle changes, 
perhaps precisely overlapping sites of damage, cannot be detected via 
immunofluorescence microscopy. H4K20me2, which is also highly abundant and 
does not appear to change in abundance following DNA damage as assessed by 
conventional techniques such as western blot, was detected by immunofluorescence 
only after DNA damage was induced by laser irradiation (Pei et al, 2011).  
In the previous chapter, we demonstrated the interaction of 14-3-3 proteins 
with PRMT5 in the context of cytoplasmic proteins. In the nucleus, 14-3-3 isoforms 
mediate G1/S and G2/M cell cycle checkpoints after DNA damage (Mohammad & 
Yaffe, 2009). While we have previously shown that pT634 mediates 14-3-3 
interactions, in this chapter we have demonstrated that phosphorylation of threonine 
634 in PRMT5 also mediates its interaction with the FHA domain of MDC1. 
ATM, ATR and DNA-PKcs substrates are thought to be involved in the 
formation of foci, whereas checkpoint effector kinases (Chk1, Chk2 and MK2) 
ensure that the cell cycle arrests to allow time for repair prior to cell division. 14-3-3 
proteins interact with substrates of checkpoint kinases, while FHA domains have 
been shown to interact with substrates of “foci” kinases (Mohammad & Yaffe, 2009). 
Our studies indicate that PRMT5 pT634 interacts with both the FHA domain of 
MDC1 and 14-3-3 proteins. Consistently, the C-terminus of PRMT5 contains motifs 
know to interact with FHA domains and 14-3-3 proteins: motif III of 14-3-3 (RXX 
[pS/pT]XX-COOH) and the pThr+3 rule of FHA binding modules (pTXX(I/L/V) 
(Ganguly et al, 2005; Mahajan et al, 2008). This dual motif may indicate that PRMT5 
could be involved in both processes. Indeed, PRMT5 methylates at least two 
proteins with key functions in cell cycle checkpoint control, p53 and Rad9. 
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In collaboration with Dr. Stephan Richard, we observed that loss of PRMT5 
did not alter the activation of the DNA damage checkpoint that leads to cell cycle 
arrest, or sensitize cells to etoposide-induced cell death (Data not shown). One 
possible explanation is that very little PRMT5 is necessary to support its functions. 
This is evidenced by the notion that PRMT5 null mice are not viable and that no ES 
null cells could be generated. In contrast, PRMT5 KD cells are relatively easy to 
maintain in culture. In addition, our experience working with inducible PRMT5 KO 
MEF cells indicates that the levels of SDMA remained stable long after PRMT5 was 
depleted. Until recently, it was thought that arginine methylation may be a semi-
permanent PTM; however, recent findings indicate otherwise. Yet, these findings 
show that although ADMA was removed by a subset of JmjC-containing enzymes, 
MMA and SDMA are not greatly suitable to be demethylated by these enzymes 
(Walport et al, 2016). Considering the nature of SDMA and that little PRMT5 is 
needed for its biological function, we can deduce that cells would not be strongly 
affected by PRMT5 deficiency in knockdown experiments, thus explaining the lack of 
phenotype following DNA damage. Simultaneous suppression of PRMT5 by shRNA 
and a PRMT5 inhibitor may help to overcome this problem and clarify the role of 
PRMT5 in DDR. 
 
5.7. Future studies 
 
Although our knowledge of the role of PRMT5 as an epigenetic writer 
continues to grow, there are still many mechanistic details that remain to be clarified. 
Development of antibodies specifically recognizing PRMT5 pT634 modifications 
would help to clarify many of these questions. Additionally, we generated stable 
inducible MEF PRMT5 KO cells and lentiviral vectors harboring myc-tagged PRMT5 
and PRMT5T634A . These will be useful for future rescue experiments that will provide 
valuable information on the role of phosphorylation in foci formation and cell cycle 
arrest, using more precise methods such as ChIP analysis of I-PpoI induced cells.  
We cannot rule out the possibility that an impaired checkpoint response might 
be observed in other cell models. PRMT5 localization changes during development 
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and in cancer (Gu et al, 2012; Kim et al, 2014; Liang et al, 2007; Shilo et al, 2013). 
In malignant neoplasms, cytoplasmic localization of PRMT5 is usually correlated 
with the worst outcome. Our experiments were carried out in cancer cell lines where 
PRMT5 is mostly cytoplasmic. The fact that these are cancer cells could mean that 
the machineries necessary for the “normal” behavior of PRMT5 could be already 
compromised in these cells. Repeating these experiments using other cell types 
could strengthen the results.  
Additionally, transcriptional regulation by PRMT5 may alter DDR. Indeed p53 
signaling genes (Cdkn1a, Mdm2, Ccng1) and DDR genes (Ercc5, Btg2, Rev1) are 
upregulated in Prmt5 mouse null primordial germ cells (Kim et al, 2014). In 
Arabidopsis, PRMT5 deficiency in root stem cells causes cell death and defective 
cell cycle progression in response to DNA damage. Also, loss of PRMT5 function 
increases DNA damage-induced apoptosis in C. elegans (Li et al, 2016; Yang et al, 
2009). However, the precise role of PRMT5 in DSB repair remains unclear. We 
observed an interaction between PRMT5 and MDC1, under certain conditions, and 
we detected elevated levels of the H4R3me2s mark at DSBs. These preliminary 
observations suggest that a temporary repressive chromatin structure may be 
formed at the site of damage, which could be partially regulated by the 
phosphorylation of PRMT5. 
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Chapter 6: Significance 
 
Post-translational modifications play a pivotal role in the function of proteins, 
in part by mediating protein-protein interactions, which promote the assembly of 
multiprotein complexes. We investigated the function of a subset of phosphorylated 
residues on PRMT5, with special emphasis on new discoveries related to potential 
cross-talk between arginine methylation and protein kinases. 
This study increased our scientific knowledge regarding arginine methylation. 
We observed that Src mediated phosphorylation of PRMT5 facilitates the interaction 
of PRMT5 with many SH2-domain containing proteins. Likewise, we have 
determined that PRMT5 is phosphorylated by AKT and SGK near the C-terminus at 
threonine 634. This creates a binding motif that allows interaction with 14-3-3 
proteins. We also observed that under unphosphorylated conditions, the C-terminus 
of PRMT5 interacts with the PDZ domain of NHERF2, which has enabled us to 
investigate, for the first time, the membrane association of PRMT5, the existence of 
PRMT5’s substrate at the plasma membrane, and the role of PRMT5 in the 
regulation of ion exchangers. Moreover, phosphorylation of PRMT5 at T634, also 
promotes its interaction with the FHA domain of MDC1, which may bring it to sites of 
DSBs, therefore connecting the phosphorylation of PRMT5 to DDR. 
Consequently, we propose the existence of kinase-mediated signaling 
networks that coordinate PRMT5 interactions with several binding partners and in 
turn, position it as a key player for many different biological functions. Regulation of 
protein-RNA binding, DNA repair, and ion-exchanger function are just a few 
examples where PRMT5 phosphorylation may be an integral part of cellular 
regulatory mechanisms. Since PRMT5 phosphorylation is mediated by Src and Akt, 
which are frequently dysregulated in many cancers and are linked to cell growth and 
survival pathways, future studies will aim to clarify the events regulated by 
phosphorylated PRMT5 in cancer. 
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One of the major roles of PRMT5 phosphorylation that we have identified is 
the PDZ/14-3-3 switch, which may regulate many biological functions. The 
importance of the PDZ/14-3-3 binding switch in mammalian cells was first suggested 
after discovering that the HPV E6 oncoprotein has adopted this mechanism to 
facilitate host infection (Boon & Banks, 2013). This prompted us to speculate that 
many more proteins may posses this unique C-terminal motif and could switch their 
binding between 14-3-3 proteins and PDZ domain interaction networks. Indeed, we 
have identified other mammalian proteins, ERBB4, PGHS2 and IRK1, which just like 
PRMT5, possess this dual C-terminal regulatory motif and switch from binding PDZ 
domains to binding 14-3-3 proteins upon phosphorylation.  
Both 14-3-3 and PDZ-domain containing proteins have been strongly 
implicated in synaptic functions (Berg et al, 2003; Foote & Zhou, 2012; Paquet et al, 
2006). We expected to explore the role of this switch in synapses using a mouse 
knock-in model. However, the 14-3-3/PDZ dual motif at the C-terminus of PRMT5 
was essential for viability as no homozygous mutant embryos were alive in our 
knock-in mouse models. Therefore, developing a conditional knock-in Nestin-
Cre/PRMT5Δ+HA/flox mouse and/or knock-in mouse that can separate the interaction 
of PRMT5 with 14-3-3 proteins and PDZ domains will be a value tool to explore the 
roles of PRMT5 in synaptic transmission and other cellular processes. 
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1.  OVERVIEW OF PROFILING SERVICE 
Introduction 
 
The Kinexus Kinase/Phosphatase Profiling Services access a large and diverse panel of highly active 
protein kinases and protein phosphatases for screening substrates and bioactive compounds. These 
active enzyme preparations are subjected to rigorous quality control analyses and are extensively 
assayed against a panel of biologically relevant substrates and optimized synthetic peptides to ensure that 
all test reactions are performed under optimal assay conditions. These protein kinase/phosphatase 
profiling services determine the extent of phosphorylation or dephosphorylation of a selected substrate to 
understand the putative mechanisms of action of bioactive compounds and to support the identification of 
the upstream protein kinases and protein phosphatases and their substrate proteins in signalling networks. 
All of the protein kinases and phosphatases can be profiled against a given compound or substrate using 
a single concentration of the compound/substrate or at multiple concentrations. In addition, the protein 
kinase assays can be performed under varying ATP concentrations to evaluate potential competition of 
test inhibitory compounds with respect to the ATP substrate. 
The protein kinase and phosphatase activity profiling services offered by Kinexus use a very economical 
and convenient approach to facilitate the drug discovery continuum with a three to four-week turnaround of 
your specific profiling results. Substrates (proteins or peptides) can be supplied by the client as stock 
solutions of known concentration, as solid material in vials, or in 96-well plates. 
 
Enzyme and Substrate Targets 
Kinexus has a diverse and ever-expanding range of target proteins that are actively being pursued 
from a drug development perspective, with a main focus on signalling proteins, including active 
protein kinases and protein phosphatases. Except for receptor-tyrosine protein kinases, these highly 
purified active enzymes are usually generated from the full-length human genes and are based on 
wild-type sequences, unless explicitly stated. Most of these preparations of recombinant enzymes do 
not harbor activating mutations. We also produce antibodies for the detection of these enzymes and 
substrate peptides for assaying their enzymatic activities. With most proteins featuring on average 
40 or more potential phosphosites, synthetic substrate peptides can be valuable probes to 
investigate specific phosphosites and the kinases and phosphatases that target them. We can 
produce analogues of target substrate sequences that can be useful to confirm the actual sites of 
phosphorylation in cases where multiple candidate phosphosites are clustered close together. In 
addition, peptide substrate analogues are helpful to define critical surrounding amino acids for 
specific protein kinase recognition. Kinexus’ In Silico Kinase Substrate Prediction Services can be 
useful for narrowing done protein kinases that may target a specific phosphosite. 
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Comparison of Substrates 
For comparisons of kinase substrates, the proteins or peptides should be of similar size, number of 
phosphosites, and concentrations whenever possible. There are two common approaches for 
comparing substrates. One is to measure the level of phosphorylation from the test substrate against 
a known control substrate. The disadvantage of this method is that the control substrates are 
normally optimized proteins or peptides that may be used at higher concentrations than the test 
substrate (typically 1 mg/ml), making a direct comparison difficult. Protein substrates usually have 
higher affinity and lower Km values than peptide substrates for most protein kinases.  Control 
substrates may also have multiple phosphorylation sites or they may be used at saturating 
conditions, and therefore a high count from a control substrate, while showing the kinase is active, 
may not directly be compared to a test substrate. 
 
The other approach for comparing substrate profiling is to place greater emphasis on the highest 
counts for the test substrate by many diverse protein kinases, as this indicates how well the lead 
kinases phosphorylates the substrate relative to other tested kinases. This is the approach taken 
for this order.  It should, however, be appreciated that the specific enzyme activities of different 
preparations of the same kinase may show some variability when assayed at different times and 
direct comparison of different kinases for the same substrate can be misleading. If there is a wild 
type and mutant version of the same peptide, then a comparison of the difference in counts between 
these two peptides and the % change from control (CFC) can be particularly instructive for 
determining the effect of the mutation. Once a short-list of the top kinases has been selected based 
on the results from this assay, they can be assayed against both the WT and MT peptides. 
 
The profiling data for the PRMT5 [T634] wild type peptide when assayed against 295 protein 
kinases, using the radiometric assay method with [γ-33P]-ATP, showed low to excellent 
phosphorylation with counts ranging from 102 cpm up to as high as 412,000 cpm.  (Table 1 provides 
a listing of the counts observed for the kinases selected). Of the 295 kinases tested, there were 55 
kinases (representing about 20% of the total number selected) that generated signals greater than 
100,000 cpm. From this subset, 31 kinases produced counts between 100,000 to 200,000 cpm 
(highlighted in light blue), 14 kinases had counts between 200,000 to 300,000 cpm (highlighted in 
dark blue), 9 kinases gave counts between 300,000 to 400,000 cpm (highlighted in light purple) and 
1 kinase  (SGK2) with a count greater than 400,000 cpm. It is often observed that kinases from the 
same families act on substrates in a similar manner. In this order, SGK1, SGK2 and SGK3 gave the 
highest counts collectively of all the groups, ranging from 333,000 cpm to 412,000 cpm. The CAMK2 
alpha, beta, delta and gamma kinases were also observed with high counts ranging from 341,000 to 
384,000 cpm. Other kinase groups which gave reasonably high counts included DAPK1/2/3, 
MAPKAP2/3, MRCK alpha and beta, RSK1/2/3, ROCK1/2, PIM 1/2/3, PKAc alpha, beta, gamma, 
TTBK1/2 and TLK1/2.   
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of phosphorylation of the substrate obtained with the 295 different protein kinases, the lower range 
of phosphorylation, i.e. less than 25,000, should be discounted.  
 
From the assay results, 55 protein kinases (representing approximately 20% of all the kinases 
tested) showed a strong preference for the PRMT5 [T634] peptide. This was based on the higher 
counts observed, from 100,000 up to 412,000 cpm.  There were a further 46 kinases (representing 
15% of the kinases), with moderate counts ranging from 25,000 to 100,000. The remaining 194 
kinases (representing 65% of the kinases) gave counts less than 25,000 cpm. The next step would 
be to assay a subset of these kinases against both the PRMT5 [T634] and [A634] peptides to 
determine the effect of phosphorylation that can be attributed to the threonine at position 634. 
 
In comparing the top candidates for the protein kinases that specifically target the T634 site, it 
should be appreciated that each of these preparations of protein kinases were generated as 
recombinant proteins and every attempt was made to produce them in the most active states. 
Nonetheless, we cannot rule out the possibility that additional phosphorylation or other covalent 
modifications of these enzymes or the presence of other as yet unidentified activating subunits or 
compounds that are available physiologically are still needed for their maximal specific enzyme 
activity. Furthermore, during the expression and purification procedures, there may be varying levels 
of the ratios of active compared to inactive enzyme molecules for each kinase preparation. This can 
results in variable Vmax values for each protein kinase from one preparation to another. However, 
the relative affinity of a purified protein kinase for a purified substrate is less variable, and 
determination of the relative Km of the top ranked protein kinases for the same peptide substrate 
could provide a better assessment of the protein kinases that are likely to target the T634 site 
physiologically.  
 
It should also be appreciated that there may be protein kinases that demonstrate higher affinities for 
PRMT5 and phosphorylate the T634 site than apparent from this study with the peptide based on the 
amino acid sequences surrounding this site. Certain protein kinases and substrates feature 
additional sequences that act as secondary docking sites to further improve kinase-substrate 
recognition. However, these experiments with the synthetic peptide substrates should markedly 
narrow down the candidate proteins kinases, which can be tested later against recombinant PRMT5. 
In preparation for this, it may be worthwhile to develop a phosphosite-specific antibody for the T634 
site. To our knowledge, phosphorylation of the C-terminus of PRMT5 has not been previously 
reported, nor has it been predicted with our Kinase Substrate Predictor algorithms. If a substantial 
drop in phosphorylation of the A634 site is observed with the lead protein kinases identified from this 
study, then the development of a phosphosite-specific antibody is warranted, and Kinexus could 
assist you for such an objective. We have recently developed over 400 phosphosite-specific 
antibodies in-house. 
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APPENDIX A - METHODOLOGY 
 
The assay condition for the various protein kinase targets were optimized to yield acceptable 
enzymatic activity. In addition, the assays were optimized to give high signal-to-noise ratio. 
 
Protein Kinase Assays 
A radioisotope assay format was used for profiling evaluation of the kinase activities towards their 
substrates and all assays are performed in a designated radioactive working area. Protein kinase 
assays were performed at ambient temperature for 20-40 minutes (depending on the kinase) in a 
final volume of 25 µl according to the following assay reaction recipe: 
 
Component 1. 5 µl of diluted active protein kinase (~10-50 nM final protein 
concentration in the assay) 
Component 2. 5 µl of assay solution of peptide substrate 
Component 3. 10 µl of kinase assay buffer  
Component 4. 5 µl of [γ-33P] ATP (250 µM stock solution, 0.8 µCi) 
 
The assay was initiated by the addition of [γ-33P] ATP and the reaction mixture incubated at ambient 
temperature for 20-40 minutes, depending on the protein kinase tested. After the incubation period, 
the assay was terminated by spotting 10 µl of the reaction mixture onto a multiscreen 
phosphocellulose P81 plate. The multiscreen phosphocellulose P81 plate was washed 3 times for 
approximately 15 minutes each in a 1% phosphoric acid solution. The radioactivity on the P81 plate 
was counted in the presence of scintillation fluid in a Trilux scintillation counter.  
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39 MYLK4 22,995 517 22,478 
40 NIM1 23,362 523 22,839 
41 PKN2/PRK2 8,357 476 7,881 
42 PRKG1 31,218 518 30,700 
43 PRKG2 57,702 488 57,214 
44 PKC alpha 63,234 649 62,585 
45 PKC beta I 58,868 756 58,112 
46 PKC beta II 230,971 430 230,541 
47 PKC delta 5,364 437 4,927 
48 PKC epsilon 11,596 489 11,107 
49 PKC eta 29,446 566 28,880 
50 PKC gamma 16,603 469 16,134 
51 PKC iota 10,586 578 10,008 
52 PKC theta 15,836 699 15,137 
53 PAK1/CDC42 10,764 468 10,296 
54 ACVR2A Protein 26,635 500 26,135 
55 ACVR2B Protein 1,231 566 665 
56 AKT1 184,959 627 184,332 
57 AKT2 12,433 429 12,004 
58 AKT3 257,538 549 256,989 
59 ALK2 1,973 433 1,540 
60 ALK3 (BMPR1A) 2,179 548 1,631 
61 ALK4 5,074 400 4,674 
62 ALK6 (BMPR1B) 7,432 589 6,843 
63 ALK7 Protein 1,427 505 922 
64 ASK1 29,008 479 28,529 
65 AURORA A 10,109 564 9,545 
66 AURORA B 112,766 553 112,213 
67 AURORA C 39,424 399 39,025 
68 BMPR2 18,775 656 18,119 
69 BRAF 2,174 478 1,696 
70 BRSK1 19,619 555 19,064 
71 BRSK2 21,155 628 20,527 
72 BUB1B 1,639 479 1,160 
73 CDC7/DBF4 22,449 569 21,880 
74 CDK1/CyclinA1 4,610 463 4,147 
75 CDK1/CyclinA2 5,117 512 4,605 
76 CDK1/CyclinB1 4,103 589 3,514 
77 CDK2/CyclinA1 1,683 551 1,132 
78 CDK2/CyclinA2 2,076 504 1,572 
79 CDK2/CyclinE1 1,288 499 789 
80 CDK2/CyclinO 3,566 571 2,995 
81 CDK3/CyclinE1 1,149 359 790 
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82 CDK4/CyclinD1 907 403 504 
83 CDK4/CyclinD3 982 529 453 
84 CDK5/p25 2,378 633 1,745 
85 CDK5/p29 569 467 102 
86 CDK5/p35 3,716 529 3,187 
87 CDK6/CyclinD1 3,608 596 3,012 
88 CDK6/CyclinD3 8,522 612 7,910 
89 CDK7/CyclinH1 12,102 507 11,595 
90 CDK8/CyclinC 809 498 311 
91 CDK9/CyclinK 1,798 648 1,150 
92 CHK1 210,205 535 209,670 
93 CHK2 99,045 467 98,578 
94 CK1 alpha 1 10,017 445 9,572 
95 CK1 alpha 1L 7,371 532 6,839 
96 CK1 delta 12,127 489 11,638 
97 CK1 epsilon 9,763 477 9,286 
98 CK1 gamma 1 25,407 545 24,862 
99 CK1 gamma 2 19,697 474 19,223 
100 CK1 gamma 3 17,083 536 16,547 
101 CK2 alpha 1 5,062 379 4,683 
102 CK2 alpha 2 1,084 559 525 
103 CLK1 21,728 626 21,102 
104 CLK2 118,742 468 118,274 
105 CLK3 13,239 525 12,714 
106 CLK4 7,438 541 6,897 
107 COT 3,748 555 3,193 
108 DAPK3 230,541 655 229,886 
109 DMPK 17,551 349 17,202 
110 DRAK1 (STK17A) 33,520 623 32,897 
111 DYRK1 alpha Pro 9,739 596 9,143 
112 DYRK2 19,942 528 19,414 
113 DYRK3 3,653 539 3,114 
114 DYRK4 Pro 950 516 434 
115 EIF2AK1 (HRI) 6,007 566 5,441 
116 EIF2AK2 31,138 589 30,549 
117 EIF2AK3 59,548 526 59,022 
118 ERK1 2,503 555 1,948 
119 ERK2 878 475 403 
120 ERK5 31,027 656 30,371 
121 ERN2 (IRE2) 2,305 544 1,761 
122 GCK 339,562 688 338,874 
123 GLK 162,112 745 161,367 
124 GRK1 19,154 854 18,300 
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125 GRK2 2,639 633 2,006 
126 GRK5 4,332 588 3,744 
127 GRK6 7,091 457 6,634 
128 GRK7 3,195 567 2,628 
129 GSK3 alpha 2,611 543 2,068 
130 GSK3 beta 4,793 529 4,264 
131 Haspin (GSG2) 19,563 645 18,918 
132 HGK 159,611 677 158,934 
133 HIPK1 10,249 388 9,861 
134 HIPK2 5,806 569 5,237 
135 HIPK3 5,213 510 4,703 
136 HIPK4 2,876 495 2,381 
137 HPK1 257,847 649 257,198 
138 HUNK 3,476 653 2,823 
139 ICK 4,983 589 4,394 
140 IKK alpha 4,743 480 4,263 
141 IKK beta 7,507 458 7,049 
142 IKK epsilon 3,163 486 2,677 
143 IRAK2 1,167 459 708 
144 IRAK4 177,356 648 176,708 
145 JNK1 4,300 444 3,856 
146 JNK2 2,818 515 2,303 
147 JNK3 1,597 547 1,050 
148 KHS1 75,444 625 74,819 
149 KSR1 5,995 551 5,444 
150 LATS1 1,225 526 699 
151 LATS2 9,232 636 8,596 
152 LIMK1 4,594 475 4,119 
153 LKB1/M025 alpha 3,011 517 2,494 
154 LOK 2,345 534 1,811 
155 LRRK2 1,470 676 794 
156 MAK 3,022 566 2,456 
157 MAPKAPK2 200,974 456 200,518 
158 MAPKAPK3 166,901 438 166,463 
159 MAPKAPK5 11,683 519 11,164 
160 MARK1 3,376 499 2,877 
161 MARK2 8,334 553 7,781 
162 MARK3 5,378 539 4,839 
163 MARK4 8,153 565 7,588 
164 MEK1 1,039 475 564 
165 MEK2 709 538 171 
166 MEK6 680 560 120 
167 MEKK1 8,563 429 8,134 
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168 MEKK2 8,682 512 8,170 
169 MEKK3 10,340 528 9,812 
170 MEKK6 3,807 633 3,174 
171 MELK 10,379 526 9,853 
172 MINK1 8,767 476 8,291 
173 MLK1 60,286 644 59,642 
174 MLK2 13,272 520 12,752 
175 MLK3 3,018 478 2,540 
176 MLK4 5,718 537 5,181 
177 MNK1 17,368 614 16,754 
178 MNK2 42,864 539 42,325 
179 MRCK alpha 161,286 523 160,763 
180 MRCK beta 207,962 626 207,336 
181 MSK1 141,334 519 140,815 
182 MSK2 15,640 492 15,148 
183 MSSK1 3,446 681 2,765 
184 MST1 143,512 537 142,975 
185 MST3 46,290 528 45,762 
186 MST4 29,854 614 29,240 
187 MYO3 alpha 15,796 518 15,278 
188 MYO3 beta 43,757 492 43,265 
189 MYT1 Protein 3,525 633 2,892 
190 NDR 3,016 683 2,333 
191 NDR2 (STK38L) 1,673 588 1,085 
192 NEK1 23,983 526 23,457 
193 NEK11 54,857 531 54,326 
194 NEK2  109,414 549 108,865 
195 NEK3 39,624 678 38,946 
196 NEK4 Pro 3,469 569 2,900 
197 NEK5 59,451 634 58,817 
198 NEK6 6,511 512 5,999 
199 NEK7 2,337 470 1,867 
200 NEK8 4,557 444 4,113 
201 NEK9 24,390 593 23,797 
202 NIK 9,344 638 8,706 
203 NLK 2,773 528 2,245 
204 NUAK1 4,200 420 3,780 
205 NUAK2 8,101 518 7,583 
206 p38 alpha 1,395 538 857 
207 p38 beta 929 568 361 
208 p38 delta 1,836 446 1,390 
209 p38 gamma 1,124 522 602 
210 p70S6K 94,339 575 93,764 
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211 p70S6Kb 110,186 589 109,597 
212 PAK2 Protein 1,480 475 1,005 
213 PAK3 101,509 633 100,876 
214 PAK4 2,203 649 1,554 
215 PAK6 2,787 543 2,244 
216 PAK7 4,937 512 4,425 
217 PASK 352,653 590 352,063 
218 PCTK1(CDK16)Cyclin Y 2,523 423 2,100 
219 PDHK1 2,456 534 1,922 
220 PDHK2 1,842 524 1,318 
221 PDHK3 2,349 508 1,841 
222 PDHK4 1,037 432 605 
223 PDK1 30,725 561 30,164 
224 PEAK1 1,595 579 1,016 
225 PFTK1(CDK14) 15,762 547 15,215 
226 PHKG1 7,860 475 7,385 
227 PHKG2 62,052 469 61,583 
228 PIM1 102,821 533 102,288 
229 PIM2 132,196 557 131,639 
230 PIM3 103,235 589 102,646 
231 PKAc alpha 179,415 677 178,738 
232 PKAc beta 266,334 487 265,847 
233 PKAc gamma 257,313 548 256,765 
234 PKC mu 38,992 547 38,445 
235 PKC nu 48,384 573 47,811 
236 PKC zeta 23,285 558 22,727 
237 PKD2 93,492 653 92,839 
238 PKN1/PRK1 5,438 467 4,971 
239 PKN3/PRK3 7,251 576 6,675 
240 PLK1 7,910 487 7,423 
241 PLK2 3,954 378 3,576 
242 PLK3 2,485 456 2,029 
243 PLK4 31,591 533 31,058 
244 PRKX 11,770 529 11,241 
245 QIK 7,309 500 6,809 
246 RAF1 42,244 531 41,713 
247 RIPK2  2,030 522 1,508 
248 RIPK5 996 486 510 
249 ROCK1  173,900 567 173,333 
250 ROCK2 373,406 586 372,820 
251 RSK1 286,594 577 286,017 
252 RSK2 158,605 571 158,034 
253 RSK3 153,085 574 152,511 
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254 RSK4 62,177 566 61,611 
255 SBK1 20,661 478 20,183 
256 SGK1 359,318 590 358,728 
257 SGK2 413,507 852 412,655 
258 SGK3 334,212 765 333,447 
259 SIK 16,235 562 15,673 
260 SLK 59,897 535 59,362 
261 SNRK 10,156 470 9,686 
262 SRPK1 7,155 568 6,587 
263 SRPK2 12,273 524 11,749 
264 STK19 13,414 512 12,902 
265 STK3 47,674 530 47,144 
266 STK32C (YANK3) 9,528 475 9,053 
267 STK33 9,488 458 9,030 
268 STK36 3,462 587 2,875 
269 STK39 (STLK3) 35,322 544 34,778 
270 TAK1-TAB1 5,913 579 5,334 
271 TAOK1 124,379 599 123,780 
272 TAOK2 94,544 476 94,068 
273 TAOK3 250,114 657 249,457 
274 TBK1 36,775 544 36,231 
275 TESK1 Pro 1,948 589 1,359 
276 TGFBR1 (ALK5) 2,134 583 1,551 
277 TGFBR2 6,864 516 6,348 
278 TLK1 136,414 466 135,948 
279 TLK2 154,368 544 153,824 
280 TOPK 23,905 582 23,323 
281 TSSK1B 12,457 488 11,969 
282 TSSK2 15,372 475 14,897 
283 TTBK1 187,091 597 186,494 
284 TTBK2 193,626 590 193,036 
285 TTK 47,653 634 47,019 
286 TYK2 (JTK1) 6,088 510 5,578 
287 ULK1 35,196 486 34,710 
288 ULK2 45,081 528 44,553 
289 ULK3 35,135 636 34,499 
290 VRK1 6,391 489 5,902 
291 WEE1 Protein 4,946 598 4,348 
292 ZAK 54,155 478 53,677 
293 GRK3 3,597 461 3,136 
294 MEK5 2,540 566 1,974 
295 SIK3 4,198 398 3,800 
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1.  OVERVIEW OF PROFILING SERVICE 
Introduction 
 
The Kinexus Kinase/Phosphatase Profiling Services provide access to a large and diverse panel of highly 
active protein kinases and protein phosphatases for screening substrates and bioactive compounds. 
These active enzyme preparations are subjected to rigorous quality control analyses and are extensively 
assayed against a panel of biologically relevant substrates and optimized synthetic peptides to ensure that 
all test reactions are performed under optimal assay conditions. These protein kinase/phosphatase 
profiling services determine the extent of phosphorylation or dephosphorylation of a selected substrate to 
understand the putative mechanisms of action of bioactive compounds and to support the identification of 
the upstream protein kinases and protein phosphatases and their substrate proteins in signalling networks. 
All of the protein kinases and phosphatases can be profiled against a given compound or substrate using 
a single concentration of the compound/substrate or at multiple concentrations. In addition, the protein 
kinase assays can be performed under varying ATP concentrations to evaluate potential competition of 
test inhibitory compounds with respect to the ATP substrate. The protein kinase and phosphatase activity 
profiling services offered by Kinexus use a very economical and convenient approach to facilitate the drug 
discovery continuum with a three to four-week turnaround of your specific profiling results. Substrates 
(proteins or peptides) can be supplied by the client as stock solutions of known concentration, as solid 
material in vials, or in 96-well plates. 
 
Enzyme and Substrate Targets 
Kinexus has a diverse and ever-expanding range of enzymes that are actively being pursued from a 
drug development perspective, with a main focus on signalling proteins, including active protein 
kinases and protein phosphatases. Except for receptor-tyrosine protein kinases, these highly purified 
active enzymes are usually generated from the full-length human genes and are based on wild-type 
sequences, unless explicitly stated. Most of these preparations of recombinant enzymes do not 
harbor activating mutations. We also produce antibodies for the detection of these enzymes and 
substrate peptides for assaying their enzymatic activities. With most proteins featuring on average 
40 or more potential phosphosites, synthetic substrate peptides can be valuable probes to 
investigate specific phosphosites and the kinases and phosphatases that target them. Our open-
access PhosphoNET (www.phosphonet.ca) provides predictions of the most likely protein kinases 
that target over 960,000 known or predicted phosphosites in human proteins. We can produce 
analogues of target substrate sequences that can be useful to confirm the actual sites of 
phosphorylation in cases where multiple candidate phosphosites are clustered close together. In 
addition, peptide substrate analogues are helpful to define critical surrounding amino acids for 
specific protein kinase recognition. Our In Silico Kinase Substrate Prediction Services can be useful 
for narrowing done non-human protein kinases that target specific phosphosites in other species. 
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4.   RESULTS 
Evaluation  
Kinexus evaluated the activity of 18 protein kinases against the the two peptides by employing the 
standardized assay methodology outlined in Appendix A.  The results observed as activity of each 
peptide substrate are presented in Table 1. The intra-assay variability was determined to be less 
than 10%.  
 
Comparison of Substrates 
For comparisons of kinase substrates, the proteins or peptides should be of similar size, number of 
phosphosites, and concentrations whenever possible. There are two common approaches for 
comparing substrates. One is to measure the level of phosphorylation from the test substrate against 
a known control substrate. The disadvantage of this method is that the control substrates are 
normally optimized proteins or peptides that may be used at higher concentrations than the test 
substrate (typically 1 mg/ml), making a direct comparison difficult. Protein substrates usually have 
higher affinity and lower Km values than peptide substrates for most protein kinases.  Control 
substrates may also have multiple phosphorylation sites or they may be used at saturating 
conditions, and therefore a high count from a control substrate, while showing the kinase is active, 
may not directly be compared to a test substrate. 
 
The other approach for comparing substrate profiling is to place greater emphasis on the highest 
counts for the test substrate by many diverse protein kinases, as this indicates how well the lead 
kinases phosphorylates the substrate relative to other tested kinases. It should, however, be 
appreciated that the specific enzyme activities of different preparations of the same kinase may 
show some variability when assayed at different times and direct comparison of different kinases for 
the same substrate can be misleading. If there is a wild type and mutant version of the same 
peptide, then a comparison of the difference in counts between these two peptides and the % 
change from control (CFC) can be particularly instructive for determining the effect of the mutation.  
This is the approach taken for this order.   
 
The first screening of the PRMT5 [T634] wild type peptide was against 295 protein-serine-threonine 
and dual-specificity kinases (Order #3220). The objective was to determine the best candidate 
kinases which showed the greatest affinity (as measured by the highest counts) for the peptide 
substrate. From that study, 18 kinases, with counts from 249,000 to 412,000 cpm, were selected for  
further examination against the wild type PRMT5 [T634] and its mutated peptide, PRMT5 [A634]. 
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In comparing the top candidates for the protein kinases that specifically target the T634 site, it 
should be appreciated that each of these preparations of protein kinases were generated as 
recombinant proteins and every attempt was made to produce them in the most active states. 
Nonetheless, we cannot rule out the possibility that additional phosphorylation or other covalent 
modifications of these enzymes or the presence of other as yet unidentified activating subunits or 
compounds that are available physiologically are still needed for their maximal specific enzyme 
activity. Furthermore, during the expression and purification procedures, there may be varying levels 
of the ratios of active compared to inactive enzyme molecules for each kinase preparation. This can 
results in variable Vmax values for each protein kinase from one preparation to another. However, 
the relative affinity of a purified protein kinase for a purified substrate is less variable, and 
determination of the relative Km of the top ranked protein kinases for the same peptide substrate 
could provide a better assessment of the protein kinases that are likely to target the T634 site 
physiologically.  
 
It should also be appreciated that there may still be protein kinases that demonstrate higher affinities 
for PRMT5 and phosphorylate the T634 site than those that were apparent from this study with the 
peptide based on the amino acid sequences surrounding this site. Certain protein kinases and 
substrates feature additional sequences that act as secondary docking sites to further improve 
kinase-substrate recognition. However, these experiments with the synthetic peptide substrates 
should markedly narrow down the candidate proteins kinases, which can be tested later against 
recombinant PRMT5. In preparation for this, it may be worthwhile to develop a phosphosite-specific 
antibody for the T634 site. To our knowledge, phosphorylation of the C-terminus of PRMT5 has not 
been previously reported, nor has it been predicted with our Kinase Substrate Predictor algorithms. 
With the substantial drop in phosphorylation of the A634 site as observed with the lead protein 
kinases identified from this study, we believe that the development of a phosphosite-specific 
antibody is warranted, and Kinexus could assist you for such an objective. We have recently 
developed over 400 phosphosite-specific antibodies in-house. 
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APPENDIX A - METHODOLOGY 
 
The assay condition for the various protein kinase targets were optimized to yield acceptable 
enzymatic activity. In addition, the assays were optimized to give high signal-to-noise ratio. 
 
Protein Kinase Assays 
A radioisotope assay format was used for profiling evaluation of the kinase activities towards their 
substrates and all assays are performed in a designated radioactive working area. Protein kinase 
assays were performed at ambient temperature for 20-40 minutes (depending on the kinase) in a 
final volume of 25 µl according to the following assay reaction recipe: 
 
Component 1. 5 µl of diluted active protein kinase (~10-50 nM final protein 
concentration in the assay) 
Component 2. 5 µl of assay solution of peptide substrate 
Component 3. 10 µl of kinase assay buffer  
Component 4. 5 µl of [γ-33P] ATP (250 µM stock solution, 0.8 µCi) 
 
The assay was initiated by the addition of [γ-33P] ATP and the reaction mixture incubated at ambient 
temperature for 20-40 minutes, depending on the protein kinase tested. After the incubation period, 
the assay was terminated by spotting 10 µl of the reaction mixture onto a multiscreen 
phosphocellulose P81 plate. The multiscreen phosphocellulose P81 plate was washed 3 times for 
approximately 15 minutes each in a 1% phosphoric acid solution. The radioactivity on the P81 plate 
was counted in the presence of scintillation fluid in a Trilux scintillation counter.  
 
 
APPENDIX B
GST-­‐PDZ Domains
Protein Domain Acc # Size AA sequence
1 a-1-syntrophin(1/1) DPZ Q61234 81-164 = 84 RVTVRKADAGGLGISIKGGRENKMPILIS
KIFKGLAADQTEALFVGDAILSVNGEDLS
SATHDEAVQALKKTGKEVVLEVKYMK 
2 β1-syntrophin (1/1) PDZ Q99L88 111-194 = 84 GVKVLKQELGGLGISIKGGKENKMPILIS
KIFKGLAADQTQALYVGDAILSVNGADL
RDATHDEAVQALKRAGKEVLLEVKYMR 
3 γ 1-syntrophin (1/1) PDZ Q925E1 57-140 = 84 TVTIRRQTVGGFGLSIKGGAEHNIPVVIS
KISKEQRAELSGLLFIGDAILQINGINVRK
CRHEEVVQVLRNAGEEVTLTVSFLK 
4 γ2-syntrophin (1/1)  PDZ Q925E0  73-156 = 84 TVTLRRQPVGGLGLSIKGGAEHGVPVVI
SKIFKDQAADQTEMLFIGDAVLQVNGIN
VENATHEEVVHLLRNAGDDVTITVEYLR 
5 Chapsyn-110 (2/3) PDZ Q91XM9 193-280 = 88 EIKLFKGPKGLGFSIAGGVGNQHIPGDN
SIYVTKIIDGGAAQKDGRLQVGDRLLMV
NNYSLEEVTHEEAVAILKNTSDVVYLKV
GKPT 
6 Chapsyn-110 (3/3) PDZ Q91XM9 421-502 = 82 KVVLHKGSTGLGFNIVGGEDGEGIFVSFI
LAGGPADLSGELQRGDQILSVNGIDLRG
ASHEQAAAALKGAGQTVTIIAQYQP 
7 Cipp (3/10) PDZ Q63ZW7 365-­‐453 = 89 SVELVKKDGQSLGIRIVGYVGTAHPGEAS
GIYVKSIIPGSAAYHNGQIQVNDKIVAVD
GVNIQGFANQDVVEVLRNAGQVVHLTL
VRRK
8 Cipp (5/10) PDZ Q63ZW7 688-­‐774 = 87 TVELVKDCKGLGFSILDYQDPLDPTRSVIVI
RSLVADGVAERSGELLPGDRLVSVNEFSL
DNATLAEAVEVLKAVPPGVVHLGICKP
9 Cipp (8/10) PDZ Q63ZW7 1472-­‐1555 = 84 IIEISKGRSGLGLSIVGGKDTPLDAIVIHEVY
EEGAAARDGRLWAGDQILEVNGVDLRSS
SHEEAITALRQTPQKVRLVVYRDE
10 Cipp (9/10) PDZ Q63ZW7 1568-­‐1650 = 83 LVDLQKKTGRGLGLSIVGKRSGSGVFISDI
VKGGAADLDGRLIRGDQILSVNGEDMRH
ASQETVATILKCVQGLVQLEIGRLR
11 Cipp (10/10) PDZ Q63ZW7 1709-­‐1795 = 87 TVEIIRELSDALGISIAGGKGSPLGDIPIFIA
MIQANGVAARTQKLKVGDRIVSINGQPL
DGLSHTDAVNLLKNAFGRIILQVVADT
12 Radil (1/1) PDZ Q69Z89 1000-­‐1085 = 86 MVELERGPSGLGMGLIDGMHTPLGAQG
LYIQTLLPGSPAASDGRLSLGDQILEVNGS
SLRGVSYMRAVDLIRHGGKKMRFLVAKS
D
13 Dlgh3 (1/1) PDZ Q6XE40 135-­‐218 = 84 VKIVRLVKNKEPLGATIRRDEHSGA
VVVARIMRGGAADRSGLVHVGDELR
EVNGIAVLHKRPDEISQILAQSQGS
ITLKIIPAT 
14 Dvl1 (1/1) PDZ Q3U2D3 251-­‐323 = 73 TVTLNMERHHFLGISIVGQSNDRGDGGIY
IGSIMKGGAVAADGRIEPGDMLLQVNDV
NFENMSNDDAVRVLRE
15 Dvl2 (1/1) PDZ Q60838 267-­‐339 = 73 TVTLNMEKYNFLGISIVGQSNERGDGGIYI
GSIMKGGAVAADGRIEPGDMLLQVND
GST-­‐PDZ Domains
MNFENMSNDDAVRVLRD
16 Dvl3 (1/1) PDZ Q61062 249-­‐321 = 73 TVTLNMEKYNFLGISIVGQSNERGDGGIYI
GSIMKGGAVAADGRIEPGDMLLQVNEIN
FENMSNDDAVRVLRE
17 Erbin (1/1) PDZ Q80TH2 1311-­‐1400 = 90 EIRVRVEKDPELGFSISGGVGGRGNPFRP
DDDGIFVTRVQPEGPASKLLQPGDKIIQA
NGYSFINIEHGQAVSLLKTFHNAVDLIIVR
EV
18 GRASP55 (1/1) PDZ Q99JX3 5-­‐75 = 71 QSVEIPGGGTEGYHVLRVQENSPGHRAG
LEPFFDFIVSINGSRLNKDNDTLKDLLKAN
VEKPVKMLIYSSK
19 Grip1 (6/7) PDZ Q925T6 672-­‐754 = 83 TVELKRYGGPLGITISGTEEPFDPIIISSLTK
GGLAERTGAIHIGDRILAINSSSLKGKPLSE
AIHLLQMAGETVTLKIKKQT
20 Grip2 (5/7) PDZ E0CXS4 555-­‐638 = 84 TFHVKLPKKRSVELGITISSaSRKR
GEPLIISDIKKGSVAHRTGtLEPGD
KLLAIDNIRLDNCPMEDAVQILRQC
EDLVKLKIR
21 Harmonin (2/3) PDZ Q9ES64 211-­‐295 = 85 KVFISLVGSRGLGCSISSGPIQKPGIFVSHV
KPGSLSAEVGLETGDQIVEVNGIDFTNLD
HKEAVNVLKSSRSLTISIVAGAGRE
22 HtrA1 (1/1) PDZ Q9QZK6 365-­‐467 = 103 TESHDRQAKGKAVTKKKYIGIRMMSLTSS
KAKELKDRHRDFPDVLSGAYIIEVIPDTPA
EAGGLKENDVIISINGQSVVTANDVSDVI
KKENTLNMVVRRGNE
23 HtrA3 (1/1) PDZ Q9D236 365-­‐450 = 86 IRMRTITPSLVEELKAANPDFPAVSSGIYV
QEVVPNSPSQRGGIQDGDIIVKVNGRPL
ADSSELQEAVLNESSLLLEVRRGNDDLL
24 Interleukin 16 (1/4) PDZ Q9QZP6 213-­‐299 = 87 NIVLMKGQAKGLGFSIVGGKDSIYGPIGIY
VKSIFAGGAAAADGRLQEGDEILELNGES
MAGLTHQDALQKFKQAKKGLLTLTVRTR
25 LARG (1/1) PDZ Q8R4H2 72-­‐151 = 80 CVIIQKDDNGFGLTVSGDNPVFVQSVKE
DGAAMRAGVQTGDRIIKVNGTLVTHSN
HLEVVKLIRSGSYVALTVQGRPPGS
26 LIN-­‐7A (1/1) PDZ Q8JZS0 108-­‐190 = 83 VVELPKTDEGLGFNVMGGKEQNSPIYISR
IIPGGVAERHGGLKRGDQLLSVNGVSVE
GEHHEKAVELLKAAKDSVKLVVRYTP
27 Lin7c (1/1) PDZ O88952 93-­‐175 = 83 VVELPKTEEGLGFNIMGGKEQNSPIYISRII
PGGIADRHGGLKRGDQLLSVNGVSVEGE
HHEKAVELLKAAQGKVKLVVRYTP
28 Lnx1 (2/4) PDZ O70263 385-­‐467 = 83 HVILNKSSPEEQLGIKLVRRVDEPGVFIFN
VLNGGVADRHGQLEENDRVLAINGHDL
RFGSPESAAHLIQASERRVHLVVSRQ
29 Lnx1 (3/4) PDZ O70263 508-­‐593 = 86 VVSVWKDPSESLGMTVGGGASHREWDL
GST-­‐PDZ Domains
PIYVISVEPGGVISRDGRIKTGDILLNVNGI
ELTEVSRTEAVAILKSAPSSVVLKALEV
30 Lrrc7 (1/1) PDZ Q80TE7 1398-­‐1488 = 91 EQFCVRIEKNPGLGFSISGGISGQGNPFKP
SDKGIFVTRVQPDGPASNLLQPGDKILQA
NGHSFVHMEHEKAVLLLKSFQNTVDLVI
QREL
31 Magi-­‐1 (2/6) PDZ Q6RHR9 464-­‐546 = 83 HTKLRKSSRGFGFTVVGGDEPDEFLQIKSL
VLDGPAALDGKMETGDVIVSVNDTCVLG
HTHAQVVKIFQSIPIGASVDLELCR
32 Magi-­‐1 (4/6) PDZ Q6RHR9 833-­‐915 = 83 DIFLWRKETGFGFRILGGNEPGEPIYIGHI
VPLGAADTDGRLRSGDELICVDGTPVIGK
SHQLVVQLMQQAAKQGHVNLTVRR
33 Magi-­‐1 (6/6) PDZ Q6RHR9 1132-­‐1214 = 83 TVELERGAKGFGFSLRGGREYNMDLYVL
RLAEDGPAERCGKMRIGDEILEINGETTK
NMKHSRAIELIKNGGRRVRLFLRRGD
34 Magi-­‐2 (2/6) PDZ Q9WVQ1 425-­‐509 = 85 STTLKKSNMGFGFTIIGGDEPDEFLQVKS
VIPDGPAAQDGKMETGDVIVYINEVCVL
GHTHADVVKLFQSVPIGQSVNLVLCRGY
35 Magi-­‐2 (5/6) PDZ Q9WVQ1 919-­‐1009 = 91 DVVIHRKENEGFGFVIISSLNRPESGATITV
PHKIGRIIDGSPADRCAKLKVGDRILAVNG
QSIINMPHADIVKLIKDAGLSVTLRIIPQE
36 Magi-­‐2 (6/6) PDZ Q9WVQ1 1139-­‐1221 = 83 TVDMEKGAKGFGFSIRGGREYKMDLYVL
RLAEDGPAIRNGRMRVGDQIIEINGESTR
DMTHARAIELIKSGGRRVRLLLKRGT
37 Magi-­‐3 (1/6) PDZ Q9EQJ9 18-­‐108 = 91 CAVSWAGPPGDLGAEIRGGAERGEFPYL
GRLRDEAGGGGGTCCVVSGKAPSPGDVL
LEVNGTPVSGLTNRDTLAVIRHFREPIRLK
TVKPG
38 Magi-­‐3 (2/6) PDZ Q9EQJ9 413-­‐495 = 83 RASLKKSTMGFGFTIIGGDRPDEFLQVKN
VLKDGPAAQDGKIAPGDVIVDINGNCVL
GHTHADVVQMFQLVPVNQYVNLTLCR
39 Magi-­‐3 (5/6) PDZ Q9EQJ9 852-­‐939 = 88 DVTLQRKENEGFGFVILTSKSKPPPGVIPH
KIGRVIDGSPADRCGGLKVGDHISAVNG
QSIVDLSHDNIVQLIKDAGVTVTLTVVAEE
40 Mals2 (1/1) / lin-­‐7 PDZ Q9HAP6 93-­‐175 = 83 VVELPKTDEGLGFNIMGGKEQNSPIYISR
VIPGGVADRHGGLKRGDQLLSVNGVSVE
GEQHEKAVELLKAAQGSVKLVVRYTP
41 Mpp7 (1/1) PDZ Q8BVD5 139-­‐220 = 82 IIRLVKNSEPLGATIKKDEQTGAITVARIM
RGGAADRSGLIHVGDELREVNGIPVEDK
RPEEIIKILSQSKGAITFKIIPST
42 MUPP1 (1/13) PDZ Q8VBX6 138-­‐225 = 88 IFELLKPPCGGLGFSVVGLRSENRGELGIF
VQEIQEGSVAHRDGRLKETDQILAINGQV
LDQTITHQQAISILQKAKDTVQLVIARGS
43 MUPP1 (5/13) PDZ Q8VBX6 693-­‐779 = 87 SIELEKGSRGLGFSILDYQDPIDPANTVIVI
GST-­‐PDZ Domains
RSLVPGGIAEKDGRLFPGDRLMFVNDINL
ENSTLEEAVEALKGAPSGMVRIGVAKP
44 MUPP1 (10/13) PDZ Q8VBX6 1614-­‐1697 = 84 TIEISKGQTGLGLSIVGGSDTLLGAIIIHEVY
EEGAACKDGRLWAGDQILEVNGIDLRKA
THDEAINVLRQTPQRVRLTLYRDE
45 MUPP1 (11/13) PDZ Q8VBX6 1710-­‐1792 = 83 TIELQKRPGKGLGLSIVGKRNDTGVFVSDI
VKGGIADADGRLMQGDQILMVNGEDV
RHATQEAVAALLKCSLGAVTLEVGRVK
46 MUPP1 (12/13) PDZ Q8VBX6 1847-­‐1933 = 87 TVEIKKGPADSLGLSIAGGVGSPLGDVPIFI
AMMHPNGVAAQTQKLRVGDRIVTICGT
STDGMTHTQAVNLMKNASGSIEVQVVA
GG
47 MUPP1 (13/13) PDZ Q8VBX6 1972-­‐2055 = 84 TITLDRGPDGLGFSIVGGYGSPHGDLPIYV
KTVFAKGAAAEDGRLKRGDQIIAVNGQS
LEGVTHEEAVAILKRTKGTVTLMVLS
48 NHERF-­‐1 (1/2) PDZ P70441 14-­‐94 = 81 LCCLEKGPNGYGFHLHGEKGKVGQFIRLV
EPGSPAEKSGLLAGDRLVEVNGENVEKET
HQQVVSRIRAALNAVRLLVVDPE
49 NHERF-­‐1 (2/2) PDZ P70441 149-­‐229 = 81 LCTMKKGPNGYGFNLHSDKSKPGQFIRA
VDPDSPAEASGLRAQDRIVEVNGVCME
GKQHGDVVSAIKGGGDEAKLLVVDKE
50 NHERF-­‐2 (1/2) PDZ Q9JHL1 11-­‐91 = 81 LCRLVRGEQGYGFHLHGEKGRRGQFIRR
VEPGSPAEAAALRAGDRLVEVNGVNVEG
ETHHQVVQRIKAVEGQTQLLVVDKE
51 NHERF-­‐2 (2/2) PDZ Q9JHL1 151-­‐231 = 81 LCHLRRGPQGYGFNLHSDKSRPGQYIRSV
DPGSPASHSGLRAQDRLIEVNGQNVEGL
RHAEVVARIKAQEDEARLLVVDPE
52 nNOS (1/1) PDZ Q9Z0J4 17-­‐99 = 83 SVRLFKRKVGGLGFLVKERVSKPPVIISDLI
RGGAAEQSGLIQAGDIILAVNDRPLVDLS
YDSALEVLRGIASETHVVLILRG
53 OMP25 (1/1) PDZ Q8K4F3 13-­‐100 = 88 EINLTRGPSGLGFNIVGGTDQQYVSNDS
GIYVSRIKEDGAAAQDGRLQEGDKILSVN
GQDLKNLLHQDAVDLFRNAGCAVSLRV
QHRL
54 PAR-­‐3 (3/3) PDZ Q99NH2 590-­‐677 = 88 EVPLNDSGSAGLGVSVKGNRSKENHADL
GIFVKSIINGGAASKDGRLRVNDQLIAVN
GESLLGKANQEAMETLRRSMSTEGNKRG
MIQ
55 PAR3B (1/3) PDZ Q5SV53 201-­‐289 = 89 TRAVEISGEGDPLGIHVVPFFSSLSGRILGL
FIRGIEENSRCKQEGLFQENECIVKINNVE
LLDKTFAQAQDVFRQAMKSPSVILHVLL
56 PAR6B (1/1) PDZ Q9JK83 157-­‐250 = 94 RVRLYKYGTEKPLGFYIRDGSSVRVTPHGL
EKVPGIFISRLVPGGLAQSTGLLAVNDEVL
EVNGIEVSGKSLDQVTDMMIANSRNLIIT
GST-­‐PDZ Domains
VRPAN
57 Pdlim5 (1/1) PDZ Q3UGD0 2-­‐85 = 84 SNYSVSLVGPAPWGFRLQGGKDFNMPL
TISSLKDGGKASQAHVRIGDVVLSIDGISA
QGMTHLEAQNKIKACTGSLNMTLQRAS
58 Pdzk1 (1/4) /
NHRF3/ NaPiCap1
PDZ Q9JIL4 9-­‐90 = 82 ECKLSKQEGQNYGFFLRIEKDTDGHLIRVI
EEGSPAEKAGLLDGDRVLRINGVFVDKEE
HAQVVELVRKSGNSVTLLVLDGD
59 Pdzk1 (3/4) /
NHRF3/ NaPiCap1
PDZ Q9JIL4 243-­‐323 = 81 VVVIKKGSNGYGFYLRAGPEQKGQIIKDIE
PGSPAEAAGLKNNDLVVAVNGKSVEALD
HDGVVEMIRKGGDQTTLLVLDKE
60 Pdzk11 (1/1) PDZ Q9CZG9 47-­‐129 = 83 IVTLKKPPGAQLGFNIRGGKASQLGIFISK
VIPDSDAHRAGLQEGDQVLAVNDVDFQ
DIEHSKAVEILKTAREISMRVRFFPY
61 Pdzk3 (1/4)
/NHRF4/NaPiCap2
PDZ Q99MJ6 49-­‐130 = 82 FCLLSKEEEKTFGFHLQQHLGKADHVVCR
VDPGTSAQRQGLREGDRILAVNNNIVAH
EDHAVVVRYIRASGPRVLLTVLAQH
62 Pdzk3 (3/4) /
/NHRF4/NaPiCap2
PDZ Q99MJ6 263-­‐346 = 84 CLNIEKGPEGFGFLLREEKGLDGRLGQFL
WDVDPGLPADKAGMKAGDRLVAVAGE
SVDGLGHEETVSRIRAQGSCVSLIVVDPE
63 Pdzk3 (1/6) PDZ E9Q1M1 81-­‐ 179 = 99 ETVGLSFGNIPVFGDYGEKRRGGKKRKTHQGPVLDVGCIWVTELRKNSPAGKSGKVRLRDEILSLNGQLMVGVDVSGASYLAEQCWNGGFIYLIMLRRF
64 Pdzk3 (2/6) PDZ E9Q1M1 342-­‐ 419 = 78 DGLGIQVSGGRGSKRSPHAIVVTQVKEGGAAHRDGRLSLGDELLVINGHLLVGLSHEEAVAILRSATGMVQLVVASKE
65 PDZ-­‐RGS3 (1/1) PDZ Q9DC04 18-­‐95 = 78 QITIRRGKDGFGFTICCDSPVRVQAVDSG
GPAERAGLQQLDTVLQLNERPVEHWKC
VELAHEIRSCPSEIILLVWRVV
66 PSD95 (1/3) PDZ Q62108 65-­‐151 = 87 EITLERGNSGLGFSIAGGTDNPHIGDDPSI
FITKIIPGGAAAQDGRLRVNDSILFVNEVD
VREVTHSAAVEALKEAGSIVRLYVMRR
67 PSD95 (2/3) PDZ Q62108 160-­‐246 = 87 EIKLIKGPKGLGFSIAGGVGNQHIPGDNSI
YVTKIIEGGAAHKDGRLQIGDKILAVNSV
GLEDVMHEDAVAALKNTYDVVYLKVAKP
68 PSD95 (3/3) PDZ Q62108 313-­‐393 = 81 RIVIHRGSTGLGFNIVGGEDGEGIFISFILA
GGPADLSGELRKGDQILSVNGVDLRNAS
HEQAAIALKNAGQTVTIIAQYK
69 PTP-­‐BL (2/5) PDZ Q64512 1357-­‐1442 = 86 EVELAKTDGSLGISVTGGVNTSVRHGGIY
VKAIIPKGAAESDGRIHKGDRVLAVNGVS
LEGATHKQAVETLRNTGQVVHLLLEKGQ
70 SAP102 (2/3) PDZ P70175 244-­‐330 = 87 EVNLLKGPKGLGFSIAGGIGNQHIPGDNS
IYITKIIEGGAAQKDGRLQIGDRLLAVNNT
NLQDVRHEEAVASLKNTSDMVYLKVAKP
GST-­‐PDZ Domains
71 SAP102 (3/3) PDZ P70175 404-­‐484 = 81 KIILHKGSTGLGFNIVGGEDGEGIFVSFILA
GGPADLSGELRRGDRILSVNGVNLRNAT
HEQAAAALKRAGQSVTIVAQYR
72 SAP97 (1/3) PDZ Q811D0 224-­‐311 = 88 EITLERGNSGLGFSIAGGTDNPHIGDDSSI
FITKIITGGAAAQDGRLRVNDCILRVNEA
DVRDVTHSKAVEALKEAGSIVRLYVKRRK
73 SAP97 (2/3) PDZ Q811D0 319-­‐406 = 88 EIKLIKGPKGLGFSIAGGVGNQHIPGDNSI
YVTKIIEGGAAHKDGKLQIGDKLLAVNSV
CLEEVTHEEAVTALKNTSDFVYLKVAKPT
74 SAP97 (3/3) PDZ Q811D0 466-­‐547 = 82 KVVLHRGSTGLGFNIVGGEDGEGIFISFIL
AGGPADLSGELRKGDRIISVNSVDLRAAS
HEQAAAALKNAGQAVTIVAQYRP
75 Scrb1 (1/4) PDZ Q80U72 714-­‐801 = 88 TLTIVRQTGGLGISIAGGKGSTPYKGDDE
GIFISRVSEEGPAARAGVRVGDKLLEVNG
VALQDAEHHEAVEALRGAGAAVQMRV
WRER
76 Scrb1 (2/4) PDZ Q80U72 848-­‐936 = 89 AACLVRSEKGLGFSIAGGKGSTPYRAGDG
GIFISRIAEGGAAHRAGTLQVGDRVLSIN
GVDMTEARHDHAVSLLTAASPTISLLLER
ET
77 Scrb1 (3/4) PDZ Q80U72 990-­‐1079 = 90 EICLPRAGGPLGLSIVGGSDHSSHPFGVQ
DPGVFISKVLPRGLAARCGLRVGDRILAV
NGQDVREATHQEAVSALLRPCLELCLLVR
RDP
78 Semcap3 (1/2) PDZ Q69ZS0 249-­‐339 = 91 TLVLHRDSGSLGFNIIGGRPCVDNQDGSS
SEGIFVSKIVDSGPAAKEGGLQIHDRIIEV
NGKDLSRATHDQAVEAFKTAKEPIVVQV
LRRT
79 Shank1 (1/1) PDZ D3YZU1 663-­‐757 = 95 TVLLQKKDSEGFGFVLRGAKAQTPIEEFTP
TPAFPALQYLESVDEGGVAWRAGLRMG
DFLIEVNGQNVVKVGHRQVVNMIRQGG
NTLMVKVVMVT
80 Shank3 (1/1) PDZ Q4ACU6 570-­‐664 = 95 VAILQKRDHEGFGFVLRGAKAETPIEEFTP
TPAFPALQYLESVDVEGVAWRAGLRTGD
FLIEVNGVNVVKVGHKQVVGLIRQGGNR
LVMKVVSVT
81 Shroom (1/1) PDZ Q9QXN0 24-­‐109 = 86 FVYLEALLEGGAPWGFTLKGGLERGEPLII
SKIEEGGKADSVSSGLQAGDEVIHINEVAL
SSPRREAVSLVKGSYKTLRLVVRRDV
82 SLIM (1/1) PDZ Q8R1G6 1-­‐84 = 84 MALTVDVAGPAPWGFRISGGRDFHTPII
VTKVTERGKAEAADLRPGDIIVAINGQSA
ENMLHAEAQSKIRQSASPLRLQLDRSQ
GST-­‐PDZ Domains
83 Tiam2 (1/1) PDZ Q6ZPF3 911-­‐997 = 87 DVQLTKTGDMTDFGFAVTVQVDEHQHL
NRIFISDVLPDSLAYGGGLRKGNEITSLNG
EPVSDLDIQQMEALFSEKSVGLTLVARPV
T
84 TIP-­‐1 (1/1) PDZ Q9DBG9 15-­‐112 = 98 RVEIHKLRQGENLILGFSIGGGIDQDPSQ
NPFSEDKTDKGIYVTRVSEGGPAEIAGLQI
GDKIMQVNGWDMTMVTHDQARKRLT
KRSEEVVRLLVTRQ
85 Whirlin (3/3) PDZ Q5MLF8 827-­‐910 = 84 LVRVRKSAATLGIAIEGGANTRQPLPRIVT
IQRGGSAHNCGQLKVGHVILEVNGQTLR
GKEHKEAARIIAEAFKTKERDYIDFL
86 ZO-­‐1 (1/3) PDZ P39447 23-­‐110 = 88 TVTLHRAPGFGFGIAISGGRDNPHFQSGE
TSIVISDVLKGGPAEGQLQENDRVAMVN
GVSMDNVEHAFAVQQLRKSGKNAKITIR
RKK
87 ZO-­‐1 (2/3) PDZ P39447 186-­‐264 = 79 KVTLVKSRKNEEYGLRLASHIFVKEISQDSL
AARDGNIQEGDVVLKINGTVTENMSLTD
AKTLIERSKGKLKMVVQRDE
88 ZO-­‐2 (1/3) PDZ Q9Z0U1 10-­‐97 = 88 TVTLQKDSKRGFGIAVSGGRDNPHFENG
ETSIVISDVLPGGPADGLLQENDRVVMV
NGTPMEDVLHSFAVQQLRKSGKIAAIVV
KRPR
89
1
ZO-­‐3 (1/3) PDZ Q9QXY1 287-­‐365 = 79 GVLLTKSKANEEYGLRLGSQIFIKEMTRTG
LATKDGNLHEGDIILKINGTVTENMSLTD
ARKLIEKSRGKLQLVVLRDS
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Certificate of Analysis 
Product Name:  Microinjection Ready Validated                               
Product Number: CRSPMVA 
Lot Number: 879 
Target Gene: PRMT5 mus musculus 
 
 
Description of Product:  
 
5 x 50uL of ready-to-inject CRISPR/Cas9*  
 
*premixed Cas9 and sgRNA in microinjection buffer  
 
 
sgRNA Target Site Sequence 5’3’:  
gRNA/PAM Site:  atggtataggagcggccggtagg (complementary) 
 
 
Validated Primers: 
 
Primer Name Sequence 5’-3’ 
sgRNA #1 Forward ccgcctgtgtctttcgtatt 
sgRNA #1 Reverse gttggccaccatgacattag 
 
 
 
 
 
 
 
 
 
Please store all reagents at: –80C. Spin down reagents before opening. 
For microinjection guidelines please reference our tech bulletin at 
http://www.sageresearchlabs.com/crisprtech  
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CRISPR/Cas9 Validation:  
    
          
                   
       
 
 
 
 
 
 
 
 
 
 
 
Cel-1 assay resolved on 10% TBE-PAGE 
 
All gRNAs were transfected into Mouse Neuro2A cells and genomic DNA was harvested 24 hours 
post transfection. This DNA was used as template for a mismatch sensitive PCR assay to detect 
CRISPR/Cas9-mediated mutations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2033 Westport Center Dr, Saint Louis, MO, 63146, USA 
www.sageresearchlabs.com  
 
Genotyping Protocol: 
 
1. Prepare a PCR reaction with the following reaction components: 
 
 
Reaction components Volume (µL) 
Final 
concentration 
DNA template 1 -- 
10 uM Primer F 5 1 uM 
10 uM Primer R 5 1 uM 
Sigma JumpStart Taq 
ReadyMix (P2893) 
25 1X 
H2O 14 -- 
  50 µl reaction   
 
2. PCR cycling conditions 
 
Cycle Step 
Temp 
(C) 
Time 
 
1 95 5 min  
2 95 30s  
x35 
cycles 
3 60 30s 
4 68 40s 
5 68 5 min  
 
3.    Sequencing the PCR Product / Mutation Analysis 
 
Send all PCR product to sequencing for mutation analysis. For best results it is recommended that 
the PCR products undergo a purification step to remove residual dNTPs and primers prior to 
sequencing. 
 
Expected wild type band size: 336bp 
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